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MOSPD1 belongs to a class of proteins that have a major sperm protein (MSP) 
domain at the N terminus and two transmembrane domains at the C terminus and are 
thought to act as membrane adaptor proteins. Previous work in the laboratory 
indicated that the closely related, mammalian-specific, Mospd 3 plays a role in the 
development and function of the heart as homozygous Mospd 3 gene trap neonates 
displayed a right ventricle defect characterised by a thinning of the right ventricle 
wall. The function of Mospd 1 is not known. Whilst Mospd 3 is mammalian specific 
Mospd 1 is conserved in all vertebrates including Danio rerio (zebrafish).  
 
The aims of this thesis were to investigate the possibility of genetic redundancy 
between Mospd 1 and Mospd 3 by identifying the sub-cellular localisation of 
MOSPD1 and MOSPD3 in both cells and tissues and to investigate the function of 
MOSPD1. Mouse monoclonal antibodies specific for MOSPD1 and MOSPD3 were 
generated and tested to ensure they did not cross react. MOSPD1 was found to be 
localised to the nucleus whilst MOSPD3 was located in the nucleus and cytoplasm. 
The sub-cellular localisation of these proteins changes during the cell cycle as they 
were localised to the cytoplasm during cell division, possible due to the breakdown 
of the nuclear membrane during cell division.  
 
To investigate the function of Mospd 1 during early development Mospd 1 gene 
expression was knocked down using morpholino anti-sense knockdown technology. 
A morpholino was generated against the splice-site between exons 2 and 3 of the 
zebrafish Mospd 1 gene and injected into early embryos. At doses that significantly 
reduced the level of Mospd 1, to below 50 %, the embryos developed normally and 
did not exhibit any gross morphological phenotypes when compared to both non-
injected and 5 mispair control morpholino-injected embryos. A morpholino targeted 
to the start site of the Mospd 1 gene confirmed the lack of a gross morphological 
phenotype. In conjunction with the zebrafish functional tests the tools were generated 
to assess the role of Mospd 1 in a mammalian system. A conditional allele of Mospd 
 ii 
1 was generated in mouse embryonic stem (ES) cells which could be used to 
generate a conditional Mospd 1 mouse. The electroporation of a Cre recombinase 
plasmid into the conditional Mospd 1 ES cell line resulted in the generation of Mospd 
1 null ES clones which could be used for functional studies both in vitro and in vivo. 
The Mospd 1 null ES cells were able to self-renew, expressed ES cell specific 
markers and were able to differentiate into cardiomyocytes. However, Mospd 1 null 
cells showed a reduced ability to differentiate into osteoblasts compared to wild type 
cells and showed changes in the expression of genes involved in Epithelial to 
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1.1. Why study Mospd 1? 
Motile sperm domain-protein (Mospd) 1 is a member of the Mospd gene family. 
There is very little information about the localisation of MOSPD1 in the literature. It 
has recently been suggested that Mospd 1 may play a role in Epithelial- 
Mesenchymal Transition (EMT) (Thaler et al., 2010). The only other clue to the 
function of Mospd 1 is evidence that the closely related Mospd 3 gene is involved in 
cardiac development (Pall et al., 2004). MOSPD1 has a Major Sperm Protein (MSP) 
domain and two transmembrane domains. The MSP domain is predicted on the 
secondary protein structure and conservation of important residues from the MSP 
protein found in nematodes. 
 
 
1.1.1. MSP in Nematodes 
Major Sperm Protein (MSP) (NCBI Accession AAA28115.1) is a 14.5 kDa 
cytoskeletal protein that gets its name from the fact that it is the most abundant 
protein in nematode sperm, making up 17 % of the total protein content (Klass and 
Hirsh, 1981). More than 60 % of all MSP domain proteins, identified to date, are 
found in nematodes (Tarr and Scott, 2005a). MSPs are involved in male reproduction 
as the expression of many of these proteins is up-regulated in the male germ line 
(Tarr and Scott, 2004). Nematode sperm use a crawling motion, rather than a 
flagellum based motion used by mammalian sperm. Instead of using an actin-based 
system for motility nematode sperm depend exclusively on the cytoskeletal protein, 
MSP, which acts in a cyclical and pH dependent manner (Italiano et al., 1999). MSP 
deficiency results in infertility in the organism (Nelson and Ward, 1981). In 
Caenorhabditis elegans (C. elegans) it has also been found to be involved in 
signalling pathways that promote oocyte meiotic maturation, ovulation and sheath 
cell contraction (Miller et al., 2001). MSP binds to the membranes of oocytes and 
sheath cells via the VAB-1 Ephrin receptor protein-tyrosine kinase resulting in the 




MSP is composed of a 7-stranded β-sandwich (Figure 1.1 A) made up of a 3-
stranded sheet opposing a 4-stranded sheet (Bullock et al., 1996; Tarr and Scott, 
2005b). Through the sheet structure of the IgG-like domain MSP can interact with 
other proteins as the IgG domain is involved in protein-protein interactions (Bork et 
al., 1994). MSP belongs to the Immunoglobulin (IgG) superfamily based on its IgG-
like fold and is similar in structure to the amino terminal of PapD, a bacterial 
chaperonin. In solution MSP dimerizes (Haaf et al., 1996) and these dimers 
polymerize to form helical microfilaments. These microfilaments coil around each 
other to form filaments which then coil around each other to form larger macrofibers 
(Figure 1.1 B) (King et al., 1994).  
 
 
1.1.2. Vesicle Associated Proteins (VAPS) 
MSP domain-containing proteins are found in a wide range of organisms including 
yeast (Kagiwada et al., 1998), plants (Laurent et al., 2000), insects (Pennetta et al., 
2002) and mammals (Nishimura et al., 1999). A family of MSP domain-containing 
proteins, called VAMP-associated proteins (VAPs), have been identified and their 
functions studied. VAPs have an N terminal MSP domain and a C terminal 
transmembrane domain making them similar to the MOSPD family. The first VAP 
that was identified was in the sea slug Aplysia and it was named VAP-33 due to it 
binding to VAMP (synaptobrevin), a synaptic vesicle protein, and its 33 kDa size 
(Skehel et al., 1995). VAP33 was localised to the central nervous system (CNS) and 
gills of Aplysia and was important for synaptic transmission. The VAP33 homolog in 
Drosophila melanogaster (Drosophila), DVAP-33, is expressed at neuromuscular 
junctions in larvae and is involved in mediating the interactions between the pre-













Figure 1.1: Structure of MSP. A: 3-dimensional (3D) representation of the 
MSP fold. The MSP monomer is comprised of seven -strands, each 
designated by a letter, that fold to form a sandwich. B: The coiling of MSP. 
MSPs polymerize to form subfilaments. Two subfilaments coil around each 
other to form filaments which then further coil around each other to form 
macrofibers. (Images taken from Tarr and Scott, 2005b (A) and King et al., 
1994) (B)). 
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VAPs are widely expressed in mammalian tissues (Nishimura et al., 1999); (Soussan 
et al., 1999); (Skehel et al., 2000) and mammalian homologs of VAP33 are called 
VAPA, VAPB and VAPC (Nishimura et al., 1999). The rat homolog of VAPB was 
termed ERG30 when it was first discovered as it was localised to the endoplasmic 
reticulum (ER) and Golgi apparatus (Golgi) (Soussan et al., 1999). Inhibition of 
ERG30 (rat VAPB) resulted in an inhibition of intra-Golgi transport and an 
accumulation of vesicles due to this inhibition. Mouse VAP is localised to the ER 
and microtubules (Skehel et al., 2000).  
 
 
A mutation in VAPB has been identified that causes some forms of the 
neurodegenerative disease amyotrophic lateral sclerosis (ALS) (Nishimura et al., 
2004). ALS is characterised by the loss of motor neurons from the brain stem, spinal 
cord and motor cortex. The P56S mutation in the MSP domain was identified in 
families with autosomal dominant ALS. The alteration of this conserved proline 
residue was due to a cytosine to thymine (C166T) mutation in exon 2 of the VAPB 
gene. Other patients with this mutation suffer from spinal muscular atrophy (SMA), 
another neurodegenerative motor disease (Nishimura et al., 2004).  The MSP domain 
of wild type VAPB forms a seven stranded IgG-like beta sandwich and the P56S 
mutation results in loss of the secondary structure of VAPB (Shi et al., 2010). This 
misfolding of the VAPB protein leads to the protein becoming insoluble and forming 
aggregates in the ER. This mutated VAPB interferes with the ER’s unfolded protein 
response (UPR) which is important for preventing the accumulation of misfolded 
proteins in the ER (Kanekura et al., 2006). Studies using drosophila VAP have found 
that the N terminal of VAP (the MSP domain) is cleaved, secreted and binds to 
EPHRIN (EPH) receptors in the same way as MSP in nematodes. This indicates a 
conserved role for the MSP domain in EPH receptor binding and cell signalling. 
When the human P56S mutation is introduced into drosophila VAP it inhibits the 
secretion of the MSP domain resulting in aggregation of the protein (Tsuda et al., 
2008).  The fact that both MSP in nematodes and VAPs bind EPH receptors may 
provide a further clue to a possible role of the MSP domain in MOSPD proteins.  
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1.1.3. Major Sperm Protein (MSP) domain-containing proteins 
The Mospd gene family actually belongs to a much larger MSP domain-containing 
family which is found in a wide range of organisms and evidence suggests the MSP 
domain plays a role in protein-protein interactions (Bork et al., 1994). The MSP 
domain consensus sequence was built from 171 sequences of MSP-domain 
containing family members from a wide range of species. The MSP domain 
consensus sequence has four invariant (P7, N29, K40 and P51) and eight highly 
conserved residues (L3, R34, F37, K38, V39, T42, 69R and 79N) that are important 
for MSP domain folding (Tarr and Scott, 2004).  
 
 
Overall sequence similarity between the MSP domain in proteins and MSP from 
nematodes is only 35 % (Figure 1.2 A). However, the presence of an MSP domain is 
predicted based on secondary structure and conservation of important residues (Tarr 
and Scott, 2004). This secondary structure is the IgG-like fold important for protein-
protein interactions. The MSP domain in mouse VAP shares 48 % sequence identity 
with the MSP domain consensus sequence and has all four invariant residues as well 
as six of the eight highly conserved residues (Figure 1.2 B).   
 
 
843 proteins that contain at least one MSP domain are currently found in the Pfams 
database (Bateman et al., 2004) and these are divided into Types I-V based on the 
relative position of the MSP domain. Type II MSP domain proteins are between 150 
and 350 amino acids in length and contain the MSP domain in the N terminus. They 
can be subdivided by the absence (IIa) or presence of one (IIb) or two (IIc) 
transmembrane domains in the C-terminus (Tarr and Scott, 2005b). Mospd 1 falls 
into the Type IIc category. The MSP domain in MOSPD1 shares 33 % sequence 
homology with the MSP domain consensus sequence (Tarr and Scott, 2004). It has 
three of the four invariant residues and five of the eight highly conserved residues 







A: MSP (C. elegans) and MSP domain (MSPD) 
 
 
MSP    GDIQTQPNAKIVFNAPYDDKHTYHIKVINSSARRIGYGTKTTNMKRLGVDPPCGVLDPKE   
       G     P    VF  P D   T      N S  RI    KTTN KR  V PP G L P E 
MSPD   GELKLDPPVTVVFPNPFDKQGTSTLTLKNPSDKRIAFKVKTTNNKRYRVRPPYGILEPGE   
 
MSP    AVLLAVSCDAFAFGQEDTNNDRITVEWTNTPDGAAKQFRREW-FQGDGMVRRKNLPIEY   
        V LA     F  G    N D   V  T  P GAA   R    FQ    V     P   




B: MSP domain of VAPA and MSP domain (MSPD) 
 
 
VAPA    LVLDPPSDLKFKGPFTDVVTTNLKLQNPSDRKVCFKVKTTAPRRYCVRPNSGIIDPGSIV   
        L LDPP    F  PF    T  L L NPSD    FKVKTT   RY VRP  GI  PG  V 
MSPD    LKLDPPVTVVFPNPFDKQGTSTLTLKNPSDKRIAFKVKTTNNKRYRVRPPYGILEPGESV   
 
VAPA    TVSVMLQPFDYDPNEKSKHKFMVQ   
              Q F   P  K K KF VQ 




C: MSP domain of MOSPD1 and MSP domain (MSPD) 
 
 
MOSPD1             PVFFVFPTELIFYADDQSTHKQVLTLYNPYEFALKFKVLCTTPNKYVVV   
                   P   VFP       D Q T    LTL NP      FKV  T    Y V  
MSPD        GELKLDPPVTVVFPNPF----DKQGTS--TLTLKNPSDKRIAFKVKTTNNKRYRVR   
 
MOSPD1     DAAGAVKPQCCVDIVIRHRDVRSCHYGVIDKFRLQVSEQSQRKALGRKEVIAT   
              G   P   V   I  R          DKF  Q  E     A    E 
MSPD       PPYGILEPGESVNLAITQR-FKGLPKKNKDKFAVQYTEAPSGAADKAREAFKFQAQA 
 
MOSPD1 
MSPD       GVGETKIPVVFE   
 
 
Figure 1.2: Protein sequence alignment between the MSP domain 
consensus sequence and MSP (C. elegans), mouse VAPA and MOSPD1 
MSP domains. Letters in red correspond to identical sequence, residues 
highlight in green are invariant and residues highlighted in yellow are highly 
conserved. 
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1.1.4. Mospd gene family 
Mospd 1 belongs to the Mospd gene family which is characterised by encoding an N 
terminus Major Sperm Protein (MSP) domain and a transmembrane (TM) domain in 
the C terminus. There are four Mospd gene family members in the mouse including 
Mospd 1 (NM_027409), Mospd 2 (NM_029730), Mospd 3 (NM_030037) and Mospd 
4 (NM_028086) (Figure 1.3). Mospd 2 also encodes a Cellular retinaldehyde 
binding/ triple function (CRAL-TRIO) domain and a nuclear localisation signal 
(NLS). Mospd 1 and Mospd 3 are the most similar family members as they encode 
the MSP domain in the N terminal and two C terminus TM domains. Although 
MOSPD1 (NP_081685) and MOSPD3 (NP_084313) only share 38 % overall protein 
sequence identity the majority of the shared sequence is located in the MSP and TM 
domains (Figure 1.4). The similarity of Mospd 1 and Mospd 3 could indicate the two 
may be genetically redundant.   
 
 
Mospd 1 is located on the X chromosome in mice and humans. MOSPD proteins are 
highly conserved as there is a high sequence homology between mouse Mospd 1 
(NM_027409.4) and human Mospd 1 (NM_019556.1) of 87 %. Mospd 3 is located 
on chromosome 5 and is thought to be mammalian specific. Mouse Mospd 3 
(NM_030037.1) and human Mospd 3 (NM_001040097) have a high sequence 
similarity of 87 %. This conservation in sequence between species indicates these 
















Figure 1.3: Schematic representation of members of the Mospd gene 
family. The four members of the Mospd gene family encode a Major Sperm 
Protein (MSP) domain (blue) and at least one transmembrane (TM) domain 
(green) at the C terminus. MOSPD2 also encodes a Cellular retinaldehyde 
binding/ triple function (CRAL-TRIO) domain (pink) and a nuclear localisation 






























MOSPD1      MHQQKRQ-PELVEGN----------------LPVFVFPTELIFYADDQSTHKQVLTLYNP  
            M     Q  ELV                    PV VFP  L F AD  S   Q LTLYNP  
MOSPD3      MRRGAPQDQELVGPGAPGRGSRGSPPSSGPVVPVLVFPPDLVFRADQRSGPRQLLTLYNP 
 
MOSPD1      YEFALKFKVLCTTPNKYVVVDAAGAVKPQCCVDIVIRHRDVRSCHYGVIDKFRLQVSEQ-  
               AL F VLCT P KY V DA G VKPQ C DIVIRH     HY V D FR    SE   
MOSPD3      TGTALRFRVLCTAPAKYTVFDAEGYVKPQSCIDIVIRHVAPVPSHYDVQDRFRIELSEEG    
 
MOSPD1      SQRKALGRKEVIATLLPSA---KEQQKEEEEKRIKEHLTESVFFEQSCQPGKNRAVSSGP   
                  GRK     L   A     Q   E                   Q            
MOSPD3      TEGRVVGRKDITSVLRAPAYPLELQGHSEPTPNPGPPVWTGLTPARHLQENAPQQLATSS   
 
MOSPD1      SLLTVFLGVVCIAALMLPTLGDMESLVPLYLHLSVNQKLVAAYILGLITMAILRT   
             LL    GV   A L LP      S  P  LH S  QKLVAAY LGL TM  LRT 





Figure 1.4: Protein sequence alignment between mouse MOSPD1 and 
MOSPD3. MOSPD1 and MOSPD3 (NCBI accession NP_081685 and 
NP_084313, respectively) share 38 % sequence identity. Letters in red 
correspond to identical sequence, letters in blue represent the MSP domains 









1.1.5. Discovery of Mospd 3 
The only clue for the function of the Mospd gene family came from a gene trap 
integration into the Mospd 3 gene (McClive et al., 1998; Pall et al., 2004).  Gene 
trapping in ES cells has been used to perform large scale mouse mutagenesis 
(Hansen et al., 2003; Skarnes et al., 2004). The vector used in the gene trapping 
screen contained a promoter-less β-galactosidase (lac Z) reporter gene immediately 
downstream of a splice acceptor site and a termination sequence (poly A tail). The 
vector also contains a selection cassette (Forrester et al., 1996). The trapped gene 
regulates the lac Z expression and due to the stop signal, downstream sequences of 
the trapped gene are prevented from being transcribed resulting in a mutant gene 
transcript being generated. The biological role of the trapped gene can be identified 
after germ line transmission.  
 
 
The gene trap screen, in which Mospd 3 was discovered, identified twenty genes that 
were responsive to retinoic acid (RA) treatment in a study to identify genes involved 
in embryonic development (Forrester et al., 1996). Retinoic acid is known to affect 
the patterning of tissues during embryogenesis. Nine of the gene trap integrations 
were found to be induced by RA whilst eleven were found to be repressed. One of 
these genes repressed by RA, the R124 integration, chimeras showed lacZ staining in 
the heart, branchial arch and dorsal hindbrain (Forrester et al., 1996). Using 5’ 
RACE-PCR it was shown that the gene trap vector had integrated into the 5’ UTR of 
the Mospd 3 gene. The insertion was mutagenic and mice homozygous for the gene 
trap did not express Mospd 3 in their tissues indicating a null allele had been 
generated. The expression of the neighbouring genes, S7 and Polce, was not affected 
and, therefore, any phenotype observed was most likely due to the lack of Mospd 3 







1.1.6. Phenotype of Mospd 3 gene trap mice 
There were significantly fewer mice homozygous for the gene trap integration 
observed due to a neonatal lethality in these animals (Pall et al., 2004). 50 % of these 
homozygotes died within 24 hours of birth due to a right ventricle defect. The 
neonates showed dilated right ventricles and a thinning of the right ventricular 
parietal wall (Figure 1.5). The myocardium did not show any obvious fatty or fibrous 
replacement which is often seen in hearts with cardiomyopathies. Overall there was a 
37 % reduction in the right ventricular wall and a 56 % increase in right ventricle 
volume when homozygotes were compared to wild type and heterozygous littermates.  
The compact myocardium was narrowed and the number and size of the trabeculae 
carnae was reduced resulting in the thinning right ventricular wall (Pall et al., 2004).  
This cardiac phenotype in a closely related family member of Mospd 1 may provide 
a clue to the function of Mospd 1 and could indicate that Mospd 1 may also be 
involved in cardiac development. To investigate a possible mechanism for a thinning 
of the right ventricular wall a literature search to look for similar cardiac phenotypes 
was carried out. 
 
 
1.1.7. Comparable right ventricle phenotypes 
Similar right ventricle defects to that observed in the mice homozygous for the gene 
trap integration into Mospd 3 have been found in several genes coding for 
desmosome components. Desmosomes are large protein complexes that are 
important in maintaining cell adhesion. They are important for providing mechanical 
strength by forming a 3D structure, as they anchor intermediate filaments to the 
cytosolic membrane. They play a vital role in maintenance of tissue integrity and are 
concentrated at the junctions of epithelia and cardiac muscle, tissues requiring high 
strength. Desmosomal proteins form a complex (or plaque) that links intermediate 
filaments of cells. Desmosomes span the intercellular space between adjacent cells 
and they are less than 1 µm in diameter (Figure 1.6). Desmosomes are made up of 
three areas including an extracellular core with the transmembrane proteins 









Figure 1.5: Transverse sections from E19 Mospd 3 gene trap mice. Heart 
section from a mouse heterozygous for the Mospd 3 gene trap (a & c) and a 
homozygous null heart section (b & d).  The homozygote heart (b) shows a 
thinning of the right ventricle wall, indicated by the arrow, compared to the 
heterozygote heart (a). LV: left ventricle; RV: right ventricle. Scale bar for a & 
b = 100 µm and for c & d = 25 µm. Sections were stained with H & E. (Figure 











Figure 1.6: Structure of a desmosome. A: A desmosome on an electron 
micrograph. B: Schematic of a desmosome showing the components and the 
relative distances from the plasma membrane (PM). DP: desmoplakin; PG: 
plakoglobin; PKP: plakophilin; KIF: keratin intermediate filaments; IDP: inner 






The outer dense plaque (ODP) of desmosomes has the C terminal of DSC and DSG 
linked to plakoglobin (PG) which is in turn linked to the N terminal of desmoplakin 
(DP). Plakophilin (PKP) is bound to PG to further stabilize the plaque. The inner 
dense plaque (IDP) contains the C terminal of DP which bind keratin intermediate 
filaments (KIFs) (Garrod and Chidgey, 2008; Delva et al., 2009). 
 
 
Like the Mospd 3 gene trap mice the majority of Plakoglobin (Pg) null mice die at 
mid-gestation due to cardiac defects. E10.5 PG null mice hearts had a thin ventricle 
wall and the ventricular trabeculae, atria and endocardial cushions were not well 
developed. There was further evidence of cardiac dysfunction due to blood pooling 
within the heart and surrounding area. Null embryos that lived past E10.5 died at 
birth and in addition to the cardiac phenotype also showed skin blistering and 
detaching epidermis (Bierkamp et al., 1996). Ruiz et al. (1996) also generated PG 
null mice with a similar cardiac phenotype. Between E12 and E16 most PG null mice 
died due to cardiac rupture resulting in the pericardium being filled with blood. 
There were no desmosomes present in the intercalated discs between cardiomyocytes 
in the nulls. Mice heterozygous for PG were normal at birth. However, they 
developed cardiac defects and dysfunction by 10 months and this was exacerbated by 
exercise (Kirchhof et al., 2006).  
 
 
Another desmosome component that when deficient shows a similar cardiac 
phenotype to the Mospd 3 gene trap homozygote nulls is Desmoplakin (Dp). 
Homozygous targeted disruption of the dp gene in mice results in death at E6.5 
shortly before implantation (Gallicano et al., 1998). Tissue -specific dp deletion in 
cardiac tissue results in embryonic lethality in the majority of the mice. Those that 
survived at birth died within approximately two weeks due to cardiac defects. The 
hearts of these mice were less well developed, the chambers enlarged and there was 
fatty and fibrous replacement of the cardiomyocytes. The cytoskeleton was 
unorganized and there was blood within the pericardial sac. Mice heterozygous for 
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dp in the heart developed cardiac defects only after birth as they aged, with 20 % 
dying within 6 months with the same phenotype as the homozygous animals (Garcia-
Gras et al., 2006).  
 
 
Mice null for plakophilin 2 (PKP2) died at mid-gestation (E110.5-E11) and their 
hearts showed thinning of the chamber walls, reduced trabeculae in the ventricles and 
perforations in the heart resulting in leakage of blood into the pericardial sac. The 
cytoskeleton was disorganized and there was a change of DP localization from 
adhering junctions to cytoplasmic aggregates (Grossmann et al., 2004).  
 
 
As mutations in genes encoding desmosome components result in similar thinning of 
the right ventricle wall to that of mice homozygous for the gene trap integration into 
Mospd 3 it may be that Mospd 3 is required for desmosomes. If this association with 
desmosomes is true for Mospd 3 it may also be for Mospd 1 due to their similar 
structure. There is a human condition with a similar cardiac phenotype to that of 
homozygous Mospd 3 gene trap mice.  
 
 
1.1.8. Arrhythmic Right Ventricular Cardiomyopathy  
Mutations in desmosome components in humans result in a disease known as 
Arrhythmic Right Ventricular Cardiomyopathy (ARVC) which is characterized by 
dilatation and dysfunction of the right ventricle and thinning of the right ventricle 
wall. A loss of cardiomyocytes which are replaced by fatty and fibrous tissue 
(Fontaine et al., 1999) occurs. It is an inherited disease that causes ventricular 
arrhythmias, cardiac failure and sudden death, especially in young adults (Thiene et 
al., 1988). The disease affects approximately 1 in 5000 individuals and is a familial 
disease with incomplete penetrance and variable expressivity (Nava et al., 1987; 
Nava et al., 1988). Mutations in the desmosome components Plakoglobin (McKoy et 
al., 2000), Desmoplakin (Norgett et al., 2000), Plakophilin 2 (Gerull et al., 2004), 
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Desmoglein 2 (Awad et al., 2006; Pilichou et al., 2006) and Desmocollin 2 (Heuser 
et al., 2006; Syrris et al., 2006) have been identified in ARVC patients.  
 
 
The first mutation in desmosomes that was implicated in the pathogenesis of ARVC 
was in the Plakoglobin (Pg) gene. Individuals that carried a mutation in Pg 
demonstrated ARVC as well as skin abnormalities and woolly hair (Protonotarios et 
al., 1986). This disease, also known as Naxos disease, is an autosomal recessive 
syndrome, characterized by a two base pair deletion in the Pg gene (McKoy et al., 
2000). It is completely penetrant by adolescence in individuals homozygous for the 
mutant PG protein (Protonotarios et al., 2001).  
 
A disease similar to Naxos disease was identified in which individuals had woolly 
hair, skin abnormalities and cardiomyopathy. This disease, known as ‘Carvajal 
Syndrome’ (Rao et al., 1996) was found to be an autosomal recessive disease and 
was the result of a mutation in the Desmoplakin (Dp) gene. This mutation was a 
deletion in exon 24 which results in a truncated protein being formed due to the 
introduction of a premature stop codon (Norgett et al., 2000).   
 
The majority of cases of ARVC show mutations in the Plakophilin 2 (Pkp2) gene. 25 
Pkp2 mutations were identified which included nonsense mutations, splice site 
mutations, missense mutations, insertion and deletion mutations (Gerull et al., 2004). 
These mutations were located throughout the gene but there were higher incidence in 
the C- terminal coding region. Pkp2 is the only Plakophilin expressed in 
cardiomyocytes (Klymkowsky, 1999).  
 
Similarly to Pkp2 Desmoglein 2 (Dsg2) is also the only desmoglein expressed in 
cardiomyocytes (Schafer et al., 1994). Individuals with mutations in Dsg2 exhibit 
ARVC but do not show the hair and skin abnormalities associated with mutations in 
plakoglobin and desmoplakin (Awad et al., 2006; Pilichou et al., 2006). Pilichou et 
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al. (2006) identified nine mutations in Dsg2 with seven of these mutations located in 
the extracellular domains which are important for adhesion. Awad et al. (2006) 
identified a further 5 mutations in the Dsg2 gene implicated in ARVC. Mutations in 
another desmosomal cadherin, Desmocollin 2 (Dsc2), have also been identified. Two 
mutations which both resulted in truncated DSC2 protein were identified by Syrris et 
al. (2006) and a mutation in a splice acceptor site of the Desmoglein 2 gene resulted 
in the introduction of a premature termination codon and reduced levels of transcript 
(Heuser et al., 2006).  The complete loss of DSG2 is lethal in mice. Dsg2 null mice 
die just after implantation (Eshkind et al., 2002). The desmosomal genes that are 
involved in ARVC are listed in Table 1.1.    
 
 
The human ARVC disease has a similar phenotype to the homozygous Mospd 3 gene 
trap mice as they both show a thinning of the right ventricular wall. This could 
indicate that the loss of Mospd 3 could result in ARVC or a similar condition. If 
Mospd 1 has a similar function to Mospd 3 then a mutation in the Mospd 1 gene may 
also result in a similar human disease. 50 % of ARVC cases are due to a mutation in 
a known desmosome component (den Haan et al., 2009; Bhuiyan et al., 2009) and 
the cause of the other 50 % of cases is unknown. It is possible that mutations in 





Mouse phenotype Human disease References                           
Plakoglobin Pg Nulls: embryonic 
lethality at E10.5 due to 
ventricular defects; skin 
blistering 
 
Hets: ARVC by 6 
months 
ARVC with skin defects 
and woolly hair 
Bierkamp et al., 1996 
Kirchhof et al., 2006 
McKoy et al., 2000 
Desmoplakin Dp Nulls: embryonic 
lethality at E6.5  
 
Hets: ARVC by 6 
months 
ARVC with skin defects 
and woolly hair 
Gallicano et al., 1998 
Garcia-Gras et al., 2006 
Norgett et al., 2000 
Plakophilin 2 Pkp2 Nulls: die at 
midgestation due to 
cardiac defects 
 
ARVC Grossman et al., 2004 
Gerull et al., 2004 
Desmoglein 2 Dsg2 Nulls: Embryonic lethal 
 
 
ARVC Eshkind et al., 2002 
Awad et al., 2006; 
Pilichou et al., 2006 
Desmocollin 2 Dsc2 Mouse knockout not 
reported to date 
ARVC with skin defects 
and woolly hair 
Heuser et al., 2006 
Syrris et al., 2006 
 
Table 1.1: Desmosome components implicated in ARVC and the phenotypes associated with mutations in these 
proteins.   
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1.1.9. A link between Mospd 1 and EMT 
A recent study found that Mospd 1 expression was higher in mesenchymal-derived 
cells and increased during the differentiation of osteoblastic, myoblastic and 
adipocytic cells, all of which are mesenchymal cell types. Mospd 1 expression 
increased in dense (confluent) cell cultures compared to sparse cell cultures (Thaler 
et al., 2010).   
 
 
 siRNA knockdown of Mospd 1 gene expression in the MC3T3-E1 osteoblastic cell 
line resulted in the down regulation of numerous osteoblastic and mesenchymal 
genes and a shift to more epithelial gene expression. Osteoblastic genes, such as 
Runx 2 and Osteocalcin were down regulated as well as mesenchymal genes such as 
Vimentin and Smooth muscle actin. Runx 2 is a transcription factor required for 
osteoblast formation whilst Osteocalcin is a marker of osteoblast differentiation. Up 
regulation of epithelial genes such as E-cadherin (Cdh1), Emp1 and Trp63 (Thaler et 
al., 2010) occurred in cells when Mospd 1 expression was knocked down. EMP1 is a 
protein localised to epithelial membranes and can be used as a marker for epithelial 
cells. TRP63, which is also known as P63, is a transcription factor that is a homolog 
of the tumour suppressor P53. P63 is required for the formation of the epidermis as 
demonstrated by the lack of epidermis in mice with a targeted disruption of the p63 
gene. This loss of epidermis results in their death shortly after birth due to 
dehydration (Mills et al. ,1999; Yang et al., 1998). P63 serves as the switch for the 
initiation of epithelial stratification during epidermal development (Koster et al., 
2004). The loss of P63 also results in craniofacial and limb defects (Yang et al., 1998; 
Wolff et al., 2009). The cadherin found in osteoblasts, Cdh11, was down regulated 
in cells treated with Mospd 1 siRNA. Expression of genes involved in EMT was also 
found to be altered in Mospd 1 knockdown cells. There was a down regulation of the 
E-cadherin repressor genes Snai1 and Snai2 (Thaler et al., 2010). This suggested a 
reduction in Mospd 1 could result in the down regulation of Snai1 and Snai2 leading 
to the up regulation of E-cadherin and resulting in MET. Therefore, it could be 
hypothesised that Mospd 1 may be involved in regulation of Snail and Snai2 and thus 




1.1.10. Epithelial- Mesenchymal Transition (EMT)  
Epithelial cells show plasticity and can change into mesenchymal cells through a 
process known as Epithelial- Mesenchymal Transition (EMT) (Greenburg and Hay, 
1982). During normal development cells that arise in one area of the embryo need to 
move to other areas of the embryo. Epithelial cells do not have migratory properties 
and, therefore, need to change into mesenchymal cells which are more mobile (Hay, 
1968). EMT is required during embryogenesis to form the three germ layers 
beginning during gastrulation. When EMT is disrupted an organism cannot proceed 
past the blastula stage as it fails to undergo gastrulation. During EMT the 
characteristics of epithelial cells change to those of mesenchymal cells and this 
switch is governed by complex signalling and transcription factor networks.  
 
Epithelial cells have adherens junctions, tight junctions, gap junctions and 
desmosomes at their cell junctions. Epithelial cells form layers of cells with a basal 
lamina and have an apical-basal polarity. Whilst epithelial cells can be motile they 
remain within the epithelial layer. Mesenchymal cells differ in that they do not form 
layers of cells, do not have a basal lamina and the actin cytoskeleton polarised and 
these cells can easily migrate. They also differ in morphology as mesenchymal cells 
are more spindle-like whereas epithelial cells usually grow in clusters with cell-cell 
contacts always maintained and are more regular in shape (Greenburg and Hay, 
1982).  
 
During EMT cell adhesion molecules are down regulated allowing tight junctions, 
adherens junctions and desmosomes to dissociate. This allows cells to lose cell-cell 
contacts and become more mobile and thus change into mesenchymal cells (Figure 
1.7). The reverse process whereby mesenchymal cells can change into epithelial cells 
is known as Mesenchymal- Epithelial Transition (MET). During embryogenesis 
several rounds of EMT and MET are required for proper development.  
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Mutations in desmosome components have been described in previous sections and 
result in a similar phenotype to that of the homozygous gene trap Mospd 3 mice (Pall 
et al., 2004) indicating a possible link between desmosomes and Mospd genes. Given 
this possible link and the loss of desmosomes due to down regulation of E-cadherin 
during EMT it is possible that MOSPD proteins are involved in EMT and, therefore, 
disruption of them may result in desmosome disruption and a cardiac phenotype.  
 
 
1.1.11. E-Cadherin (Cdh1) involvement in EMT 
Cadherins are a family of calcium-dependent cell adhesion molecules. E-cadherin 
(Cdh1) was the first cadherin identified and is the form found in epithelial cells 
where it is important for cell adhesion (Takeichi, 1988) as well as for apical-basal 
polarity of epithelial cells (Gumbiner, 1988). E-CADHERIN is located in adherens-
junctions at cell junctions.  
 
 
E-cadherin is expressed in the ectoderm and epithelial regions derived from the 
endoderm of the developing mouse embryo (E7.5 to E9.5) but is absent from regions 
undergoing EMT and mesoderm (Cano et al., 2000). E-cadherin is essential as E-
cadherin null mice are embryonic lethal, do not develop past the 32 cell stage and die 
around implantation as they do not form normal blastocysts (Larue et al., 1994; 
Riethmacher et al., 1995). Due to this early embryonic lethal phenotype it was 
difficult to assess the role of E-cadherin in development past this point in mice. 
Morpholino knockdown of E-cadherin in zebrafish embryos resulted in a 60 % 
reduction in embryo survival as well as defects in cell movements resulting in 
inhibition of epiboly and gastrulation.  Cell cleavage patterns and compaction were 
also disrupted in morpholino-injected embryos (Babb and Marrs, 2004).  
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Figure 1.7: Epithelial -Mesenchymal Transition (EMT) and Mesenchymal -Epithelial Transition (MET). Epithelial and 
mesenchymal cells show plasticity and can interchange by the processes of EMT and MET. Epithelial cells and mesenchymal 
cells have different markers. During EMT tight junctions, adherens-junctions and desmosomes dissociate and epithelial cells 
change into mesenchymal cells. During the reverse process, MET, these junctions and desmosomes associate and epithelial 
cells form. Various transcription factor and signalling networks control EMT and MET. (Figure taken from (Thiery and Sleeman, 
2006). 
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The E-cadherin promoter has an E-pal regulatory element consisting of a 
palindromic sequence (Behrens et al., 1991). This E-pal element, containing two E 
boxes, is a site that can bind transcription factors, resulting in changes of E-cadherin 
expression. E-cadherin expression is repressed by the transcription factors Snai1 
(Cano et al., 2000) and Snai2 (Slug) (Bolos et al., 2003) by binding of SNAI1 and 
SNAI2 to the E-pal element.   
 
 
1.1.12. Snai1 and Snai2 (Slug) transcription factors 
The Snail family are zinc finger transcription factors that are essential regulators of 
EMT. Snail is expressed in the primitive streak pre-migratory and migrating neural 
crest cells of the developing mouse embryo as well as other regions undergoing EMT 
and in the mesoderm (Smith et al., 1992; Cano et al., 2000). Loss of Snai1 is 
embryonic lethal as Snai1 null mice fail to undergo gastrulation due to defects in 
EMT (Carver et al., 2001). Snai2 (Slug) is expressed during early embryonic 
development during organogenesis with high expression in mesenchyme and organs 
from the mesoderm (Oram et al., 2003). 
 
 
Snai1 and Snai2 have high homology at the N terminal as they both have a SNAG 
transactivation domain and at the C terminal where they have 4-5 zinc fingers. The 
intermediate region of the Snai2 gene has a Slug domain which is 29 amino acids in 
length and its function is not known (Manzanares et al., 2001).  
 
 
Snail transcription factors bind to the E box (CAGGTG) in the E-pal element. Snai1 
is a repressor of E-cadherin and results in a down regulation of epithelial genes such 
as desmosome components and up regulation of mesenchymal genes such as 
Vimentin and Fibronectin (Cano et al., 2000). The up regulation of Snai1 results in 
decreased cell–cell contacts through a reduction in desmosomes and adherens 
junctions. This dissociation of cell junctions results in cells becoming more 
migratory and, therefore, mesenchymal through EMT. Snai2 also has the ability to 
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repress E-cadherin expression and induce EMT. An increase in mesenchymal marker 
gene expression and migratory cells is observed when Snai2 is expressed. Snai2 
binds the E-box of E-cadherin but with a lower affinity to that of Snai1 (Bolos et al., 
2003). Increase in Snai2 expression by transfection resulted in the loss of 
Desmoglein and Desmoplakin expression indicating a loss of desmosomes. These 
changes were accompanied by a loss of epithelial properties and a gain of 
mesenchymal properties (Savagner et al., 1997). Increased Snai1 and Snai2 repress 
E-cadherin expression resulting in less cell-cell attachment and an increase in 
mesenchymal properties and markers. 
 
 
1.1.13. EMT in cancer 
Whilst EMT has an important role to play during embryogenesis there is less 
requirement for the process in adult tissues. In fact EMT in certain circumstances is 
involved in pathological processes such as cancer. EMT has been implicated in 
tumour progression of epithelial tumours. Tumour cells express high levels of Snail 
and can reduce their cell adhesion properties resulting in a decrease in cell-cell 
contacts (Cano et al., 2000). Cells can then cross the basement membrane and have 
mesenchymal characteristics such as migration properties. This allows the cells to 
migrate from the primary tumour location to secondary locations and thus EMT is 
involved in metastasis of tumours. Many of the same transcription factors and 
signalling molecules are involved in this tumour progression through EMT as during 
normal development. The loss of E-cadherin has been shown to be involved in 
tumour progression (Perl et al., 1998) and Snai1 repression of E-cadherin has been 









1.2. Functional study of genes  
As described in the previous sections there are possible clues to the function of 
Mospd 1 from the structure and function of MSP in nematodes and other MSP 
domain- containing proteins, such as VAPs even Mospd 3, as well as the recent 
finding that Mospd 1 may be involved in EMT in osteoblast cells (Thaler et al., 
2010). Models are required to investigate the function of Mospd 1 in vivo and in vitro. 
To study the function of Mospd 1 in vivo a model organism like Danio rerio 
(zebrafish) is an option due to the presence of a Mospd 1 gene in its genome. 
 
 
1.2.1.1. Mospd 1 expression in zebrafish 
The zebrafish genome only has one copy of the Mospd 1 gene (NCBI accession 
007878.1) located on chromosome 14. As no gene duplications of Mospd 1 have 
occurred in the zebrafish genome Mospd 1 can be studied in this organism without 
the complications of a duplicate. As there is no Mospd 3 gene found in the zebrafish 
genome the possibility of genetic redundancy between Mospd 1 and Mospd 3 in 
zebrafish is not an issue.  
 
However, whilst Mospd 3 is not found in the zebrafish genome Mospd 2 is expressed 
and is located on chromosome 9. Whole mount in situ hybridisation (WISH) on 
zebrafish embryos has demonstrated that Mospd 2 is ubiquitously expressed in pre-
gastrula embryos. This expression is observed from the 2 cell stage to 64 cell stage 
indicating maternal expression of Mospd 2 in zebrafish embryos (Hong et al., 2010). 
There is 28 % sequence identity between zebrafish MOSPD1 and MOSPD2 and, 
therefore, there is the possibility that MOSPD2 may compensate for the loss of 
MOSPD1. There is no information reported in the literature about the expression of 
Mospd 2 in embryos past 8 hpf or the function of Mospd 2.    
 
 
WISH performed in a high throughput screen to investigate the expression patterns 
of zebrafish genes in zygotic embryos (0-0.75 hours) to the hatching pec fin 
developmental stage (60-72 hours) revealed that Mospd 1 RNA was expressed 
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throughout the embryo (Figure 1.8) and was not localised to a particular region of the 
developing embryo (Thisse et al., 2004) from www.zfin.org). It is not known 
whether the Mospd 1 mRNA expression reflects the protein expression. MOSPD1 is 
highly conserved between mouse (NCBI accession NP_081685.1) and zebrafish 




1.2.1. 2. Zebrafish as a model organism 
Zebrafish are an excellent model organism to examine developmental processes as 
they possess many advantages. They are easy and inexpensive to maintain and large 
numbers of embryos can be accessed from the earliest developmental stages as 
zebrafish have high fecundity and eggs are externally fertilised. The transparency of 
the embryos facilitates the observation of organ development in vivo by light 
microscopy.  The entire zebrafish genome has been sequenced 
(www.sanger.ac.uk/Projects/D_rerio) aiding genetic studies in this organism. 
 
 
Zebrafish provide advantages over the use of classical model organisms, such as C. 
elegans and Drosophila, as zebrafish are vertebrates and, therefore, are 
evolutionarily closer to mice and humans. Many biochemical and biological 
processes are conserved from zebrafish to humans allowing processes specific to 
vertebrates to be investigated. Zebrafish embryos do not require normal blood 
circulation during early development as they acquire sufficient oxygen through 
diffusion (Burggren and Pinder, 1991). This allows embryos that have cardiovascular 
defects to survive and develop and facilitates phenotypic assessment of these fish 
(Chen et al., 1996). This is advantageous compared to using mice as a model 
organism as it allows mutations that act at early stages of development and are 
embryonic lethal to be assessed which would be difficult to study in mice as mouse 









Figure 1.8: Expression of Mospd 1 RNA in developing zebrafish 
embryos. Whole mount in situ hybridisation of Mospd 1 in zebrafish embryos 
from the one cell stage to the hatching pec fin stage was performed and 
Mospd 1 was found to be expressed throughout the embryo (Thisse et al., 




















Zebrafish   QQQSRQPDLVEGSLPVFVFPTELVFYADEQASHKQVLTLYNPYEFALKFKVLCTAPNKYA   
             QQ RQP LVEG LPVFVFPTEL FYAD Q  HKQVLTLYNPYEFALKFKVLCT PNKY  
Mouse       HQQKRQPELVEGNLPVFVFPTELIFYADDQSTHKQVLTLYNPYEFALKFKVLCTTPNKYV   
 
Zebrafish   VVDATGAVKPQCCVDIVIRHRDVRSCHFGVIDKFRLQVSEQSQRKALGRKEVMATLLPSA   
            VVDA GAVKPQCCVDIVIRHRDVRSCH GVIDKFRLQVSEQSQRKALGRKEV ATLLPSA 
Mouse       VVDAAGAVKPQCCVDIVIRHRDVRSCHYGVIDKFRLQVSEQSQRKALGRKEVIATLLPSA   
 
Zebrafish   AQEQPQTRPQEEERRMKEQLADRVFFEQTAFQTESRTASGGPSLLTVLLGLVCMAALMLP   
               Q       EE R KE L   VFFEQ       R  S GPSLLTV LG VC AALMLP 
Mouse       KEQQKEE----EEKRIKEHLTESVFFEQSCQPGKNRAVSSGPSLLTVFLGVVCIAALMLP   
 
Zebrafish   TLGEQESTVPVYLHLSVNKKLVAAYVLGLLTMVILRT   
            TLG  ES VP YLHLSVN KLVAAY LGL TM ILRT 




Figure 1.9: Protein sequence alignment between zebrafish MOSPD1 and 
mouse MOSPD1. Zebrafish MOSPD1 and mouse MOSPD1 (NCBI 
accession NP_998534.1 and NP_081685.1, respectively) share 77 % 










1.2.1.3. Zebrafish development 
Zebrafish embryos develop through periods, from a one cell embryo to an embryo 
with well developed organs by 72 hours post fertilisation (hpf,) when the embryos 
are kept at 28.5 ºC (Figure 1.10). The developmental period from a one cell newly 
fertilised zebrafish egg until the first cleavage occurs is known as the zygotic period 
and it lasts from 0-0.75 hpf. During this time the cytoplasmic movement is activated 
and cytoplasmic streaming occurs. This is followed by the cleavage period (0.75-
2.25 hpf) where cells divide every 15 minutes until there are 128 cells and this marks 
the beginning of the blastula period (2.25-5.25 hpf) (Kimmel et al., 1995). Mid 
blastula transition (MBT) occurs during this period which is characterised by 
lengthening of the cell cycle and the onset of zygotic gene expression (Kane and 
Kimmel, 1993). This is followed by the beginning of epiboly which is when the yolk 
syncytial layer (YSL) and the blastoderm spread around the yolk cell.  
 
 
The gastrula period (5.25-10 hpf) begins at 50 % epiboly and the primary germ 
layers and embryonic axis are formed at this time. There are two germ layers formed 
during gastrulation, namely the epiblast (definitive endoderm) which will give rise to 
the epidermis, central nervous system and neural crest and the hypoblast which gives 
rise to the mesoderm and endoderm structures (or mesendoderm). Following 
gastrulation is the segmentation period (10-24 hpf) in which the primary organs, such 
as the heart and pronephric kidneys, begin to develop as well as the eye. Tail 
morphogenesis occurs resulting in the elongation of the embryo and the yolk extends. 
The somites develop in the trunk and tail of the embryo during this period from 3 
somites (at 11 hpf) to 26 somites (at 22 hpf). These somites later form the myotome. 
Neuromeres, develop which give rise to the brain structures such as the midbrain and 
hindbrain (Kimmel et al., 1995).   
 
 
The pharyngula period (24-48 hpf) is characterised by the continuous lengthening of 





Figure 1.10: Stages of zebrafish development. Sketches of zebrafish 
embryos at different stages showing the periods of development (from 
zygotic to hatching) are shown. Image adapted from sketches in Kimmel et al. 
(1995).   
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The pharyngeal arches develop which gives rise to structures such as the jaw and 
gills. Pigmentation commences, the fins begin to develop and the embryo becomes 
sensitive to touch and is able to swim when freed from the chorion. The embryos 
hatch from the chorion during the hatching period (48-72 hpf) allowing them to swim 
freely.  The embryos have a protruding mouth and show behavioural traits such as 
avoidance and food seeking from this time. From 72 hpf onwards embryos continue 
to develop rapidly (Kimmel et al., 1995).  
 
 
1.2.1.4. Zebrafish heart development 
The heart is the first organ to develop in zebrafish embryos and is comparable to the 
early human heart. At approximately 22 hpf heart tube contraction begins which is 
followed by circulation by 24 hpf. By 36 hpf the heart tube has looped and there are 
co-ordinated contractions of the chambers. There are two chambers, the atrium and 
the ventricle, separated by valves and an outflow tract called the bulbous arteriosis 
(Stainier et al., 1993). The heart beats at about 140 beats/ minute by 48 hpf (Denvir 
et al., 2008) and by this time there is also strong blood circulation in the head and tail. 
 
 
1.2.1.5. Zebrafish Resources 
ZFIN (the Zebrafish Model Organism Database (www.zfin.org)) is an online 
database of information about zebrafish research that allows the zebrafish research 
community access to a wide range of protocols, gene information and zebrafish 
research findings. The Zebrafish International Resource Centre (ZIRC) is able to 
provide zebrafish lines and WISH probes to the scientific community. These 
resources facilitate research and are another advantage when using zebrafish as a 
model organism.  
 
 
Transgenic zebrafish lines have been generated that assist in the study of various 
developmental processes. For example, a transgenic line with GFP under the control 
of the Cardiac myosin light chain 2 (Cmlc2) promoter has been developed which 
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shows fluorescence in myocardial cells (Huang et al., 2003).  The fli1-GFP zebrafish 
transgenic line has the GFP gene fused to the Friend leukaemia integration 1 (Fli1) 
gene and is used to visualise the vasculature during embryogenesis (Lawson and 
Weinstein, 2002).  In Gata-1-GFP transgenic zebrafish the GFP is under the control 
of the erythroid-specific Gata 1 promoter and this allows visualisation of blood cells 
in circulation to be monitored (Long et al., 1997).  
 
 
1.2.1.6. Mutagenesis studies in zebrafish 
Large-scale mutagenesis studies have been carried out on zebrafish to identify genes 
involved in zebrafish development (Driever et al., 1996; Haffter et al., 1996). 
Zebrafish have been exposed to ethylnitrosourea (ENU) which is a powerful mutagen 
that introduces point mutations into the genome (Bode, 1984). This allows the 
identification of the gene causing the phenotype to be determined by sequencing. 
Haffter et al. (1996) isolated mutant embryos displaying a visible phenotype when 
assessed by light microscopy and characterised 1163 mutants. By using 
complementation crosses they assigned 894 mutants to 372 genes which were 
involved in morphogenesis, organogenesis, pattern formation and differentiation. 
Another ENU screen was carried out on zebrafish in the same year and 577 mutants 
were identified which were involved in embryogenesis (Driever et al., 1996).  
 
 
Large-scale mutagenesis screens of the zebrafish genome have identified many 
mutations that affect the cardiovascular system (Stainier et al., 1996; Chen et al., 
1996). Stainier et al. (1996) identified 58 mutations and Chen et al. (1996) identified 
53 cardiovascular mutations. Mutations that have been identified have been 
subdivided into those that affect cardiac morphogenesis and those that affect cardiac 
function. Most heart mutants show oedema that progressively worsens, being 
observed firstly in the pericardial sac and the majority of these mutants die by 7 dpf. 
Mutations that affect the vasculature have been identified that result in 
haemorrhaging (blood pooling) after circulation begins (Stainier et al., 1996). 
However, these large-scale ENU mutant screens have limits such as genes with 
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subtle phenotypes could go undetected. They are time-consuming and redundancy in 
identification of genes occurs.  
 
 
1.2.1.7. Morpholinos antisense oligonucleotides 
Morpholino gene knockdown is an established technology in zebrafish and is used 
for functional genomics. Morpholinos are designed and manufactured by Gene Tools 
(www.gene-tools.com) and are able to knockdown gene expression allowing the 
characterisation of the function of genes during early development. They are short 
antisense oligonucleotides that are comprised of the standard nucleic acid bases (A, 
C, G and T). However, morpholine rings replace ribose rings and 
phosphorodiamidate linkages are present instead of phosphodiester bonds found in 
DNA and RNA resulting in a net neutral charged oligonucleotide (Summerton and 
Weller, 1997) (Figure 1.11). This results in morpholinos being stable as they are 
resistant to nuclease activity (Hudziak et al., 1996). Morpholinos do not induce an 
immune response and have a high affinity for RNA. Morpholinos are most effective 
for the first two to three days post fertilisation (dpf) and as most organ systems 
develop during this time morpholinos are excellent tools for developmental research.   
 
 
Morpholinos are injected into embryos between the 1-16 cell stages and the 
development of the embryos monitored. A 3’carboxyfluorescein tag on the 
morpholino allows the injected embryos to be monitored for successful uptake and 
even distribution in the cells. 5 mis-pair morpholinos are used as a negative control 
as they are highly similar to the specific injected morpholino but should not cause 
knockdown of the gene of interest due to the 5 base pair changes. These controls are 











Figure 1.11: Comparison of the structure of a morpholino (MPO) and 
DNA. Morpholinos are comprised of the standard nucleic acid bases (B). 
Morpholine rings and phosphorodiamidate linkages in morpholinos replace 
the deoxyribose rings and phosphodiester bonds found in DNA. Morpholinos 






Morpholinos can act either by blocking translation in the cytosol or by blocking pre-
mRNA splicing in the nucleus depending where they are targeted to. Translational 
blocking morpholinos can be targeted anywhere from the 5’cap through to about 25 
bases 3’ to the translational start site. Therefore, morpholinos targeted to the 5’ 
untranslated region (UTR) or morpholinos targeted to the start site of the mRNA can 
be used to block translation. It is hypothesised that binding of the morpholino hinders 
the scanning of the 5’ UTR by the small ribosomal unit (40S) so it cannot identify 
the start codon. Therefore, the large ribosomal unit (60S) is not recruited and as the 
full ribosomal complex is not formed translation of the mRNA is blocked (Figure 
1.12 A) (Summerton, 1999;  Hardy et al., 2010).  
 
 
Small ribonucleoprotein particles (snRNP) form the spliceosome which binds to pre-
mRNA at specific binding sites. This is required for normal splicing of pre-mRNA 
where introns are removed resulting in the formation of mRNA. Morpholinos 
targeted to snRNP binding sites (splice junctions) of genes can alter pre-mRNA 
splicing by blocking the recognition of the spliceosome (Figure 1.12 B). This can 
result in the targeted exon being excluded (exon skipping) or inclusion of an intron in 
the mRNA). Quantitative real-time PCR can be used to determine the level of 
knockdown using splice-site morpholinos.  
 
 
1.2.1.8. Morpholinos to knockdown expression in zebrafish 
Morpholinos targeted to the start site of genes have been used to demonstrate the 
effectiveness of morpholinos in blocking translation. A morpholino targeted to the 
start site of the Green fluorescent protein (Gfp) gene was injected into GFP 
transgenic zebrafish embryos and the reduction in GFP expression monitored by 
fluorescent microscopy and measured by western blotting (Nasevicius and Ekker, 
2000). Injection of 4.5 ng of the GFP morpholino into embryos resulted in inhibition 
of GFP expression and a reduction of GFP activity by 80 %. This inhibition of 
expression was sequence-specific as the 4 base pair mis-pair morpholino injected as 









Figure 1.12: Mechanism of action of morpholinos. The mechanism for a 
translational blocking morpholino (A) and a splice-inhibiting morpholino (B) 








The knockdown was also dose-dependent as an increase in the dose resulted in a 
further reduction in GFP activity. However, at an increased dose non-specific defects 
were observed (Nasevicius and Ekker, 2000).     
 
 
Morpholinos have been used to phenocopy zebrafish mutants identified in large scale 
mutagenesis studies. Table 1.2 shows examples of phenocopies of known zebrafish 
mutants.  As the zebrafish genome has undergone partial duplication some genes 
have duplicates and, therefore, studying their function can be complicated by genetic 
redundancy. Morpholinos can also be co-injected against 2 different genes to knock 
down these functionally redundant genes thus facilitating the assessment of the 
function of genes (Bahary et al., 2007; Cermenati et al., 2008).   
 
 
1.2.1.9. Zebrafish to model human diseases 
Many of the mutants identified in the mutagenesis screens displayed phenotypes that 
corresponded to particular human disorders. Zebrafish are now widely used as a 
model for human diseases. For example, mutations in the desmosomal gene, 
Desmocollin 2 are associated with the human arrhythmic right ventricular 
cardiomyopathy (ARVC) due to cellular junction defects and a thin right ventricle 
wall. Morpholino mediated knockdown of Desmocollin 2 in zebrafish embryos 
results in contractility defects and reduced desmosome plaque area (Heuser et al., 
2006) modelling ARVC.   Another example is Bicaudal C (Bicc1) whose morphants 
have kidney cysts which are similar to those observed in polycystic kidney disease 
where mutation in Bicc 1 gene have been identified (Bouvrette et al., 2010). 
Zebrafish models of muscular dystrophy have been used to study the disease. 
Morphants of the Fukutin-related protein (Fkrp) display altered somatic structures, 
muscle fibre organisation and a reduction in alpha-dystroglycan glycosylation which 
is a feature of muscular dystrophy (Kawahara et al., 2010). There are many more 
diseases that are being modelled in zebrafish and this allows the function of genes 
involved in the pathogenesis of disorders to be studied as well as possible treatments. 
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Gene name Mutant name Phenotype Reference 
Chordin Dino U-shaped somites, abnormal tail fin, blood 
island 
Hammerschmidt et al. 
(1996) 
Nasevicius and Ekker, 2000 
BMP7 Snailhouse Dorsalisation Lele et al. (2001) 
Protein kinase Cλ Heart and soul Heart patterning defects Peterson et al. (2001) 




response c (nrc) 
Unanchored cone photoreceptor ribbons and 
abnormal synaptic transmission 
Van Epps et al. (2004) 
Fibrillin-2  Puff daddygw1 Disruption of notochord and vascular 
development 
Gansner et al. (2008) 
Protoporphyrinogen 
oxidase (ppox) 
montalcino Deficient in haemoglobin, anaemic and 
porphyric 
Dooley et al. (2008) 
Table 1.2: Phenocopies of known zebrafish mutations.  
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1.2.2. Functional study of genes using Embryonic Stem (ES) 
cells 
 
1.2.2.1. ES cells as a tool for mammalian development 
Embryonic stem (ES) cells are pluripotent cells derived from the inner cell mass 
(ICM) of the developing blastocyst that can differentiate into all cell types (Evans 
and Kaufman, 1981; Martin, 1981). They can be maintained in vitro in an 
undifferentiated state by culturing them in the presence of Leukaemia Inhibitory 
Factor (LIF) (Smith et al., 1988). ES cells can give rise to all three germ layers and 
when differentiated can form three dimensional aggregates of cells known as 
embryoid bodies (EBs). These EBs show a mixed population of different cell types 
(Doetschman et al., 1985).  
 
 
ES cells provide a useful tool to study development as they can be made to 
differentiate into any cell type depending on culture conditions. The addition of 
different growth factors or drugs or co-culturing ES cells with other cell types can 
direct differentiation towards a particular lineage. ES cells have been differentiated 
into various types of cells in vitro including cardiomyocytes (Doetschman et al., 
1985), haematopoietic cells (Nakano et al., 1994), neuronal cells (Fraichard et al., 
1995), adipocytes (Dani et al., 1997), chondrocytes (Kramer et al., 2000) and 
osteoblasts (Buttery et al., 2001). In this way ES cells provide a useful in vitro model 
to study differentiation and development as well as the gene expression changes that 
accompany different lineage specification.  
 
 
1.2.2.2. In vitro ES cell differentiation into cardiomyocytes 
When ES cells differentiate, by the formation of EBs, they form different types of 
cells including spontaneously beating cells (Doetschman et al., 1985). These beating 
regions are made up of different types of cardiomyocytes such as sinus nodal (pace-
maker-like), atrial-like and ventricular-like cells (Maltsev et al., 1993). These ES-
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derived cardiomyocytes have similar morphology to cardiomyocytes in vivo and 
show intercalated disks and myofibrillar Z bands (Doetschman et al., 1985; 
Hescheler et al., 1997). They express cardiac specific genes such as α- and β-cardiac 
myosin heavy chain (α-mhc and β-mhc) which are expressed during cardiac 
development in 9 day (E9) embryos (Robbins et al., 1990). As ES-derived 
cardiomyocytes continue to differentiate they show different electrophysiological 
properties, as measured by patch clamp studies on isolated cardiomyocytes, and the 
presence of different ion channels (Maltsev et al., 1994) due to the presence of the 
different types of cardiomyocytes present. As these ES-derived cardiomyocytes share 




Within an EB only about 5 % of the cells are beating cardiomyocytes and as there is 
no known cell surface marker specific to cardiomyocytes isolation of a pure 
population of cardiomyocytes is challenging. Transgenic ES cell lines have been 
established to increase the numbers of cardiomyocytes able to be made and purified. 
(Klug et al., 1996) generated an ES cell line with the α-cardiac myosin heavy chain 
(α-Mhc) gene, which is expressed in all types of cardiomyocytes, linked to a 
neomycin resistance gene. When these ES cells were differentiated and selected with 
G418 only cardiomyocytes survived. Another transgenic ES cell line was established 
with GFP under the control of the α-actin promoter which resulted in all 
cardiomyocytes expressing GFP allowing FACS analysis of ES cell derived 
cardiomyocytes (Kolossov et al., 1998). To isolate ventricular cardiomyocytes a 
transgenic ES cell line with GFP under the control of the ventricular specific myosin 
light chain 2V gene (Mlc-2v) was established (Muller et al., 2000). Percoll 
purification and FACS resulted in a 97 % level of purification allowing subsequent 
analysis of these ventricular cardiomyocytes. Only about 0.2 % of the cells in the 




ES cells have been used to study the role of genes thought to be essential in cardiac 
development such as the c-JUN NH2-terminal kinase (JNK)/ stress-activated protein 
kinase-associated protein 1 (Jsap 1). Jsap 1 null ES cells have impaired 
cardiomyocyte differentiation ability as there is a significant reduction in the 
percentage of beating EBs formed by these null cells compared to wild type ES cells. 
These Jsap 1 null ES cells also show a reduction in Nkx 2.5 expression as well as 
cardiac structural genes (Sato et al., 2005).  
 
 
1.2.2.3. In vitro ES cell differentiation into bone 
An alternative to using Mesenchymal Stem Cells (MSCs) isolated from bone marrow 
to generate osteoblasts is differentiating ES cells into cells of the osteoblast lineage 
using the appropriate culture conditions. Media supplemented with β-
glycerophosphate, ascorbic acid and dexamethasone has been shown to enhance 
osteoblast formation (Buttery et al., 2001) as well as being required for bone 
mineralization. ES cells co-cultured with fetal osteoblasts show enhanced osteoblast 
formation indicating other factors may be involved in bone formation (Buttery et al., 
2001).   
 
It has been reported that Mospd 1 expression is high in mesenchymal cell types 
including osteoblastic MC3T3-E1 cells (Thaler et al., 2010) and that siRNA 
knockdown of Mospd 1 in these cells results in changes in expression of genes 
involved in EMT. However, Thaler et al. (2010) did not investigate the role of 
Mospd 1 in other mesenchymal cell types. ES cells can be differentiated along the 
osteoblastic lineage to investigate the role of Mospd from earlier time points. This is 
the advantage of using ES cells to investigate the function of genes in vitro.  
 
1.2.2.4. Gene targeting using ES cells 
In order to introduce changes into the genome of a cell a DNA vector and an 
endogenous gene can undergo homologous recombination if there is sufficient 
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homology between the two DNA sequences. Homologous recombination and, 
therefore, genetic modification in mammalian cells is possible (Smithies et al., 1985). 
Gene targeting in ES cells has the advantage of allowing functional analysis of the 
gene of interest. Genetically modified ES cells can be transplanted into a developing 
blastocyst to produce germ-line chimeric animals which when crossed can result in 
homozygous transgenic animals (Robertson et al., 1986;  Gossler et al., 1986). This 
can be useful to studying the function of genes. However, sometimes the loss of a 
gene can be embryonic lethal and, therefore, the role of this gene at later stages 
cannot be studied using this system. In order to study genes such as these ES cells 
carrying a conditional allele are generated which are then injected into blastocysts 
resulting in the generation of chimaeras. Crossing of these chimaeras can then result 




1.2.2.5. Cre recombinase mediated excision of a gene  
Cre recombinase (Cre), from the bacteriophage P1 can cause site-specific 
recombination at lox P sites (Sauer and Henderson, 1989). Lox P sites are 34 bp 
sequences made up of two palindromic 13 bp sequences surrounding an asymmetric 
8 bp sequence. A conditional allele is an allele where lox P sites are inserted flanking 
the region of the DNA sequence that is to be removed. These loxP sites are placed in 
a region that will not affect normal transcription of the gene, normally in an intron. 
These conditional alleles should express the gene of interest until exposed to Cre at 
which time recombination occurs and the lox P flanked sequence is deleted. CRE 
forms a dimer at lox P sites and as a tetramer it induces recombination (Figure 1.13). 
Upon introduction of Cre the lox P flanked sequence is irreversibly removed.  
  
 
The deletion of the lox P flanked sequence can be done in vitro by electroporation of 
a plasmid with the Cre gene. Alternatively ES cells carrying the lox P flanked allele 
can be injected into blastocysts and transgenic mice with the floxed allele in their 









Figure 1.13: Schematic of Cre recombinase/ loxP recombination. A: A 
conditional allele with lox P sites in the intron of the gene on either side of 
exon Y. B: Two Cre recombinase molecules bind to each lox P site. C: Exon 
Y is removed and D: Recombined allele showing that exon Y has been 
removed. Purple boxes = exons, red triangle = lox P sites, yellow circles= 
Cre recombinase. (Figure adapted from Cvetkovic and Sigmund, 2000). 
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When these mice are crossed with Cre expressing mice recombination at the lox P 
sites results in the deletion of the lox P flanked sequence resulting in offspring 
lacking that DNA sequence and allowing the function of the gene of interest to be 
studied. If the mice express Cre in a specific tissue it results in a deletion only in that 




Inducible Cre-lox systems are available allowing Cre to be expressed at a particular 
time point during development. Cre has been shown to be able to be controlled 
temporally by a tetracycline responsive promoter (St-Onge et al., 1996). For example, 
to investigate the temporal requirements for the Vascular endothelial growth factor 
(Vegf) gene in the development of the vasculature of the retina and choroid of the eye 
an inducible conditional transgenic mouse line was established (Le et al., 2010). 
Tetracycline- induced mice with Cre under the control of the Retinal Pigment 
Epithelium (RPE)-specific gene Vitelliform macular dystrophy 2 (Vmd2) promoter 
(Le et al., 2008) were crossed with mice carrying a conditional knockout of Vegf. 
Upon feeding doxycycline (in sucrose) to the pregnant mice Vegf was knocked out. 
This resulted in the finding that loss of VEGF at E10 or E13 resulted in the reduction 
of vascular density of the choroid and reduced photoreceptor function. However, loss 
of VEGF after E15 did not affect choroid vasculature indicating that VEGF is 
important prior to this time point (Le et al., 2010).   
 
 
Another recombinase capable of site-specific recombination in mammalian cells is 
Flp recombinase (Flp) from Saccharomyces cerevisiae (yeast) (O'Gorman et al., 
1991). Flp recombinase recognises FRT sites which consist of an 8 bp core sequence 
flanked by two 13 bp repeated sequences (Andrews et al., 1985). FRT sites can be 
introduced into alleles to generate conditional alleles. Both FRT and lox P sites can 
be introduced into DNA when generating a conditional allele to allow removal of a 
selection marker. For example a conditional allele of the histone methyltransferase 
Smyd1 gene was generated which had an frt-neo-frt cassette in intron 1 and lox P 
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sites flanking exon 1 of the gene (Diehl et al., 2010). Flp recombinase- mediated 
deletion of the selection marker was carried out in vivo and the mice then crossed 
with mice expressing Cre under the control of the cardiac specific Nkx 2.5 promoter 




Even though there is little knowledge of the localisation and function of MOSPD1 
there are clues provided by the structure and function of MSP in nematodes and the 
MSP domain-containing proteins such as VAPs as well as the phenotype of the 
Mospd 3 gene trap mice. The recent finding indicating a possible role in EMT in 
osteoblasts for Mospd 1 (Thaler et al., 2010) provides another clue to the function of 
Mospd 1 and this thesis aims to build on these clues to investigate both the sub-
cellular localisation and function of MOSPD1 using both in vivo and in vitro systems. 
 47 
1.3. Aims 
 Expression analysis 
o Generate and test the tools required for expression analysis (specific 
monoclonal antibodies) 
o Assess the sub-cellular localisation of MOSPD1 and MOSPD3 to 
determine whether they localise to the same sub-cellular 
compartments 
 in vitro using immunocytochemistry (ICC) on human 
keratinocytes (HaCaTs). 
 in vivo using immunohistochemistry (IHC) on mouse tissue 
sections including ear, heart, kidney and skeletal muscle  
 
 Assess the function of Mospd 1 
o In vivo using zebrafish embryos 
 Assess the phenotype of embryos injected with morpholinos to 
knockdown Mospd 1  
 
 Measure knockdown of Mospd 1 expression using qPCR 
 
 
o In vitro using ES cell differentiation 
 Generate the tools to assess the function of Mospd 1  
 Generate a Mospd 1 conditional allele by targeting 
Mospd 1 in ES cells 
 
 Generate a Mospd 1 null ES cell line by expressing Cre 
recombinase in targeted Mospd 1 null ES cells 
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 Phenotypically characterise the Mospd 1 null clones to assess 
whether: 
  Mospd 1 plays a role in ES cell proliferation and/or 
self renewal  
 
 Mospd 1 is required for differentiation either in early 
differentiation, cardiomyocyte or osteoblast 
differentiation. 
 
 Mospd 1 is involved in EMT by measuring genes 






























MATERIALS AND METHODS 
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2.1. Molecular biology techniques 
 
2.1.1. Transformation of bacterial cells  
50 µl (1 vial) of One Shot
®
 Chemically Competent E. coli (Invitrogen) was thawed 
on ice and 1 µl of DNA was added to the cells and gently mixed. The samples were 
incubated on ice for 30 minutes, heat shocked for 30 seconds at 42 °C and transferred 
back to ice for a further 2 minutes. 250 µl room temperature Super Optimal broth 
with Catabolite repression (S.O.C.) medium (Invitrogen) was added and the mixture 
was shaken at 200 rotations per minute (rpm) at 37 °C for 1 hour. 10- 50 µl of the 
transformation reaction was plated on Luria-Bertani (LB) agar -containing specific 
antibiotic (such as 100 µg/ml ampicillin or 50 µg/ml kanamycin) plates and 
incubated at 37 °C overnight.  
 
 
2.1.2. Plasmid preparation (Minipreps and Maxipreps)  
A single bacterial colony was picked and cultured in 5 ml (for minipreps and starter 
cultures) LB containing antibiotic or 250 ml LB (for maxipreps)  containing 
antibiotic (such as 100 µg/ml ampicillin or 50 µg/ml kanamycin)  and incubated at 
37 °C overnight at 200 rpm in an orbital shaker. The cells were harvested by 
centrifugation at 6000 x g at 4 °C and DNA extracted using either a miniprep kit or a 
HiSpeed plasmid maxi kit (Qiagen).   
 
 
2.1.3. DNA preparation for electroporation into ES cells 
20 µg of the targeting vector was linearised with Pme I overnight at 37 °C and the 
digestion was subsequently phenol/ chloroform purified. An equal volume of 50:50 
phenol: chloroform solution was added to the digest and the sample centrifuged at 13 
000 rpm for 3 minutes in a Biofuge 13 bench-top centrifuge  (Heraeus Sepatech) and 
the aqueous phase transferred to a fresh eppendorf. An equal volume of chloroform 
was added and the solution re-centrifuged. The aqueous phase was transferred to a 
fresh eppendorf and the DNA precipitated using ammonium acetate and isopropanol. 
 51 
The pellet was washed with 70 % ethanol, dried and resuspended in 20 µl tissue 
grade Phosphate Buffered Saline (PBS) and stored at 4 °C, ready for electroporation.  
 
 
2.1.4. DNA extraction from ES cells 
For genomic DNA extraction of ES cells grown in 96 well plates the cells were 
washed with 100 µl PBS/well and the cells were lysed at 55 °C overnight in a 
humidified chamber, with 50 µl/well of ES cell lysis buffer (10 mM Tris, pH 7.5, 10 
mM EDTA, 10 mM NaOH, 0.5 % sarcosyl) and 1 mg/ml Proteinase K. The DNA 
was precipitated with 90 % ethanol and sodium chloride and left at room temperature 
for approximately 6-8 hours. The plates were then washed three times with 70 % 
ethanol, left to dry and subsequently stored at 4 °C. 
 
 
To extract genomic DNA from ES cells grown in 25 cm
2
 flasks, cells were first 
washed with PBS and lysed at 55 °C overnight with 2 ml of lysis buffer (4M urea, 10 
mM CDTA, 0.5 % sarcosyl, 0.1 M Tris pH8 and 0.2 M NaCl) with 1 mg/ml 
Proteinase K. The following day 2 ml of isopropanol was added to the lysate and the 
mixture rolled at 4 °C for 15 minutes. The precipitate of the genomic DNA was 
clearly visible at this point and was transferred to a fresh eppendorf and centrifuged 
at 13 000 rpm for 10 minutes. The pellet was washed twice with 70 % ethanol, dried 
and resuspended in 500 µl TE buffer and stored at 4 °C.  
 
 
2.1.5. Genomic DNA restriction digestions 
For the digestion of genomic DNA from ES cells isolated in 96 well dishes a 
digestion reaction containing 1 x Buffer H, 1 unit/µl Spe I (Roche), 100 µg/ml RNase 
A, 1 mM Spermidine, 100 µg/ml Bovine Serum Albumin (BSA) was set up, 30 µl of 
the digestion mixture was added per well and the plate incubated overnight in a 
humidified chamber at 37 °C.  For the digestion of ES cell DNA isolated from 
culture flasks 20 µg DNA was digested and the volumes adjusted accordingly and 
the digests incubated overnight at 37 °C.  
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2.1.6. Southern blots 
Electrophoresis of the digested ES cell DNA samples was done on 0.7 % agarose 
gels with 1 x Tris-borate buffer (TBE) at 25 V overnight. The DNA was then 
transferred onto N+ Membrane Hybond (Amersham) overnight. The blot was probed 
using a 5’ and 3’ probe (Appendix Table 1 shows primers used to generate probe). A 
PCR reaction containing 100 ng template DNA, 1.5 mM MgSO4, 1 x PCR buffer, 10 
µM dNTPs, 10 µM each primer and 1 unit HIFI Taq DNA polymerase (Invitrogen) 
was set up.  The PCR parameters used were 94 °C for 2 minutes followed by thirty 
cycles of 94 °C for 30 seconds, 55 °C for 1 minute, 72 °C for 45 seconds followed by 
a 72 °C incubation for 5 minutes and then a 4 °C hold. The PCR reaction was run on 
a 1 % agarose gel and the bands excised and purified using a Gel Extraction kit 
(Qiagen).  100 ng probe DNA was made up to 11 µl with distilled water, incubated at 
100 °C for 5 minutes to denature the probe. 4 µl High Prime (Roche) was added to 
the probe followed by 5 µl of P
32
-dCTP (PerkinElmer) and the probe incubated at 
37 °C for 1 hour. The probe was filtered over a Sephadex G50 column and 
hybridised to the membrane in ExpressHyb hybridisation solution (BD Biosciences) 
overnight at 65 ˚C with rolling. The blots were washed twice with 2 x SSC/1 % SDS 
followed by two 15 minute washes with 0.2 x SSC/1 % SDS and then exposed to 
Kodak film for 3-7 days at – 80 ˚C.  Autoradiographs were developed using a Konica 
SRX-101A developer.  
 
 
2.1.7. RNA extractions from cells, tissues and zebrafish 
embryos and cDNA synthesis for RT-PCR 
Total RNA was isolated using the RNeasy Mini kit (Qiagen) following the 
manufacturer’s instructions. 1 µg of total RNA of each sample was reverse-
transcribed using the High-Capacity cDNA Reverse Transcription kit (Applied 
Biosystems), which included 10 x RT buffer, 10 x RT random primers, 25 x dNTP 
mix (100 mM) and 50 U MultiScribe
TM 
Reverse Transcriptase, and following the 
manufacturer’s protocol. The parameters used were 25 °C for 10 minutes for primer 
annealing followed by 37 °C for 2 hours for reverse transcription and 85 °C for 5 
minutes to inactivate the MultiScribe
TM
 reverse transcriptase enzyme. A Hybaid PCR 
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2.1.8. cDNA synthesis for qPCR 
Total RNA was extracted as described above and treated with DNAse I to remove 
residual genomic DNA. cDNA was synthesised using the reverse transcription 
Superscript III kit (Invitrogen) which consisted of a 2x RT reaction mix and a 10x 
RT enzyme mix. These contained 2.5 µM oligo(dT), 2.5 ng/ µl ransom hexamers, 10 
mM MgCl2, 500 µM each dNTP, Superscript III RT enzyme and RNAseOUT. The 
reaction was set up with 600 ng of RNA and made up to 20 µl with nuclease-free 
water and incubated at 25 °C for 10 minutes for primer annealing, then 50 °C for 30 
minutes for cDNA synthesis and then inactivated at 85 °C for 5 minutes. cDNA was 
stored at -20 °C.  
 
 
2.1.9. Quantitative real time reverse transcriptase PCR (q-
RTPCR) 
QPCR primers and probes were designed with the assistance of Dr Melany Jackson 
in the John Hughes Bennett Laboratory and obtained from MWG Eurofins. Table 3 
in the Appendix lists the qPCR primers and probes used for gene expression analysis 
for zebrafish morpholino experiments described in section 2.4. Appendix Table 4 
lists the primers used for gene expression analysis of bone differentiation 
experiments described in section 2.2.9. Appendix Table 5 shows the efficiencies of 
the primers. QPCR was performed on an ABI 7500 FAST qPCR machine (Applied 
Biosystems) using 10 ng cDNA per reaction. The house keeping gene elongation 
factor 1 alpha (ef1α) was used as the endogenous control for the  zebrafish 
experiments and hypoxanthine-guanine phosphoribosyltransferase (hprt) for the 
bone experiments (mouse) to enable quantitation of gene expression according to the  
amount of cDNA loaded. For the qPCR of bone experiments SYBR green was used 
and a dissociation step added to the PCR. Reactions were set up in triplicate in 96 
well plates. The PCR parameters were 55 °C for 2 minutes, 95 °C for 10 minutes, 
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followed by 40 cycles of 95 °C for 15 seconds to denature the cDNA and 60 °C for 1 
minute to allow annealing and extension. Relative quantitation was calculated using 
the delta delta CT method using SDS v1.4 software from Applied Biosystems. Using 
this software the gene expression in each reaction was first normalised according to 
the endogenous control and the data was then shown as fold change in gene 
expression compared to an internal calibrator sample within each experiment.   
 
 
2.1.10. Polymerase Chain Reaction (PCR) to assess gene 
expression 
A PCR reaction contained 2 µl cDNA (served as the template DNA), 0.25 µM of 
each primer and 2 x PCR mastermix buffer (Promega) which contained 50 units/ml 
Taq DNA Polymerase in a reaction buffer (pH 8.5) with 400 µM each dNTP and 2 
mM MgCl2. The sequences for all primers used are given in Table 2 in the Appendix 
section. The PCR parameters used were a denaturation step of 94 °C for 2 minutes 
followed by thirty cycles of 94 °C for 30 seconds, an annealing step of 55 °C for 1 
minute, an extension step of 72 °C for 45 seconds followed by a 72 °C incubation for 
5 minutes and then a 4 °C hold. Individual 10 µl aliquots were analysed on a 1 % 
agarose gel.  
 
 
2.2. Cell Culture and manipulation 
 
2.2.1. Cell lines 
Human keratinocytes (HaCaTs) (Boukamp et al., 1988) were obtained from Dr Nick 
Hole, University of Durham and the HUVEC/Hybridoma cells from Dr Robin 
Barclay, University of Edinburgh. COS 7 (monkey kidney cells) cells and E14 IV ES 





2.2.2. Cell culture 
All cell types were stored at -140 ˚C. Cells were thawed rapidly in a 37 ˚C water bath 
and added to 9 ml of pre-warmed media. 
 
 
2.2.2.1. ES cell culture 
ES cells were cultured in 1 x Glasgow Minimum Essential Medium (GMEM) (Gibco) 
supplemented with 10 % Fetal calf serum (FCS), 1 mM sodium pyruvate, 1 x non-
essential amino acids (NEAA) and 0.1 mM β-mercaptoethanol. Leukaemia Inhibitory 
Factor (LIF) (1 in 1000 dilution) was added to the ES culture media. LIF was made 
by Helen Taylor and Julie Wilson by transfection of the pCAGGSLIF418 plasmid 
(Professor Austin Smith) in COS 7 cells and titration experiments performed to 
check the level of LIF required for optimal ES cell culture. New batches of FCS were 
tested for toxicity, and the ability to allow ES cell self-renewal and differentiation, by 
Helen Taylor and Julie Wilson. After thawing the cells were then centrifuged at 130 
x g for 3 minutes. The supernatant was removed and the cells resuspended in 2 ml of 
media and added to 8 ml of media in a gelatinised 25 cm
2
 flask. The flasks were 
incubated at 37 ˚C with 5 % CO2 in a Galaxy incubator (Wolf Laboratories). 
 
 
2.2.2.2. HaCaT and COS 7 cell culture 
HaCaTs and COS 7 cells were cultured in 1 x GMEM (Gibco) supplemented with 
10 % FCS, 1 mM sodium pyruvate, 1 x NEAA and 0.1 mM β-mercaptoethanol. After 
thawing, the cells were then centrifuged at 130 x g for 3 minutes. The supernatant 
was removed and the cells resuspended in 2 ml of media and added to 8 ml of media 
in a 25 cm
2
 flask. The flasks were incubated at 37 ˚C with 5 % CO2 in a Galaxy 






2.2.2.3. HUVEC/Hybridoma cell culture 
HUVEC/Hybridoma cells were cultured in 1x Iscove’s modified Dulbecco media 
(IMDM) (Sigma) supplemented with 10 % Fetal calf serum (FCS), 1 mM sodium 
pyruvate, 1 x non-essential amino acids (NEAA) and 0.1 mM β-mercaptoethanol. 
After thawing the cells were then centrifuged at 130 x g for 3 minutes. The 
supernatant was removed and the cells resuspended in 2 ml of media and added to 8 
ml of media in a 25 cm
2
 flask. The flasks were incubated at 37 ˚C with 5 % CO2 in a 
Galaxy incubator (Wolf Laboratories). 
 
 
2.2.3. Passage of cells  
Cells were passaged when they were 70-80 % confluent, generally every 2 days. The 
media was removed, the cells washed with pre-warmed PBS and incubated with 
sufficient trypsin solution (1 % trypsin, 1 % chick serum and EDTA in PBS) to cover 
the cells for 5 minutes at 37 ˚C to lift off the cells. In order to neutralise the trypsin 
the cells in trypsin solution were added to at least 5x the volume of media (FCS in 
the media inhibits trypsin) and centrifuged at 100 x g for 5 minutes. The cells were 
re-suspended with 10 ml fresh medium and a haemocytometer used to determine the 
cell number. 1 x10
6
 ES cells were plated per 25 cm
2
 gelatinised flask and the volume 
made up to 10 ml with ES cell medium including LIF. HACATs and COS 7 cells 




2.2.4. G418 concentration kill curve 
To determine the optimal concentration of G418 to use 4 x10
3
 wild type E14 IV ES 
cells were plated into each well of 6 well plates with 5 ml of media, including LIF, 
and incubated overnight. The following day the media was replaced with fresh media 
containing different concentrations (0, 100, 150, 200, 250, 300, 350, 400 µg/ml) of 
G418 (Geneticin, PAA) and LIF. The media was replaced daily and cells monitored 
to determine the optimum G418 concentration. This was defined as the minimum 
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amount of G418 that was required to kill all wild type E14 IV cells. 280 µg/ml G418 
was used for the selection of clones. 
 
 
2.2.5. ES cell electroporation 
ES cells were washed with PBS, trypsinised for 5 minutes at 37 ˚C, added to media 
and centrifuged at 100 x g to pellet the cells. The cells were resuspended in PBS and 
counted.  20 µg of the Mospd 1 targeting vector, linearised with Pme I, was 
electroporated into 3 x 10
7
 cells in a 0.6 ml volume using a BIORAD gene pulser 
electroporator in a cuvette with a gap of 0.5 cm at 0.25 kV and 500 µF-capacitance. 
The electroporated ES cells were plated onto 10 gelatinised 100 mm x 20 mm plates 
in 10 ml ES medium plus LIF for each plate. The media was replaced the following 
day with ES medium plus LIF and 280 ng/ ml G418 in 9 plates. The remaining plate 
did not contain G418 drug selection. Media was replaced every day for 
approximately 10 days, until the drug resistant colonies were ready to be picked. 
Single ES clones were picked into 3 x 96 well gelatinised plates and grown in ES cell 
medium with LIF and G418 selection until most wells were confluent. The plates 
were then triplicate plated. Cells were washed with PBS, 30 µl trypsin solution added 
per well and the cells incubated at 37 ˚C for 5 minutes. 130 µl ES cell media was 
added per well and the cells pipetted to disaggregate clumps of cells. 50 µl of the cell 
mixture was added to the wells of 3 x pre-gelatinised 96 well dishes in the same 
order. 150 µl ES cell media, including LIF and G418, was added to the wells and the 
plates incubated at 37 ˚C until 70-80 % confluent.  One of the triplicate plates was 
frozen with 10 % dimethyl sulfoxide (DMSO) in FCS and stored at – 80 ˚C. The 
remaining two plates were cultured until the wells were confluent to slightly 
overgrown and DNA was isolated from these plates. 
 
 
2.2.6. Transient Cre recombinase expression in ES cells 
5 x10
6
 Mospd 1 targeted ES cells (clone F6), were electroporated under the same 
conditions as above with 25 µg of the pCAGGS-Cre-IRESpuro plasmid (Ian 
Chambers) (Appendix Figure 4). Ten minutes after the electroporation the cells were 
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plated into a gelatinised 75 cm
2 
flask and allowed to recover for 24 hours. The cells 
were then trypsinised and plated out at a range of densities from 100 to 5000 cells 
per gelatinised 10 cm diameter plate to ensure individual clones could be picked 
from plates. The cells were cultured in ES cell medium with LIF and individual 
clones were picked after approximately 5 days. The cells were then triplicate plated, 
one plate frozen and DNA was isolated from the remaining two plates.  
 
 
2.2.7. ES cell self renewal  
500 cells were plated per well in a gelatinised 6 well dish with ES cell medium with 
LIF and left overnight. The following day the media was removed, the cells 
thoroughly washed with PBS and fresh media added to the cells. In half of the wells 
the cells were cultured with LIF and the other half without LIF. After 5 days the 
medium was removed and the cells stained for alkaline phosphatase activity using 
the Alkaline Phosphatase kit (Sigma). The cells were washed with PBS, fixed with 
fixative (67 % acetone, 25 % citrate solution, 8 % formaldehyde) for 30 seconds and 
then rinsed with water. The colour substrate solution (0.02 mM sodium nitrite, 1 
mg/ml Fast Red Violet alkaline solution and 0.8 mg/ ml naphthol AS-BI phosphate) 
was added to the wells and incubated for 15 minutes at room temperature in the dark. 
The cells were rinsed twice with water and the plates allowed to dry.  
 
 
The alkaline phosphatase staining was analysed using an inverted Leitz Labovert 
microscope and the colonies scored as either stem (pink), mixed (pink and white) or 
differentiated (white). Pictures of colonies were taken using a digital camera (Nikon) 











 ES cells were placed in a 20 ml universal tube and the volume made up to 20 
ml with normal ES cell medium including LIF. 10 µl droplets (300 cells per droplet) 
were formed on the lid of square Petri dishes using a multichannel pipette and the lid 
replaced. 15 ml of sterile water was placed in the bottom of the Petri dishes to keep 
the hanging drops hydrated. The cells in the suspension congregate at the bottom of 
the droplet to form an EB. The hanging drops were cultured at 37 ˚C for 2 days and 
then harvested by collecting the hanging drops with a pipette and centrifuging them 
at 80 x g for 3 minutes. The EB pellet was resuspended with 20 ml media and 
transferred into bacteriological dishes (Figure 2.2). Penicillin/streptomycin were 
added to the medium on the day of harvesting the EBs to prevent any bacterial 
contamination. No LIF was added to the medium to allow the cells to differentiate. 
The media was changed every 2 days and the EBs collected for experiments, washed 
with PBS and stored at -80 ˚C. To set up cardiomyocyte assays individual day 5 EBs 
were plated in gelatinised 24 well dishes and observed every day for 10 days to 
check for regions of beating cardiomyocytes. 
 
 
To prepare cells for immunocytochemistry, EBs were disaggregated by incubating 
them in 1 ml of PBS and 1 ml of Dispase including 20 µl DNAse I for 15 minutes 
with gentle shaking. The EBs were then passed through a needle (23 gauge) and 
media added to the cells to neutralise the Dispase. The cells were spun down at 100 x 
g for 5 minutes, plated on gelatinised dishes and incubated at 37 ˚C for 2 days prior 




Figure 2.1: Colonies formed in ES cell self renewal assay. Cells were 
stained for alkaline phosphatase activity A: Undifferentiated colony (stem) 
was pink; B: Mixed colony with pink and white staining C: Differentiated 














Figure 2.2: Differentiation of ES cells into embryoid bodies (EBs). 10 µl 
droplets, containing 300 cells, were formed on the lid of a square Petri dish 
(A) until all 20 ml of media containing ES cells were used to form droplets (B). 
After 2 days the EBs were harvested and cultured in a petri dish (C). D-F 
shows wild type, Mospd 1 null C10 and C11 EBs, respectively (x10 









2.2.9. Differentiation of ES cells into bone 
Hanging drops were set up as described in section 2.2.8. for wild type E14 IV ES 
cells and Mospd 1 null clones C10 and C11. On the day after the EBs were harvested 
the EBS were plated on gelatinised 75 cm
2
 flasks and cultured in ES cell medium 
excluding LIF for 4 days. The cells were lifted by incubation with trypsin for 5 
minutes at 37 ˚C and 5 x 10
4
 cells were plated in each gelatinised well of a 6 well 
culture plate.  6 plates with 2 wells per cell line were set up for each experiment. 
Three biological triplicate experiments were performed. The cells were cultured in 
Alpha MEM (Invitrogen) including 15 % FCS, 0.05mM β-mercaptoethanol, and 2 
mM glutamine. From Day 19 to the end of the experiment (Day 26) the cells were 
cultured with media supplemented with 50 mM β- glycerophosphate, 50 µg/ml 
ascorbic acid and 1 µM dexamethasone.  
 
 
Cells were collected at Day 12, 19 and 26 for RNA extraction and subsequent qPCR 
analysis. At days 12, 19 and 26 one plate was stained to check for differentiation. 
Firstly, cell culture medium was aspirated, the cells washed twice with PBS and 
fixed with ice-cold 70 % ethanol at room temperature for 1 hour. The ethanol was 
removed and the cells washed twice with water and 500 µl/ well 10 mg/ml Alizarin 
Red (Sigma) was added and the plate incubated at room temperature in the dark for 1 
hour. The cells were then washed with PBS for 30 minutes and left to dry overnight. 
All the stained colonies were counted in each of the wells. The 2 wells per cell line 
that had been stained were counted as a technical replicate and each of the three 
biological replicates were counted giving an n =3.    
 
2.2.10. Karyotyping of ES clones 
10 µl/ml KaryoMax (Colcemid, Invitrogen) was added per 25 cm
2
 flask of ES cells, 
to arrest cells at metaphase of mitosis, and incubated at 37 ˚C for 3 hours. The cells 
were then trypsinised, pelletted and resuspended slowly in 8 mls pre-warmed 
hypotonic 0.075 M KCl solution. The cells were incubated at 37 ˚C for 
approximately 12 minutes and 2 ml of fresh fixative (3:1 v/v methanol/ acetic acid 
solution) subsequently added. The cells were re-pelletted, the KCl and fixative 
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treatment repeated a further two times and the cells were dropped onto glass slides. 
The slides were allowed to dry and stored at room temperature. The slides were 
stained with 1 µg/ml DAPI (Sigma) and viewed on a Zeiss Axioskop2 microscope 
using a 63x objective lens. Approximately 30 spreads were photographed using a 
ProgRes C14 camera from Jenoptik and the numbers of chromosomes per cell 
counted.   
 
 
2.2.11. Transfection of DNA into cells 
A pCMV6-AN-GFP vector containing the Mospd 1 gene (Appendix Figure 5) was 
obtained from Origene (USA) and transformed, cultured and DNA obtained.  Mospd 
3 had previously been cloned into the eGFP vector (Appendix Figure 6) by Dr 
Richard Axton in the lab. pEYFP-Nuc and pDSRed2-ER plasmids (Appendix Figure 




To generate GFP- tagged proteins for use in western blots the MOSPD1-GFP and 
MOSPD3-eGFP plasmids were individually transfected into COS 7 cells using 
Lipofectamine 2000 (Invitrogen). On the day prior to transfection 2 x10
5
 cells were 
plated per well of a 6 well dish so that cells were 90-95 % confluent at the time of 
transfection. 4 µg DNA was diluted in 50 µl of media lacking FCS (serum free) 
whilst 10 µl Lipofectamine 2000 was added to 40 µl of serum free medium and 
incubated at room temperature for 5 minutes. The DNA and Lipofectamine 2000 
were mixed together and incubated for 20 minutes at room temperature. The 
DNA/Lipofectamine complexes were added to the cells in 2 ml COS 7 media 
containing 10 % FCS. The following day 3 ml of medium was added to each well 
and the cells incubated at 37 ˚C for a further 2 days. Untransfected COS7 cells and 




 As the human keratinocytes (HaCaTs) were unable to be successfully transfected 
using Lipofectamine 2000 a different transfection agent, Xfect
TM
 (Clonetech), was 
used. On the day prior to transfection 0.5 x10
5
 cells per well of a 24 well dish were 
plated. 1 µg DNA was diluted in 25 µl of Xfect buffer and 0.3 µl of Xfect polymer 
diluted in buffer. The DNA and polymer solution were added to each other, mixed 
thoroughly and incubated at room temperature for 10 minutes. This mixture was 
added to 250 µl media in the wells and the cells incubated at 37 ˚C. After 4 hours the 
media was changed and the cells incubated for a further 2 days.  
 
 
2.2.12. Preparation of cells for immunocytochemistry (cell 
synchronisation) 
Human keratinocytes (HaCaTs) were grown to 70 % confluency and a double 2 mM 
thymidine block was performed to synchronise the cells at S phase. Thymidine was 
added, to a final concentration of 2 mM, to growing HaCaT cultures and incubated 
for 17 hours. The thymidine-containing media was removed, the cells thoroughly 
washed with PBS and fresh medium added for 10 hours. The media was replaced 
with media containing 2 mM thymidine and the cells incubated for a further 17 hours. 
The media was removed and the cells thoroughly washed with PBS and media 
lacking thymidine was added to the cells. Cells collected immediately after the 
second thymidine treatment (time 0), were at S phase. Cells collected at 8, 9 and 11 




2.2.13. Culture of antibody-producing hybridoma cells 
The hybridoma cells were cultured in RPMI-1640 media (Invitrogen) supplemented 
with 10 % heat inactivated fetal calf serum (FCS) and 2 mM L-glutamine. The cells 
were cultured with 100 Units penicillin-100 µg/ml streptomycin. A 75 cm
2
 culture 
flask was set up with individual hybridoma clones and 40 ml of media added. The 
cells were then cultured for 2 weeks at 37 ˚C with 5 % CO2 without changing the 
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media. After 2 weeks the media was collected by pelletting the cells and collecting 
the supernatant. This supernatant, containing either α-MOSPD1 or α-MOSPD3 
antibodies was stored at -20 ˚C and working aliquots at 4 ˚C. Stocks of the individual 
hybridoma clones were increased by freezing 5 x 10
6
 cells in 10 % DMSO in FCS.  
The cells were frozen at – 80 ˚C overnight and then transferred to -140 ˚C for long 
term storage.  
 
 
2.3. Protein Analysis 
  
2.3.1. Generation of mouse monoclonal antibodies  
Monoclonal α–MOSPD1 and α–MOSPD3 specific antibodies were generated by 
Yorkshire Biosciences against chemically synthesised peptides. The MOSPD1 
peptide (MHQQKRQPELVEGNLPVFVF) and MOSPD3 peptide 
(MRRGAPQDQELVGPGAPGRG) were synthesised by Thistle Research, Glasgow. 
Hybridoma clones were pre-screened to determine which clones would be optimal 
for detection of MOSPD1 or MOSPD3. Cell lysates of COS 7 cells, transfected with 
either the MOSPD1-GFP or MOSPD3-GFP plasmid (described in section 2.2.11), 
were used in western blots and blots were probed with the different hybridoma 
clones’ supernatants. Hybridoma clones’ supernatants were also used to probe 
western blots with adult mouse heart tissue lysates and the clones with the fewest 
bands and lowest level of background were chosen for expansion and subsequent use. 
A growing flask of each clone of hybridomas was received, one clone (C9) for α-
MOSPD1 and 2 clones (E1 and E4) for α-MOSPD3.  
 
 
2.3.2. Antibody isotype determination 
A mouse monoclonal antibody isotyping test kit (AbD Serotec) was used to 
determine the isotype of each monoclonal antibody clone. Briefly, the supernatant 
was diluted to approximately 1 µg/ml in 1 % w/v BSA in PBS. 150 µl of this diluted 
supernatant was added to each development tube containing coloured microparticles, 
briefly vortexed and incubated for 30 seconds at room temperature. An isotyping 
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strip was placed into each development tube and after approximately 10 minutes blue 
bands appeared on the strip indicating the heavy and light chain composition. 
  
 
2.3.3. Protein extraction from cells and animal tissues  
The cells were washed with PBS and ice cold RIPA buffer (25 mM tris-HCl, pH 7.6, 
150 mM NaCl, 1 % NP-40, 1 % sodium deoxycholate, 0.1 % SDS) 
(ThermoScientific, UK), containing protease inhibitors (Sigma), added to each well 
and the cells scraped using a cell scraper. The cell lysates were transferred into fresh 
eppendorfs and passed through a 19G needle to shear DNA and reduce the viscosity. 
Mouse tissues were dissected and to remove excess blood were washed in ice-cold 
PBS, containing protease inhibitors. The tissues were homogenised in RIPA buffer, 
containing protease inhibitors, using metal beads in a Retsch MM301 homogeniser 
and subsequently centrifuged to pellet cell debris. The lysate was transferred to a 
fresh tube and sonicated at a setting of 50 % with 4 x 5 second pulses using a Philip 
Harris Scientific sonicator.    The samples were stored at – 20 ˚C. 
 
 
2.3.4. Gel electrophoresis and western blotting 
Protein samples were separated by 1D SDS/ polyacrylamide gel electrophoresis 
(PAGE) on a 12 % Tris-HCl gel (Bio-rad) and run alongside Kaleidoscope 
Prestained standards (Bio-Rad). 10 % (v/v) β-mercaptoethanol (Sigma) was added to 
the protein samples and the samples were heated at 100 ˚C for 5 minutes prior to 
loading. Gels were run at 80 V for approximately 2 hours with 1 x running buffer (25 
mM Tris, 192 mM glycine and 0.1 % SDS) and then semidry electrotransfer onto 
nitrocellulose membranes was performed at 15 V for 1 hour with cold transfer buffer 
(25 mM Tris, 192 mM glycine and 20 % methanol. The blots were then blocked for 1 
hour with 5 % dried milk powder (Marvel) in 1 x TBST (25 mM Tris-HCl, pH 8.0, 
125 mM sodium chloride, 0.1 % Tween 20) before hybridisation with the primary 
antibodies in blocking solution overnight at 4 °C. Table 2.1 lists the concentrations 























α-MOSPD1 1: 100 - α-mouse 
α-MOSPD3 1: 100 - α-mouse 
α-GAPDH 1:2000 Abcam α-mouse 
 
Table 2.1: Antibodies used for western blots. Primary antibodies are listed 
with the concentration the antibody was used at, the manufacturer of the 
antibody and the secondary antibody used for detection. α-MOSPD1 and α-
MOSPD3 antibodies were supernatants  from the antibody producing 












After 3x 15 minute washes in TBST the membranes were incubated with 
Horseradish -conjugated secondary antibody (α-mouse) (1:2000) for 1 hour at room 
temperature. Equal parts of ECL solution A (0.1M Tris pH 8.6, 25 mM luminal, 0.4 
mM coumaric acid) and solution B (0.1 M Tris pH 8.6 and 0.02 % hydrogen 
peroxide) were mixed and added to the western blot which was exposed to light-
sensitive film (Kodak) to visualise the antibody-antigen reactions. 
 
 
2.3.5. Propidium iodide (PI) staining and flow cytometry to 
determine cell cycle stage 
HaCaT cells were washed with PBS, trypsinised to lift the cells off the tissue culture 
flask and 1 x 10
6
 cells collected, washed with PBS, resuspended in 70 % ethanol and 
stored at -20 °C until staining. The cells were pelletted at 400 x g for 5 minutes in a 
4K15 centrifuge (Sigma Laboratory Centrifuges), the pellet was resuspended in 300 
µl propidium iodide (PI) solution (50 µg/ml PI, 100 µg/ml RNAse in PBS) and the 
cells stained for 1 hour at room temperature in the dark. The samples were analysed 
using flow cytometry (BD Facs Calibur) which was carried out under the guidance of 
Shonna Johnston using the flow cytometry facilities at the Centre for Inflammation 
Research, Queen’s Medical Research Institute, University of Edinburgh. 
Unsynchronised cells were used to set the cell cycle stages. The data was analysed 
using FlowJo Flow Cytometry Analysis Software (v7.6.1, Tree Star, Inc., USA). 
 
 
2.3.6. Preparation of tissue sections for 
immunohistochemistry 
Tissues were washed with ice-cold PBS several times to remove excess blood. 
Tissues were fixed with 4 % paraformaldehyde (PFA) overnight at 4 °C and 
transferred to 70 % ethanol and taken to be processed and sectioned by the Histology 
Core of the QMRI on a Leica TP 1050 processor. The tissues were dehydrated in an 
ethanol series, cleared using xylene and embedded in molten paraffin wax. 5 μm 
sections were cut on a paraffin microtome, floated onto a heated water bath and lifted 
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onto superfrost plus microscope slides. Slides were dried in a warm air oven at 50 °C 
overnight.  
 
2.3.7. Immunocytochemistry (ICC) 
 Cells were grown on glass coverslips in 24 well plates, washed with PBS and fixed 
with 4 % PFA in PBS for 10 minutes at room temperature, followed by 3 x 5 minute 
PBS washes.  Samples were incubated with PBS containing 0.1 % Triton X-100 for 5 
minutes to permeabilise the cells. Samples were then washed with 0.001 % Tx-
100/PBS (PBST) and blocked with 5 % donkey serum (Sigma)/PBST for 1 hour at 
room temperature. Isotype controls (IgG2b and IgG1) (Sigma and R&D Systems, 
respectively) served as negative controls. Primary antibodies (listed in Table 2.2) 
were diluted in blocking solution and incubated at 4 °C overnight in a humidified 
chamber. 3 x 5 minute PBST washes were applied to the samples followed by 
incubation with a 1: 200 dilution of secondary antibodies for 1 hour at room 
temperature in the dark. 1μg/ ml DAPI was included with the secondary antibody. 
After 3 x 5 minute PBST washes coverslips were mounted on glass microscope 
slides using a drop of Prolong Gold mounting medium (Invitrogen) and left 
overnight in the dark at room temperature to cure. The slides were subsequently 
stored at 4 °C in the dark.  
 
 
2.3.8. Immunohistochemistry (IHC) 
Sections were dewaxed by incubating the slides in xylene twice for 5 minutes and 
subsequently rehydrated through a series of ethanol (100 %, 95 %, 70 %) washes for 
20 seconds each and the slides then rinsed in tap water. Antigen retrieval was carried 
out by pressure cooking the slides for 5 minutes in 0.01 M citrate buffer (Sigma). 
The slides were rinsed with tap water and the endogenous peroxidases were blocked 
by incubating the slides with 3 % hydrogen peroxide (Sigma) in methanol for 30 
minutes at room temperature. The slides were rinsed with tap water, washed with 
0.05 M Tris buffered saline (TBS). To reduce background caused by endogenous 
mouse IgG, samples were blocked with Rodent Block M (Biocare Medical) for 30 






















α-MOSPD1 4:5 - α-mouse 




1:5 Progen α-mouse 
α-Plakophilin-2 
(Pkp2) 
1:2 Progen α-mouse 
 
Table 2.2: Antibodies used for immunocytochemistry. Primary antibodies 
are listed with the concentration the antibody was used at, the manufacturer 
of the antibody and the secondary antibody used for detection. α-MOSPD1 
and α-MOSPD3 antibodies were supernatants  from the antibody producing 












Sections were blocked with streptavidin (Vector) for 15 minutes at room temperature, 
washed with TBS and blocked with biotin (Vector) for 15 minutes at room 
temperature followed by two 5 minute TBS washes. Primary antibodies were diluted 
in Bond antibody diluent (Leica) and incubated on slides in a humidified chamber 
overnight at 4 °C. 
 
 
The slides were washed twice in TBS for 5 minutes each and mouse on mouse 
polymer HRP (Biocare Medical) added to the slides and incubated for 30 minutes at 
room temperature. The slides were washed twice in TBS for 5 minutes each and 3, 
3’-Diaminobenzidine (DAB) added to the sections. The sections were monitored for 
colour changes and slides washed with tap water after colour developed 
(approximately 2 minutes). The slides were counterstained with haematoxylin, 
dehydrated through an ethanol series (70 %, 95 %, 100 %), treated with xylene and 
mounted in Pertex. The slides were dried and pictures taken on an Olympus AX70 
microscope with an AxioCam HRc camera (Zeiss).    
 
 
2.3.9. Fluorescence microscopy 
Fluorescence microscopy was performed using an Eclipse Ti inverted fluorescence 
microscope (Nikon, Japan) and the software used to collect the images was Velocity 
(Improvision, UK). Confocal microscopy was performed in the Confocal and 
Advanced Light Microscopy (CALM) Facility in the Centre for Inflammation 
Research under the guidance of Shonna Johnston using a Leica TCS SP5 inverted 
confocal laser scanning microscope (Leica, UK). A 63x oil immersion objective was 
used. The 405 Blue Diode Laser was used to visualise DAPI staining, the argon laser, 
at a setting of 30 %, to visualise FITC and AlexaFluor 488 staining and the Helium 
Neon 2 laser for AlexaFluor 594 staining. The percentage of laser output for each 
laser was 70 % for the 405 blue diode, 15 % for the Argon laser and 50 % for the 
Helium Neon 2 laser.  The Leica SP5 confocal microscope is equipped with 3 photo 
multiplier tubes (PMTs) allowing 3 different spectral channels to be recorded at the 
same time.  
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However, as this could result in cross talk the samples were scanned with a 
simultaneous scan of DAPI and AlexaFluor 594 samples and then a sequential scan 
of FITC or AlexFluor 488 samples. The slits of the spectroscopic detection unit can 
also be adjusted to reduce cross excitation of the lasers. Figure 2.3 shows the settings 
of the emission spectrum of DAPI and the secondary antibodies used and slits used 
in confocal experiments. The slits for collection of DAPI were 410-480 nm whilst 
the slits for AlexaFluor 488 were 495-575 nm and for AlexaFluor 594 were 600-765 
nm.  The smart offset was set at 1 % per turn and the final image acquired was an 
average from 2 scans. The image resolution was 1024 x 1024 pixels and the pin hole 
setting was 1 Airy unit. Images were converted to colour and merged using Image J 
(National Institute of Health, USA).  
 
 
2.4. Zebrafish  
 
2.4.1. Zebrafish husbandry 
Wild type Golden zebrafish embryos were maintained in a Z-plex stand alone 
aquarium system (Aquatic habitats, Florida, USA) in the Queen’s Medical Research 
Institute, University of Edinburgh Zebrafish Facility and raised and maintained 
according to Lawrence, 2007. The golden strain has a defect in melanocyte 
development and is, therefore, less pigmented and useful for observing early organ 
development in vivo. For the purposes of the project the golden strain was used as a 
wild type strain. Zebrafish were kept in a 14 hour light 10 hour dark cycle. The adult 
zebrafish were fed twice daily with commercial zebrafish diet (ZM-300, Advanced 




2.4.2. Collection of zebrafish embryos (marbling) 
Zebrafish were marbled (according to Westerfield, 2007) and the embryos collected 








Figure 2.3: Confocal microscope settings.  A: Settings for Scan 1, the 
simultaneous scan of DAPI and AlexaFluor 594 samples with the laser output 
for the 405 blue diode laser at 70 % and 50 % for the Helium Neon 2 laser. B: 
Scan 2, the sequential scan of FITC or AlexFluor 488 samples with the laser 
output for the Argon laser at 15 %. The slits for collection of DAPI were 410-
480 nm, for FITC or AlexaFluor 488 were 495-575 nm and for AlexaFluor 594 
were 600-765 nm to prevent cross excitation and emission.   
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The light induces the zebrafish to mate and the female fish lay their eggs in the 
marbles which are then fertilised by the male fish. The embryos fall through the 
mesh and are collected in the bottom container. The collected embryos were then 
placed in a petri dish containing water with dilute methylene blue, which prevents 
bacteria and fungal colonisation of the water. A maximum of 60 embryos were 
placed per petri dish and embryos were maintained at 28.5 ˚C in order to allow them 
to develop normally. Embryos can be incubated for 5 dpf for experimental use 
without the requirement of a Home Office Animal License.   
 
 
2.4.3. Morpholino design 
An anti-sense morpholino against the Start (ATG) site of the zebrafish Mospd 1 gene 
(MO1) as well as a second morpholino targeted to the splice junction between exons 
2 and 3 (MO2) were designed. 5 mispair controls for both the start morpholino and 
the splice-site morpholino were also designed to serve as negative controls.  All 
morpholinos were synthesised by Gene tools (Oregon, USA). The morpholino 
sequences used are listed in Appendix Table 6). The morpholinos were 3’ labelled 
with FITC to monitor for the oligonucleotide in injected embryos. 
 
 
2.4.4. Morpholino injection procedure 
The microinjection of newly fertilised eggs was performed at the 1-16 cell 
developmental stages using a Narishige IM300 Microinjector at an approximate 
injection pressure of 16 psi. Figure 2.4A shows the injection set up.  A 1mm 
graticule with 0.01 mm divisions (Pyser-SGI Limited) was used to determine the 
bolus size of morpholino injected (Figure 2.4 B). The amount of morpholino injected 
was determined by using the radius of the injected bolus to calculate the volume of a 
sphere and then using the concentration of the injected morpholino.  
 







Figure 2.4: Injection of zebrafish embryos. A: the microscope and injection 
set up in the Zebrafish Facility. B indicates how the bolus size is determined 
by injecting the morpholino (phenol used in this picture to illustrate bolus size 
more clearly) into a drop of mineral oil placed on a graticule. C: the position 
of the needle in the zebrafish embryo when injecting the morpholino into the 
cytoplasmic streaming region (10x magnification). Pictures were taken with 
the assistance of Dr Carl Tucker.  
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Therefore, a bolus with a radius (r) of 0.05 mm resulted in a 0.5 nl volume of 
morpholino per injection. To increase the amount of morpholino injected to 1 nl two 
bursts of morpholino were injected. As both the concentration and the molecular 
weight of the morpholino were known the mass of morpholino injected could be 
accurately determined. Differing doses of morpholino (1 ng- 6ng per embryo) were 
injected into the cytoplasmic streaming region of embryos (Figure 2.4C). Embryos 
were screened with a Leica Fluo
TM 
fluorescence microscope (Leica Microsystems 
Ltd) to determine injection success and even distribution of the morpholino within 
the embryo. Embryos were checked at approximately 3-5 hours post injection to 
determine death or axis damage due to injection damage and these embryos removed.  
 
 
2.4.5. Analysis of phenotype 
Chordin knockdown experimental embryos were checked at 28 hours post 
fertilisation (hpf) for the published chordin phenotype (Nasevicius and Ekker, 2000). 
Zebrafish embryos were examined at 1, 2 and 3 days post fertilisation (dpf) for the 
Mospd 1 morpholino experiments and some experiments were monitored until 
embryos were 5 dpf. The survival of the embryos was checked every day. The 
embryos were checked for body shape, presence of a heartbeat, circulation and any 
abnormalities, such as oedema, blood pooling and any morphological differences 
noted. The embryos were defined as normal if they resembled a wild type non-
injected control, of mild phenotype if they had reduced circulation or body shape and 
severe if oedema, blood pooling, reduced heart beat and altered cardiac morphology 
and no circulation was present. Embryos were collected for RNA extraction and 
histology.   
 
 
2.5. Data analysis 
Quantifiable data was graphed and analysed using GraphPad Prism (version 5.00 for 
Windows, GraphPad Software, San Diego, California, USA). Analysis was 















CHAPTER  3: EXPRESSION AND LOCALISATION OF 




The only clue to the possible function of MOSPD1 came from a gene trap integration 
into the closely-related Mospd 3 gene. There was 50 % neonatal lethality in 
homozygote nulls and Mospd 3 was thought to play a role in the development of the 
right ventricle of the heart as neonate mice homozygous for the gene trap displayed a 
right ventricle defect characterized by a thinning of the right ventricle wall. This 
phenotype was lost upon backcrossing and it was hypothesized that there may be 
another genetic modifier (Pall et al., 2004). As Mospd 1 is highly similar in structure 
and sequence to Mospd 3 the loss of the cardiac phenotype could be due to genetic 
redundancy between Mospd 1 and Mospd 3. The sub-cellular localization of the 
MOSPD proteins could give clues to their function and whether they could be 
genetically redundant as if MOSPD1 and MOSPD3 are not co-localised than they 
cannot be redundant.  
 
 
Mospd 1 and Mospd 3 have been shown to be expressed in a wide variety of tissues 
(Katrin Buerger, PhD thesis, 2009) by RT- PCR and in situ hybridisation. However, 
there is no information on their sub-cellular localisation. To determine whether these 
proteins were localized to cellular junctions, and therefore, possibly involved in 
desmosome structure and maintenance of tissue integrity, their sub-cellular 
localisation would need to be determined. There are no reported findings on the 
localisation of either MOSPD1 or MOSPD3 using antibodies against these proteins.  
 
 
Studies using recombinant proteins can be useful to providing an idea of the 
localisation of the protein. A recent publication describes the localisation of 
MOSPD1-His transfected into MC3T3-E1 cells (Thaler et al., 2010). Full length 
MOSPD1-HIS localised to the cytoplasm, including the ER and perinuclear region, 
whilst a shorter version lacking the last exon of MOSPD1 localised to the nucleus. 
This could be due to a putative Nuclear Export Signal (NES) in the last exon of 
MOSPD1 due to the presence of the residues leucine, isoleucine, threonine and 
methionine  (Thaler et al., 2010). We used recombinant a MOSPD1-GFP fusion 
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protein and MOSPD3 tagged with Enhanced-GFP (MOSPD3-GFP) to do preliminary 
studies on MOSPD1 and MOSPD3.   
 
 
Specific antibodies are essential tools to investigate the sub-cellular localisation and 
tissue distribution of proteins. Peptides were designed to the 20 amino acids at the N 
terminal of either MOSPD1 or MOSPD3 and were designed to be specific to each. 
These peptides were synthesized by Thistle Research, and used to generate 
polyclonal antibodies against MOSPD1 and MOSPD3. These antibodies did not 
cross-react when tested on recombinant MOSPD1 and the MOSPD3-GFP fusion 
protein. However, when these polyclonal antibodies were used to test for endogenous 
MOSPD1 and MOSPD3 in mouse tissues there was a very high level of background 
making these antibodies unsuitable for use in determining the sub-cellular 
localisation and tissue distribution of MOSPD1 and MOSPD3 (Katrin Buerger, PhD 
thesis, 2009).   
 
 
Antibodies that were more specific and would result in less background were 
required for use in immunochemistry. Monoclonal antibodies are more specific as 
they are generated from a single B-cell clone fused to a myeloma cell line to form a 
hybridoma cell line (Nelson et al., 2000). Supernatant from these hybridoma cell 
cultures can be used as a source of monoclonal antibodies. These monoclonal 
antibodies can then be used to assess protein distribution, localisation and to identify 
interacting proteins using various immunological techniques such as western blotting, 
immunocytochemistry and co-immunoprecipitation.  
 80 
3.2. Aims 
To test whether MOSPD1 and MOSPD3 could be genetically redundant: 
 Assess the sub-cellular localisation of recombinant MOSPD1-GFP and 
MOSPD3-GFP 
 Generate and test the tools required (monoclonal antibodies) 
o Generate specific monoclonal α-MOSPD1 and α-MOSPD3 antibodies. 
o Test the specificity of these monoclonal α-MOSPD1 and α-MOSPD3 
antibodies using recombinant MOSPD1 and MOSPD3  
o Determine if the monoclonal antibodies could detect endogenous 
MOSPD1 and MOSPD3 by western blotting. 
 Assess the sub-cellular localisation of MOSPD1 and MOSPD3 to determine 
whether they localised to the same cellular compartments 
o in vitro using immunocytochemistry (ICC) on human keratinocytes 
(HaCaTs). 
o in vivo using immunohistochemistry (IHC) on mouse tissue sections 




3.3.1. Localisation of recombinant MOSPD1-GFP and 
MOSPD3-GFP 
To determine the localisation of recombinant MOSPD1 and MOSPD3 plasmids 
encoding MOSPD1-GFP and MOSPD3-GFP were transiently transfected into 
HaCaTS. A pCMV6-AC-GFP plasmid with the open reading frame of the Mospd 1 
gene cloned into it encoded MOSPD1-GFP (Origene) (Appendix Figure 5) whilst a 
pEGFP plasmid with the Mospd 3 gene encoded  MOSPD3-GFP (Dr Richard Axton, 
University of Edinburgh) (Appendix Figure 6). Not all cells expressed the transfected 
plasmids as transfection efficiency was only about 50 %. MOSPD1-GFP was 
localised throughout the cell, including the nucleus and cytoplasm whereas two 
distinct patterns of MOSPD3-GFP expression were observed, one where it was 
throughout the cell, like MOSPD1-GFP, and second some cells appeared to have 
more prominent MOSPD3-GFP expression in the cytoplasm compared to the nucleus 
as well as enhanced perinuclear localisation (Figure 3.1).  
 
 
3.3.2. Strategy and testing of monoclonal α –MOSPD1 and α –
MOSPD3 antibodies 
 
3.3.2.1. Generation of mouse monoclonal antibodies  
MOSPD1 and MOSPD3 share 38 % sequence homology and similar protein 
structure. They both have an MSP domain in the N terminal, two transmembrane 
domains in the C terminal and a putative Nuclear Export Signal (NES) (Figure 3.2 A 
and C). As these proteins are closely related any antibodies generated to test for their 
localisation would need to be designed so as not to cross-react. Peptides were 
designed by Thistle Research UK to correspond to the 20 amino acids at the N 
terminal of MOSPD1 and MOSPD3 (Figure 3.2 B and D) as this region has the least 






Figure 3.1: MOSPD1-GFP and MOSPD3-GFP localisation in HaCaTs. 
Cultured HaCaTs transfected with a MOSPD1-GFP plasmid and a MOSPD3-
GFP plasmid transiently expressed MOSPD1-GFP (A) and MOSPD3-GFP 




























Figure: 3.2: Strategy to generate specific α-MOSPD1 and α-MOSPD3 
monoclonal antibodies by specific peptides. A: Schematic representation 
of MOSPD1. B: Protein sequence of MOSPD1. C: Schematic representation 
of MOSPD3. D: Protein sequence of MOSPD3. Both proteins have an N 
terminal MSP domain (blue) and 2 C-terminus transmembrane domains (TM) 
(green). A putative Nuclear Export Signal (NES) (purple) is located in the last 
TM domain. The red lines in A and C show the relative position of the specific 
peptides used to generate the antibodies whilst the sequence is shown in the 
red box (C and D).   
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This should result in specific antibodies being generated against MOSPD1 and 
MOSPD3 which do not cross react. The peptide sequences were conjugated to the 
Keyhole Limpet Hemocyanin (KLH) carrier protein, by Thistle Research UK, which 
aids in eliciting an immunogenic response. These conjugated peptides were sent to 
Yorkshire Biosciences and used to generate monoclonal antibodies against MOSPD1 
and MOSPD3. The conjugated peptides were inoculated into Balb/c mice. Tail 
bleeds and enzyme linked immunosorbent assay (ELISA) was used to select optimal 
mice showing an immunogenic response to the peptides. The B cells were removed 
from splenocytes or lymph node cells and fused to SP2/0 myeloma cells to form 
hybridomas. ELISA was then used to screen hybridoma clones to select highly 
positive clones which were then expanded, supernatant collected for further analysis 
of the monoclonal antibodies and cells frozen and stored.   
 
 
3.3.2.2. Testing the specificity of α-MOSPD1 and α-MOSPD3 
antibodies 
As the α-MOSPD1 and α-MOSPD3 antibodies were going to be used to analyse the 
expression and sub-cellular localisation of MOSPD1 and MOSPD3 and these 
proteins share high sequence similarity western blot analysis was performed to assess 
whether the monoclonal α-MOSPD1 and α-MOSPD3 antibodies cross-react. The 
predicted size of MOSPD1 is 24 kDa and of MOSPD3 is 25 kDa whilst GFP is 27 
kDa so the recombinant MOSPD1-GFP and MOSPD3-GFP fusion proteins, whose 
localisation was described in Section 3.3.1., are expected to be 51 kDa and 52 kDa, 
respectively. Western blots probed with the monoclonal α-MOSPD1 antibody 
showed a protein band (~50 kDa) in the MOSPD1-GFP fusion over expressed COS7 
lysate but not in the un-transfected or MOSPD3-GFP sample (Figure 3.3). α-
MOSPD3 detected the over expressed MOSPD3-GFP fusion protein (~50 kDa) but 
not the MOSPD1-GFP fusion protein. The α-GFP antibody detected the MOSPD3-
GFP band and eGFP band (~25 kDa) from over expression of the eGFP vector but 
not the MOSPD1-GFP fusion protein as this is turbo-GFP, which is from the 
Copepod Pontellina plumata, and is not sufficiently similar to eGFP, from the 








Figure 3.3: Western blot analysis to assess cross-reactivity between 
monoclonal α-MOSPD1 and α-MOSPD3 antibodies. The antibodies were 
tested on lysates from un-transfected COS7 cells and lysates from COS7 
cells transfected with plasmids expressing MOSPD3-GFP (52 kDa), 
MOSPD1-GFP (51 kDa) or GFP (27 kDa). The western blots were probed 




The western blots were probed with α-GAPDH to serve as a loading control. These 
experiments, therefore, confirmed that the monoclonal α-MOSPD1 and α-MOSPD3 
antibodies are specific and do not cross-react.    
 
 
3.3.2.3. Testing whether endogenous MOSPD1 and MOSPD3 
could be detected using the mouse monoclonal antibodies 
Previously generated polyclonal antibodies showed high levels of non-specific 
background staining on western blots (Katrin Buerger, PhD thesis, 2009). As a result 
the polyclonal antibodies were unsuitable for investigating the expression and 
localisation of MOSPD1 and MOSPD3 in cells and tissues. It was therefore, 
important we tested whether the mouse monoclonal α-MOSPD1 and α-MOSPD3 
antibodies could detect specific endogenous MOSPD1 and MOSPD3, respectively.  
 
 
To do this adult mouse heart tissue lysate was tested by western blot using the 
monoclonal antibodies as the primary antibodies (Figure 3.4). A band was observed 
that was the predicted size of MOSPD1 (24 kDa) in the heart sample incubated with 
the α-MOSPD1 antibody and a band the predicted size of MOSPD3 (25 kDa) was 
observed in the heart sample incubated with α-MOSPD3. Bands of 50 kDa and 75 
kDa were also observed in the heart cell lysates.  However, as the western blot 
membrane probed only with secondary α-mouse antibody also detected a 75 kDa 
band this band is likely due to non-specific background. The 50 kDa band was not 
detected by secondary antibody alone and was possibly a dimer due to it being 
double the size of MOSPD1 or MOSPD3. However, as only one band, of 51 kDa, 
was observed in western blots of MOSPD1-GFP and MOSPD3-GFP (Figure 3.3), it 
indicates that these MOSPD proteins may not dimerise. If they did, you would expect 
to observe an additional 102 kDa band from the dimerised GFP-tagged proteins on 
the western blot. Wild type E14 IV ES cell lysate was used as a negative control and 
no bands were observed in the ES cell lysates in either the α-MOSPD1 or α-
MOSPD3 blots. α-GAPDH was used as a loading control and detected bands of 36 















Figure 3.4: Detection of endogenous MOSPD1 and MOSPD3 by western 
blotting using monoclonal α-MOSPD1 and α-MOSPD3. Lysates of 
undifferentiated ES cells and adult mouse heart were probed with secondary 
antibody only (A), monoclonal α-MOSPD1 (B), to detect MOSPD1 (24 kDa), 
α-MOSPD3 (C), to detect MOSPD3 (25 kDa), and α-GAPDH (D) was used 









As the western blots showed little background staining it was hoped the monoclonal 
antibodies could be used for immunohistochemistry to determine the sub-cellular 
localisation of MOSPD1 and MOSPD3. However, if the 50 kDa band observed is not 
due to a MOSPD dimer then it would be due to the monoclonal antibodies detecting 
a non-specific protein. This would call into question any results from 































3.3.3. Sub-cellular localisation of MOSPD1 and MOSPD3 
 
3.3.3.1. Determination of whether monoclonal α-MOSPD1 and 
α-MOSPD3 antibodies were suitable for localisation studies 
Testing for MOSPD1 and MOSPD3 expression in ES cells by western blots of ES 
cell lysates using the monoclonal α-MOSPD1 and α-MOSPD3 antibodies indicated 
that ES cells did not express MOSPD1 and MOSPD3 (Figure 3.4).  Mospd 1 null ES 
cells (described in Chapter 5) were chosen as the negative control for 
immunofluorescence detection of MOSPD1. α-MOSPD1 did not detect any 
MOSPD1 expression and α-MOSPD3 did not detect any MOSPD3 expression in 
these ES cells (Figure 3.5). These results indicated that both α-MOSPD1 and α-
MOSPD3 antibodies did not detect any background staining and would be suitable 
for detection of endogenous MOSPD1 and MOSPD3 expression in cells expressing 
these proteins, such as the human keratinocytes (HaCaTs).   
 
 
3.3.3.2. In vitro determination of the sub-cellular localisation 
of MOSPD1  
Given that we hypothesised that the MOSPD proteins might be localised to 
desmosomes, we tested the localisation of a known desmosome component, PKP2, 
which was localised to cell junctions (Figure 3.6) of HaCaTs. Under the same growth 
conditions and immunocytochemistry (ICC) protocol MOSPD1 was localised to the 
nuclei of cells (Figure 3.7). MOSPD1 is not localised to the cell junctions and does 
not have the same sub-cellular localisation of PKP2. In the majority of HaCaT cells 
MOSPD1 was predominantly localised to the nucleus and appears to be absent from 
the nucleoli. The IgG2b isotype control was used as a negative control for the ICC 
experiments investigating MOSPD1 localisation. However, we noted different sub-
cellular localisation in cells that appeared to be dividing so further investigated 


















Figure 3.5: Negative control for immunofluorescence with monoclonal 
α-MOSPD1 and α-MOSPD3 antibodies. Immunofluorescence was carried 
out on Mospd 1 null ES cells to check for MOSPD1 (B) and MOSPD3 (E) 
expression. DAPI was used to stain the nuclei (A and D). Merged images of 
MOSPD1 and DAPI (C) and MOSPD3 and DAPI (F) are shown. Scale bar = 



























Figure 3.6: Plakophilin 2 (PKP2) localisation in desmosomes. Cultured 
HaCaTs were immunolabelled with an antibody against PKP2 (B) and DAPI 
was used to stain the nuclei (A). A merged image of PKP2 and DAPI (C) is 


























Figure 3.7: Nuclear localisation of MOSPD1. Cultured HaCaTs were 
immunolabelled with either the IgG2b isotype control (B) or the monoclonal 
α-MOSPD1antibody (E). DAPI was used to stain the nuclei (A and D). 
Merged images of IgG2b and DAPI (C) and MOSPD1 and DAPI (F) are 






3.3.3.3. In vitro determination of the sub-cellular localisation 
of MOSPD3  
Like MOSPD1, MOSPD3 was localised to the nuclei of cells. However, MOSPD3 
was also localised to the cytoplasm of cells (Figure 3.8). There was no evidence of 
MOSPD3 being localised to desmosomes or cell junctions as the sub-cellular 
localisation differed to that of PKP2. Again the sub-cellular localisation appeared to 
be different in cells undergoing cell division.   
 
 
3.3.3.4. MOSPD1 and MOSPD3 localisation changes 
depending on the cell cycle stage 
As there was a hint of cell division altering the sub-cellular localisation of MOSPD1 
and MOSPD3 and there were few cells undergoing cell division (mitosis) in 
unsynchronised cells an increase in the number of cells undergoing mitosis was 
required to try and investigate whether MOSPD1 and MOSPD3 localisation changed 
depending on the cell cycle stage. Cells were synchronised by blocking the cells at S 
phase of the cell cycle by two blocks of 2 mM thymidine for 17 hours each. Cells 
collected when the thymidine was removed (time 0) corresponded to S phase as 
shown by PI staining. Cells were also collected at 8 hours, 9 hours and 11 hours post 
thymidine removal and these time points should increase the number of cells at G2 
phase, M phase and G1 phase, respectively. PI staining showed that synchronicity 
was lost at later time points (Figure 3.9 A).  
 
 
Four views of the cells were randomly selected on the microscope at a magnification 
of x40 and the protein localisation was determined in at least 100 cells. MOSPD1 
localisation changed in the hours post thymidine removal (Figure 3.9 B and Figure 
3.10). At 0 hours post thymidine removal 47 % of cells showed MOSPD1 staining in 
the nuclei (Figure 3.7), 26 % in a perinuclear region and 27 % nuclear and 















Figure 3.8: Nuclear and cytoplasmic localisation of MOSPD3. Cultured 
HaCaTs were immunolabelled with either the IgG1 isotype control (B) or the 
monoclonal α-MOSPD3 antibody (E). DAPI was used to stain the nuclei (A 
and D). Merged images of IgG1 and DAPI (C) and MOSPD3 and DAPI (F) 
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Figure 3.9: Localisation of MOSPD1 and MOSPD3 during the cell cycle. 
A: PI staining to determine cell cycle stage. The percentage of cells showing 







Figure 3.10: Localisation of MOSPD1 changes depending on the cell 
cycle. Cultured HaCaTs were immunolabelled with the monoclonal α-
MOSPD1antibody (B, E and H) or the Ig2b isotype control (K). DAPI was 
used to stain the nuclei (A, D, G and J). Merged images of MOSPD1 and 
DAPI (C, F and I) and IgG2b and DAPI (L) are shown. The arrows indicate 




By 8 hours post thymidine removal the percentage of cells with MOSPD1 in the 
nucleus had been reduced to 9 % with 37 % showing perinuclear staining and 37 % 
nuclear and perinuclear localisation. At this time there were also 6 % of cells with 
MOSPD1 in the nucleus and cytoplasm and 11 % with cytoplasmic staining only 
(Figure 3.9 B and 3.10 E, F, H and I), corresponding to dividing cells. At 9 hours 
post thymidine removal 5 % cells showed nuclear MOSPD1, 22 % perinuclear, 31 % 
nuclear and perinuclear, 4 % nuclear and cytoplasmic and 38 % cytoplasmic 
(dividing cells). By 11 hours post thymidine removal 73 % of cells showed MOSPD1 
localised to the nucleus, 7 % to the nucleus and perinuclear region. 12 % of cells 




MOSPD3 localisation differed between non-dividing and dividing cells. Non-
dividing cells showed MOSPD3 localised to the nucleus and cytoplasm whilst 
dividing cells showed MOSPD3 localised to the cytoplasm and not with the 
condensed chromatin (Figure 3.8). In cells synchronised with 2 mM thymidine 
100 % of cells at time O (S phase) showed MOSPD3 localised to the nucleus and 
cytoplasm. By 8 hours post thymidine removal 90 % of cells showed nuclear and 
cytoplasmic MOSPD3 whilst 10 % showed cytoplasmic staining. At 9 hours post 
thymidine removal 47 % of cells had MOSPD3 localised to the nucleus and 53 % to 
the cytoplasm. At 11 hours post thymidine removal 86 % of cells showed MOSPD3 
in the nucleus and cytoplasm and 14 % in the cytoplasm (Figure 3.9 C). Cells 
showing MOSPD3 localised to the cytoplasm were all observed to be undergoing 
cell division and the majority of these were observed at 9 hours post thymidine 
removal which showed the most cells undergoing mitosis (M phase).  
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3.3.4. MOSPD1 and MOSPD3 expression in vivo 
 
3.3.4.1. In the keratinocytes of the adult mouse ear 
The mouse ear was chosen as a source of keratinocytes to explore if MOSPD1 and 
MOSPD3 had the same sub-cellular localisation in vivo as they had in vitro in the 
HaCaTs. MOSPD1 was localised to the nuclei of the keratinocytes of the mouse ear 
and other nuclei in the ear (Figure 3.11B). There was also expression of MOSPD1 in 
the nuclei and cytoplasm of the sebaceous gland. In comparison MOSPD3 was 
expressed in the cytoplasm and nuclei of the keratinocytes in the mouse ear as well 
as the sebaceous gland (Figure 3.11 D). There were some nuclei in the cells of the 
mouse ear that were negative for MOSPD3 expression. It can, therefore, be 
concluded that MOSPD1 and MOSPD3 have the same localisation in vivo in 
keratinocytes as in vitro. The IgG2b and IgG1 isotype controls (Figure 3.11 A and C) 
were used as negative controls for MOSPD1 and MOSPD3 expression, respectively, 
and these showed no specific staining.  
 
 
3.3.4.2. MOSPD1 and MOSPD3 in the adult mouse heart 
MOSPD1 and MOSPD3 showed similar localisation in the adult mouse heart. Both 
MOSPD1 and MOSPD3 were expressed in cardiomyocytes as well as the endothelial 
cells of blood vessels (Figure 3.12 B and 3.12 D). Both proteins were predominantly 
expressed in the nuclei of cardiomyocytes but both showed a low level in the 
cytoplasm. MOSPD1 and MOSPD3 were also expressed in the cytoplasm of 
endothelial cells. Both the IgG2b and IgG1 isotype controls were negative for any 
specific staining (Figure 3.12 A and C). Confirmation of MOSPD1 and MOSPD3 
expression in endothelial cells was done using RT-PCR and immunocytochemistry 













Figure 3.11: MOSPD1 and MOSPD3 localisation in the cells of the adult 
mouse ear. Sections of adult mouse ear were immunolabelled with the 
monoclonal α-MOSPD1 (B) or α-MOSPD3 (D) antibody. The IgG2b (A) and 
IgG1 (C) isotype controls served as negative controls. The sebaceous gland 





















Figure 3.12: MOSPD1 and MOSPD3 localisation in the cells of the adult 
mouse heart. Sections of adult mouse heart were immunolabelled with the 
monoclonal α-MOSPD1 (B) or α-MOSPD3 (D) antibody. The IgG2b (A) and 
IgG1 (C) isotype controls served as negative controls. Cardiomyocyte nuclei 








3.3.4.3. MOSPD1 and MOSPD3 in the adult mouse kidney 
MOSPD1 was localised to the nucleus and cytoplasm of the cortex and medulla of 
the adult mouse kidney. The tubular epithelium (Figure 3.13 B and Figure 3.14 A) 
shows MOSPD1 in the nuclei and cytoplasm. MOSPD1 is localised to some but not 
all the nuclei in the Bowman’s Capsule.  The IgG2b isotype control did not show any 
specific staining (Figure 3.13 A).  
 
 
The localisation of MOSPD3 in the kidney was different to that of MOSPD1. 
MOSPD3 was localised to the apical brush border of the proximal convoluted tubule 
epithelium and the apical border of the parietal epithelium of the Bowman’s Capsule. 
The apical cytoplasm of the distal convoluted tubule epithelium and the nuclei of the 
proximal tubular epithelium also showed MOSPD3 staining. The nuclei outside of 
the tubules were negative for MOSPD3 expression (Figure 3.13 D and Figure 3.14 
B). The IgG1 isotype control served as a negative control (Figure 3.13 C). Figure 
3.14 shows the localisation of MOSPD1 (A) and MOSPD3 (B) at higher 
magnification.    
 
 
3.3.4.4. MOSPD1 and MOSPD3 in skeletal muscle 
MOSPD1 was localised to most of the nuclei in the skeletal muscle. However, there 
were a few nuclei negative for MOSPD1 staining. There was also cytoplasmic 
staining of the muscle cells with strong expression observed in the muscle striations 
(Figure 3.15 B). Blood vessels were also positive for MOSPD1 expression (data not 
shown). There was some non-specific background staining in the IgG2b isotype 
control but no staining in the nuclei (Figure 3.15 A).  MOSPD3 was localised to the 
cytoplasm of the muscle with strong staining of the muscle striations observed. The 
nuclei were absent for MOSPD3. A blood vessel shown in the figure was also 
positive for MOSPD3 expression (Figure 3.15 D). The IgG1 isotype control showed 










Figure 3.13: MOSPD1 and MOSPD3 localisation in the cells of the adult 
mouse kidney. Sections of adult mouse kidney were immunolabelled with 
the monoclonal α-MOSPD1 (B) or α-MOSPD3 (D) antibody. The IgG2b (A) 
and IgG1 (C) isotype controls served as negative controls. The tubular 
epithelium, apical border of the proximal convoluted tubule epithelium and 
the Bowman’s Capsule are indicated with arrows. Scale bar = 20 µm. 
Pictures were labelled with the assistance of Dr David Brownstein (University 











Figure 3.14: MOSPD1 and MOSPD3 localisation in the adult mouse 
kidney (higher magnification). Higher magnification of immunolabelled 
sections of adult mouse kidney showing the localisation of MOSPD1 (A) and 
MOSPD3 (B). The tubular epithelium, apical border of the proximal 
convoluted tubule epithelium and the Bowman’s Capsule are indicated with 
arrows. Scale bar = 20 µm. Pictures were labelled with the assistance of Dr 











Figure 3.15: MOSPD1 and MOSPD3 localisation in skeletal muscle. 
Sections of adult mouse skeletal muscle were immunolabelled with the 
monoclonal α-MOSPD1 (B) or α-MOSPD3 (D) antibody. The IgG2b (A) and 
IgG1 (C) isotype controls served as negative controls. The muscle striations, 
a blood vessel and nuclei are labelled and indicated with arrows. Scale bars 







3.3.5. MOSPD1 and MOSPD3 localisation in sub-cellular 
compartments 
 
3.3.5.1 MOSPD1 and MOSPD3 localisation in the nucleus 
A pEYFP-Nuc plasmid (nuc-YFP) (Clontech) (Appendix Figure 7), with three 
nuclear localisation signals (NLS) of the simian virus 40 large T antigen fused to the 
C terminus of YFP, was transiently transfected into HaCaTs to label the nuclei. The 
localisation of MOSPD1 and MOSPD3 was determined using the monoclonal 
antibodies against each in the cultures transfected with nuc-YFP. This served to 
confirm the co-localisation of MOSPD1 and MOSPD3 with DAPI observed in 
HaCaTs (Figures 3.7 and 3.8). MOSPD1 co-localised with nuc-YFP in cells (yellow) 
that expressed the plasmid (Figure 3.16 A-C). Due to the transfection efficiency 
being less than 100 % not all the cells expressed nuc-YFP. Cells that did not express 
the plasmid only showed MOSPD1 expression (red) showing there was no cross-
excitation of fluorescence. MOSPD3 also co-localised with nuc-YFP expression in 
the nucleus (yellow) but only MOSPD3 expression (red) was observed in the 
cytoplasm of cells with nuc-YFP, as expected, as well as in the nucleus and 
cytoplasm of cells not expressing nuc-YFP (Figure 3.16 D-F). This again showed 
that there was no cross-excitation of fluorescence signal.  
 
 
3.3.5.2 MOSPD1 localisation in the ER 
MOSPD1 observed to be localised to the perinuclear region in some cells (Figure 
3.10 B) could be due to localisation to the ER. To determine whether this was the 
case a pDSRed2-ER plasmid (Clontech) (Appendix Figure 8), with the ER targeting 
sequence from calreticulin fused to the 5’ end of DSRed2,  was transiently 
transfected into unsynchronised HaCaTs and the monoclonal α-MOSPD1 antibody 
used to detect the localisation of MOSPD1. Nuclear MOSPD1 (green) was not co-
localised with the DSRed-ER expression (Figure 3.17 A-C) but perinuclear 













Figure 3.16: MOSPD1 and MOSPD3 co-localisation with nuc-YFP. 
Cultured HaCaTs transfected with a nuc-YFP plasmid transiently expressed 
nuc-YFP (A and D). The localisation of MOSPD1 (B) and MOSPD3 (E) was 
assessed using the monoclonal α-MOSPD1 and α-MOSPD3 antibodies and 
AlexaFluor594 secondary antibody (red). Merged images of nuc-YFP and 
MOSPD1 (C) and nuc-YFP and MOSPD3 (F) are shown.  The cells labelled 
with a * indicate cells that do not express nuc-YFP as transfection efficiency 




















Figure 3.17: MOSPD1 localisation with pDSRed2-ER. A pDSRed2-ER 
plasmid transfected into unsynchronised HaCaTs transiently expressed ER-
DSRed (A and D) in some cells (red). As transfection efficiency was less than 
100 % not all cells expressed DSRed-ER. The localisation of MOSPD1 (B 
and E) was assessed using the monoclonal α-MOSPD1 antibody and 
AlexFluor488 secondary antibody (green). DSRed-ER and MOSPD1 merged 










The localisation of recombinant MOSPD1-GFP reported in this Chapter differed to 
that reported by Thaler et al. (2010) who reported that full length recombinant 
MOSPD1 tagged with HIS was localised to the ER and removal of the last exon of 
MOSPD1 resulted in MOSPD1 localisation in the nucleus. They postulated that this 
could be due to a putative nuclear export signal (NES) located in the last exon. I 
found that full length MOSPD1-GFP was localised in the cytoplasm and nuclei of 
transfected cells.  
 
 
The differences between Thaler et al. (2010) and my findings may be due to 
differences in the plasmids encoding the Mospd 1 gene that were transfected and, 
therefore, differences in the recombinant MOSPD1 proteins.  Whilst both 
recombinant proteins have C terminal tags, GFP in the recombinant MOSPD1 
reported in this chapter and HIS in Thaler et al. (2010), the two tags differ in their 
size as GFP is 27 kDa and a HIS tag does not add more than 1 kDa  to the size of the 
protein. Another possible explanation for the difference in recombinant MOSPD1 
localisation is that the localisation of MOSPD1-GFP in transfected keratinocytes is 
reported in this chapter whereas Thaler et al. (2010) reported recombinant MOSPD1-
HIS localisation in transfected MC3T3-E1 cells. Keratinocytes are epithelial cells 
whilst MC3T3-E1 cells are an osteoblastic cell line and, therefore, mesenchymal and 
so the differences in localisation may be due to the differences in the cell types. In 
the experiments reported here the localisation of MOSPD1-GFP was directly 
assessed using microscopy to assess GFP fluorescence whereas Thaler et al. (2010) 
detected MOSPD1-HIS expression by immunocytochemistry using an α-HIS  
primary antibody and a FITC-labelled secondary antibody so the difference in 
methods used to assess the localisation could also be responsible for the differences 
observed. As there are no reports in the literature for the localisation of MOSPD3 




Whilst recombinant proteins are useful in initial assessment of a protein’s 
localisation the localisation of endogenous protein is much more informative. To this 
end antibodies are a useful tool to investigate expression and localisation of 
endogenous proteins. I was able to generate monoclonal antibodies that were specific 
and did not cross-react with each other even though the two proteins, MOSPD1 and 
MOSPD3 are closely related. These monoclonal antibodies did not show the 
background that the polyclonal antibodies (Katrin Buerger, PhD thesis, 2009) did 
when detecting endogenous MOSPD1 and MOSPD3 in mouse tissues and were, 
therefore, used for determination of the tissue distribution and sub-cellular 
localisation of these proteins. The samples were treated with β-mercaptoethanol and 
boiled prior to loading on gels for western blots which should result in disruption of 
protein complexes and, therefore, the 50 kDa band may not be due to a dimer.  
Therefore, due to the presence of this extra 50 kDa band in western blots of heart 
lysates, which could be due to non-specific binding of the monoclonal antibodies, the 
sub-cellular localisation results from immunocytochemistry and 
immunohistochemistry may not be accurate.  To address this western blots could be 
carried out on lysates from Mospd 1 null day 5 embryoid bodies (described in section 
5.3.4.1.) as well as immunocytochemistry of these cells using the α-MOSPD1 
antibody. If there is no background staining it would indicate the antibody was 
specific for MOSPD1. The α-MOSPD1 and α-MOSPD3 antibodies could also be 
tested on cells in which siRNA had been used to knockdown MOSPD1 and 
MOSPD3. The monoclonal α-MOSPD1 antibody and α-MOSPD3 antibody have one 
isotype each indicating the antibodies are formed from only one B-cell clone and, 
therefore, are specific to one epitope each.    
 
 
The recombinant MOSPD1-GFP and MOSPD3-GFP localisation is slightly different 
to that of the endogenous proteins detected using the monoclonal antibodies. 
Endogenous MOSPD1 was found to be nuclear and MOSPD3 to be nuclear and 
cytoplasmic. There are a number of possible explanations for this. Firstly, 
recombinant proteins differ from their endogenous counterparts as the cDNA has 
been synthesised in vitro and this may influence the ability of the ER to synthesise 
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these proteins correctly. Secondly recombinant proteins often have the reporter tag 
on the N-terminal or C-terminal and this is not the best position for them as these 
sites are often important for correct protein folding. Incorrect folding of a protein can 
result in its accumulation in the ER (Viallet and Vo-Dinh, 2003) and it not being 
transported to the site the correctly folded protein would be. Thirdly, transfection of 
recombinant proteins results in over expression of the protein and this may have 
effects on the transfected cells and the protein’s localisation. Thaler et al. (2010) only 
observed MOSPD1-HIS in the nucleus when the last exon of Mospd 1 was removed. 
However, using the monoclonal α-MOSPD1, the endogenous protein was localised 
in the nucleus. One possible explanation is that there could be alternative isoforms of 
MOSPD1 which could include an endogenous form that does not have the last exon 
and as the peptide used to generate the antibody was at the N terminal of MOSPD1, 
the monoclonal α-MOSPD1 antibody would detect this shortened isoform. However, 
no shorter forms of MOSPD1 were detected on the western blots probed with the 
monoclonal α-MOSPD1 antibody. 
 
 
Due to the similarities between the phenotype of the homozygous MOSPD3 gene 
trap mice (Pall et al., 2004) and of mice with mutations in desmosome components 
such as Plakophilin 2 (Grossmann et al., 2004) which show neonatal lethality with a 
thinning of the right ventricle wall it was hypothesised that MOSPD3 could be part 
of the desmosome structure and, therefore, localised to the cell membrane. The 
presence of two transmembrane domains in MOSPD3, and the closely related 
MOSPD1, indicated that these proteins could be localised to membranes. The human 
keratinocyte cell line, HaCaTs, was chosen for the localisation studies as they are 
rich in desmosomes and have been used to study the localisation of desmosome 
components such as PKP2 (Mertens et al., 1996). MOSPD1 was localised to the 
nucleus and MOSPD3 to the nucleus and cytoplasm of HaCaTS in vitro. MOSPD1 
and MOSPD3 were not localised to the cell membrane and did not show the same 
desmosomal localisation of PKP2 and as MOSPD1 and MOSPD3 are not localised to 
cell junctions they do not form part of the desmosome structure and are not crucial 
components of the cell membrane. The phenotype of the Mospd 3 gene trap mouse, 
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although similar to that of desmosome mutants, is not due to a MOSPD3 
desmosomal defect based on the differences in localisation of MOSPD3 and 
desmosome components.  
 
 
Investigations to check whether MOSPD1 and MOSPD3 localisation is the same in 
vivo as it is in vitro were done by immunohistochemistry of adult mouse tissue 
sections. The mouse ear was chosen as a source of keratinocytes in vivo and 
MOSPD1 and MOSPD3 localisation was the same in these keratinocytes as in the 
HaCaTs grown in vitro. The proliferation of keratinocytes in the mouse ear are 
approximately 3 cells/ mm of tissue (Hill et al., 1981) and could possibly account for 
the nuclei that are absent for MOSPD proteins. To confirm this Bromodeoxyuridine 
(BrdU) could be used to detect proliferating cells in vivo as it is a thymidine analogue 
incorporated into DNA during S phase of the cell cycle. α-BrdU antibody could be 
used to detect the incorporated BrdU. The fact that MOSPD1 and MOSPD3 have 
similar localisation in HaCaTs and keratinocytes in vivo indicates that MOSPD 
proteins are involved in the same processes in keratinocytes in vitro as they are in 
vivo. Also it provides evidence that the immunostaining results are accurate as DAB 
staining was used to detect immunolabelled MOSPD1 and MOSPD3 in mouse tissue 
sections whilst fluorescence was used for HaCaTs.   
 
 
As the localisation of MOSPD1 and MOSPD3 was different in the few dividing cells 
observed in unsynchronised cultures it was decided to synchronise the cells to 
increase the number of dividing cells seen.  Incubation of HaCaTs with 2 mM 
thymidine results in the synchronisation of the cells at S phase and an increase in 
cells at G2 phase at 8 hours post thymidine removal, at M phase (9 hours) and G1 
phase (11 hours) (He et al., 2005). The percentage of cells showing different 
MOSPD1 localisation differed at these times indicating that MOSPD1 localisation 
changed during the cell cycle from mainly nuclear (during G1 and S phases) and 
perinuclear (S phase)  to cytoplasmic in all dividing cells (M phase). In all non-
dividing cells MOSPD3 was localised to the nucleus and cytoplasm and, therefore, 
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differed to MOSPD1 localisation. However, MOSPD3 was localised to the 
cytoplasm of all dividing cells in the same way as MOSPD1. This could be due to a 
similar role they are involved with during cell division. It is unknown whether 
MOSPD1 and MOSPD3 are actively removed from the nucleus in dividing cells or 
whether their cytoplasmic localisation is passive and only due to nuclear envelope 
breakdown that occurs during cell division. HaCaTs treated in this way lost 
synchronicity but did show increased numbers of dividing cells at 9 hours post 
thymidine which was the objective of the synchronisation. To synchronise cells at M 
phase an alternative drug such as colcemid could be used which blocks cells at 
mitosis (Lam et al., 1997). 
 
 
There are other proteins that show similar changes in localisation, to those observed 
in MOSPD1 and MOSPD3, depending on the cell cycle, such as BRCA1 (Breast 
Cancer Susceptibility gene 1) (Glover-Collins and Thompson, 2008) and PTHrP 
(Parathyroid hormone-related protein) (Lam et al., 1997). BRCA1 is a tumour 
suppressor and its localisation changes depending on the cell cycle. It has both NLS 
and NES and is localised to the nuclei of cells. During S phase BRCA1 is localised to 
the perinuclear region. This exclusion from the nucleus can be blocked by the 
antifungal agent, Leptomycin B, which is an inhibitor of the CRM1 (exportin1) 
protein (Nishi et al., 1994) involved in nuclear export. Therefore, BRCA1 export 
from the nucleus is dependent on CRM1 (Glover-Collins and Thompson, 2008). 
PTHrP localisation also changes depending on the cell cycle with dividing cells 
showing both an increased expression of PTHrP as well as  a change of localisation 
from nuclear (during G1 phase) and nuclear and perinuclear (G1/S phase) to 
cytoplasmic (M phase) (Lam et al., 1997). 
 
 
A putative NES in MOSPD1 has been reported (Thaler et al., 2010) and the presence 
of the same 4 residues, leucine, isoleucine, threonine and methionine, in MOSPD3 
could mean MOSPD3 also has this NES. The presence of this NES could explain 
how MOSPD1 and MOSPD3 are translocated from the nucleus into the cytoplasm 
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and could be due to CRM1 mediated export. Assessment of the localisation of 
MOSPD1 and MOSPD3 in cells where CRM1 has been inhibited by Leptomycin B 
treatment could address whether MOSPD protein nuclear export is dependent on 
CRM1.  As MOSPD protein localisation changes during the cell cycle it would be 
interesting to assess whether these changes in localisation are accompanied by a 
change in the level of expression of these proteins.  
 
 
The perinuclear localisation of MOSPD1, which appears to be MOSPD1 localised to 
the ER based on co-localisation of MOSPD1 and DS-Red2-ER, indicates a similarity 
to another protein family characterised by an N terminal MSP domain and a 
transmembrane domain. These are the VAMP-associated proteins (VAPs) (Weir et 
al., 1998; Nishimura et al., 1999). VAPB is localised to the ER and has a secreted 
form which binds to Ephrin (Eph) receptors (Tsuda et al., 2008). VAPA has been 
shown to be localised to the ER (Skehel et al., 2000) and Golgi apparatus (Soussan et 
al., 1999). The function of the VAP family is not fully understood. However, a 
mutated form of the VAPB protein has been implicated in Amyotrophic Lateral 
Schlerosis (ALS) (Nishimura et al., 2004). This similarity in localisation may 
indicate these proteins may share certain characteristics and possible functions. The 
transmembrane domains in MOSPD proteins could be involved in the localisation of 
these proteins in the ER, possibly on the membranes.  
 
 
Within the kidney localisation of MOSPD1 and MOSPD3 differed indicating they 
could serve different roles in this organ. The localisation of MOSPD3 to the 
membranes of the tubular epithelium could be due to the transmembrane domains in 
the MOSPD3 protein. The nuclei that are negative for MOSPD1 expression in the 
Bowman’s Capsule could be dividing cells that do not have MOSPD1 associated 
with the DNA and it is known that there are dividing cells within the Bowman’s 
Capsule (Jennette and Heptinstall, 2007).  There were similarities between the 
localisation of MOSPD1 and MOSPD3 in some tissues such as the heart where both 
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proteins were localised to nuclei and cytoplasm of endothelial cells of blood vessels 
and skeletal muscle where they were both localised to muscle striations. 
 
 
This chapter investigated the expression pattern of MOSPD1 and MOSPD3 
(summarised in Table 3.1) and whether they could be genetically redundant due to 
having the same sub-cellular localisation. The localisation of these proteins differed 
to each other with MOSPD1 being predominantly nuclear in cells tested whilst 
MOPSD3 was nuclear and cytoplasmic. However, both proteins show the same 
cytoplasmic localisation in dividing cells. Within certain tissues they exhibited 
similar localisation. Based on the evidence Mospd 1 and Mospd 3 could be 
genetically redundant as they may be able to compensate for each other in some 
tissues where they have the same localisation, such as the heart, or cells undergoing 
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Table 3.1: Localisation of MOSPD1 and MOSPD3 in HaCaTs in vitro and 
in vivo.  Localisation of recombinant and endogenous MOSPD1 and 
MOSPD3 in vitro (A) and of MOSPD1 and MOSPD3 in different adult mouse 





























Zebrafish are an excellent model organism for vertebrate development as they 
possess many advantages. They are easy and inexpensive to maintain and large 
numbers of embryos can be obtained from a single mating. These embryos can be 
assessed from the earliest developmental stages as eggs are externally fertilised and 
the embryos are transparent allowing the observation of organ development in vivo 
using simple light microscopy. Zebrafish embryos do not require normal blood 
circulation during early development as they acquire sufficient oxygen through 
diffusion (Burggren and Pinder, 1991). This allows embryos with cardiovascular 
defects to survive and develop and facilitates the phenotypic assessment of these 
embryos. This is a distinct advantage of using zebrafish as a model organism 
compared to mice as it allows mutations that act at early stages of development to be 
assessed which would be difficult to study in mice as they are dependent on normal 
blood circulation for survival.  
 
 
As Mospd 1 is a gene expressed in vertebrates it was expected that the zebrafish 
genome would have a Mospd 1 gene. Bioinformatics studies on the zebrafish genome 
have shown that a Mospd 1 gene (NCBI accession NM_007878.1) is present which 
has not undergone duplication and, therefore, there is only one copy of the Mospd 1 
gene. A Mospd 3 gene is not present in the zebrafish genome which is as expected as 
Mospd 3 is thought to be mammalian specific. Another Mospd gene family member, 
Mospd 2 is present in the zebrafish genome (NCBI accession NM_001007293.1). 
There is limited information in the literature about the expression of Mospd 1 in 
zebrafish. Whole mount in situ hybridisation (WISH) carried out on developing 
zebrafish embryos has shown that Mospd 1 is expressed throughout the embryo 
(Thisse et al., 2004). WISH shows the presence of Mospd 1 RNA transcripts but 
there is no MOSPD1 protein expression data in the literature. Zebrafish MOSPD1 
(NCBI accession NP_998534.1) and mouse MOSPD1 (NCBI accession 
NP_081685.1) share 77 % sequence identity showing the protein is highly conserved. 
Assessment of the sub-cellular localisation of MOSPD1 in embryos is important as it 
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would add information about the MOSPD1 protein expression as well as enhance 
functional studies.  
 
 
Another advantage of using zebrafish is that the expression of any gene of interest 
can be knocked down by injecting morpholinos targeted to that gene. Morpholinos 
are short oligonucleotides that are comprised of the standard nucleic bases. However, 
morpholino rings replace ribose or deoxyribose rings and phosphorodiamidate 
linkages are present instead of the phosphodiester linkages found in DNA and RNA 
(Summerton and Weller, 1997). This results in morpholinos being resistant to 
nuclease activity (Hudziak et al., 1996). Microinjection of a morpholino anti-sense 
onligonucleotide targeted to a splice junction or an exon- intron boundary can result 
in the inhibition of gene expression by inhibiting spliceosome components and 
thereby inhibiting pre-mRNA processing. This inhibition of correct splicing can 
result in a number of possible outcomes such as the deletion of the targeted exon, the 
inclusion of the targeted intron or the introduction of a frame shift or a premature 
stop codon (Morcos, 2007). These events result in gene knockdown and the level of 
this knockdown can be assessed using quantitative real-time PCR to measure the 
level of expression of the transcript of interest and comparing that to non-injected 
and negative-morpholino injected controls. 
 
 
Morpholinos that bind to the start codon or 5’UTR can inhibit translation of a protein 
by inhibiting the ribosomal initiation complex (Summerton, 1999).  Morpholinos are 
fluorescent and, therefore, the uptake and distribution of the morpholino can be 
assessed easily. Negative controls are injected at the same dose as the morpholino 
and are necessary to aid in distinguishing off target effects of morpholinos. 5 base 
pair mismatch (5MP) morpholinos serve as negative controls as they are highly 
similar in sequence to gene specific morpholinos but should not cause knockdown of 
the gene of interest. These controls are used to determine the effect of morpholino 
toxicity and to distinguish between specific phenotypes and those observed due to off 
target effects of the morpholino.     
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As a positive control microinjection of the chordin morpholino into zebrafish 
embryos was performed and the embryos assessed for the published chordin 
knockdown phenotype (Nasevicius and Ekker, 2000). Both the mild and severe 
chordin phenotypes published in the literature were observed at 2 ng and 4 ng doses 
of the chordin morpholino, respectively (Appendix Figures 10 and 11). The ability to 
replicate a published phenotype was followed by the use of morpholinos to 
knockdown Mospd 1, a relatively uncharacterised gene. In order to establish the role 
of Mospd 1 in early development both a morpholino targeted to the start site (MO1) 
of Mospd 1 and a splice-site morpholino (MO2) were generated. The splice-site 
morpholino was targeted to the splice junction between exons 2 and 3 at the 
boundary between exon 2 and intron 2. 1-16 cell embryos were injected with either 
morpholino or their 5 mispair morpholino controls. Different doses of morpholinos 
were injected into the embryos and the survival and phenotypes of these embryos 







 Assess the expression of Mospd 1 throughout early zebrafish development  
 
 Determine the sub-cellular localisation of MOSPD1 in the developing 
zebrafish embryo using the mouse monoclonal α-MOSPD1 antibody 
described in Chapter 3. 
 
 Determine the function of Mospd 1 in zebrafish embryo development using 
morpholino knockdown technology 
o Using a morpholino targeted to the start codon of Mospd 1 (MO1) to 
assess the phenotype of these embryos 
o Measuring knockdown of Mospd 1 expression using qPCR 
o Confirming any observed Mospd 1 phenotype using a splice-site 




4.3.1. Expression of Mospd 1 
 
4.3.1.1. Expression of Mospd 1 in developing embryos 
A pool of zebrafish embryos was collected at different time points from pre-mid 
blastula transition (MBT) (1 hpf) through to 5 dpf (Figure 4.1 A) and RNA extracted 
from these embryos. The cDNA synthesised from the RNA was used as a template 
for semi-quantitative RT-PCR in order to determine when Mospd 1 was expressed in 
the developing embryo. Mospd 1 is expressed from the pre-MBT stage, which 
indicates the presence of maternal Mospd 1 transcripts, right through to 5 dpf (Figure 
4.1B). The expression of Mospd 1 increases as development continues as there are 
higher levels of Mospd 1 from 2 dpf to 5 dpf. The house keeping gene β-actin was 
used as an internal control. The samples where reverse transcriptase was not added 
showed larger PCR products on the gel due to the intron-spanning primers, used for 
the RT-PCR, detecting some genomic contamination. The water control, where water 
was in place of cDNA, was negative for PCR product.  
 
 
4.3.1.2. Expression of MOSPD1 protein in zebrafish embryos 
 Whole mount in situ hybridisation (WISH) has shown that Mospd 1 transcript is 
expressed throughout the zebrafish embryo (Thisse et al., 2004). There is no 
information in the literature about the MOSPD1 protein expression pattern.  As there 
is 50 % sequence identity between the peptide used to generate the mouse 
monoclonal α-MOSPD1 antibody, described in Chapter 3, and the corresponding 
zebrafish peptide the antibody was used to try and identify the sub-cellular 
localisation of MOSPD1 in zebrafish embryos. Immunohistochemistry was 
performed on sagittal sections of 3 dpf embryos. The mouse monoclonal α-MOSPD1 









Figure 4.1: Mospd 1 expression in developing zebrafish embryos. A: 
Sketches of zebrafish embryos corresponding to the time collected for RNA 
extraction (pictures from Kimmel et al., 1995). B: RT-PCR on cDNA from pre-
MBT (1 hpf) embryos through to 5 dpf embryos using Mospd 1 and β-actin 
primers (endogenous control). Mospd 1 expression is low during early 
development (pre-MBT to 2 dpf) and increases as the embryos get older with 
a high expression observed at 3 ,4 and 5 dpf. H2O served as a negative 
control. +RT= reverse transcriptase added to cDNA reaction; -RT= reverse 
transcriptase omitted from cDNA reaction. PCR products were of the 
expected size (approximately 500 bp).  
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MOSPD 1 protein was expressed throughout the zebrafish embryo confirming the 
WISH data showing expression of Mospd 1 transcripts throughout the embryo 
(Thisse et al., 2004). MOSPD1 was found to be localised to the nuclei and cytoplasm 
of the developing embryo (Figures 4.2). There were some unstained cells within the 
embryo particularly within the heart (Figure 4.3) which could correspond to blood 
cells which are nucleated in zebrafish embryos. MOSPD1 was localised to the 
cytoplasm at the anterior of somites and nuclei in the posterior (Figure 4.4). An 
isotype control was used as a negative control and this did not show any non-specific 
staining (Figure 4.2 A). Immunohistochemistry on zebrafish embryos was also 
performed using the mouse monoclonal α-MOSPD3 antibody which did not show 
any specific staining and, therefore, confirmed the absence of MOSPD3 in zebrafish 























Figure 4.2: MOSPD1 localisation in 3 dpf zebrafish embryos. 
Immunohistochemistry on sagittal sections of 3 dpf embryos using the IgG2b 
isotype control (A), the mouse monoclonal α-MOSPD1 antibody (B) and the 
mouse monoclonal α-MOSPD3 antibody (C) are shown. Higher magnification 
of the boxed section (A-C) showing the nuclei for the embryo stained for the 
isotype control (a), MOSPD1 (b) and MOSPD3 (c). Scale bars = 100 µm (A-C) 










Figure 4.3: MOSPD1 localisation in the heart and surrounding tissue of 
a 3 dpf zebrafish embryo. A sagittal section of a 3 dpf embryo stained with 
the mouse monoclonal α-MOSPD1 antibody showing the localisation of 
















Figure 4.4: MOSPD1 localisation in the tail of a 3 dpf zebrafish embryo. 
A sagittal section of a 3 dpf embryo stained with the mouse monoclonal α-
MOSPD1 antibody showing the localisation of MOSPD1 in the tail is shown. 
A somite is indicated with the anterior (A) and posterior (P) marked.  Scale 




4.3.2. Functional analysis of Mospd 1 
 
4.3.2.1. Analysis of embryos injected with a start morpholino 
against Mospd 1  
 
4.3.2.1.1 Survival of start morpholino-injected embryos 
To assess the general toxicity of the start morpholino the survival of embryos 
injected with different doses was monitored daily for 3 dpf for 3 individual 
experiments. This survival was then compared to the survival of negative control 5 
mis-pair morpholino-injected embryos and non-injected embryos. At an injected 
dose of 1 ng 88 % of the start morpholino-injected embryos (n=171) survived to 3 
dpf compared to 90 % of the 5MP control-injected embryos (n= 181) and 92 % of the 
non-injected embryos (n=149) (Figure 4.5A). The survival curve of the morpholino-
injected embryos was not significantly different to that of the 5 mis-pair morpholino-
injected or the non-injected controls (p= 0.58) (Log-rank (Mantel-Cox) test) and a 
log rank test for trend showed no significant difference (p=0.31).    
 
 
When the dose of morpholino injected was doubled to 2 ng per embryo 72 % of the 
start morpholino-injected embryos (n=203) survived to 3 dpf compared to 68 % of 
the 5 mis-pair morpholino–injected embryos (n=190) and 84 % non-injected (n=172) 
control embryos. The survival curves (Figure 4.5B) for the start morpholino-injected 
and 5 mis-pair morpholino-injected embryos were significantly different to that of 
the non-injected control embryos (p<0.01) (Log-rank Mantel-Cox test). However, the 
difference in survival between the start morpholino-injected embryos and the 5 mis-
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Figure 4.5: Survival to 3 dpf of start morpholino-injected embryos. A:  
1ng and B: 2 ng start morpholino- injected embryo survival. Survival curves 
of Mospd 1 morpholino and 5 mis-pair morpholino-injected embryos were not 
significantly different (p=0.58) (Log-rank (Mantel-Cox) Test compared to non-
injected embryo survival (A). The survival curves for the 2 ng Mospd 1 
morpholino-injected and 5 mis-pair morpholino-injected embryos were 
significantly different to that of non-injected controls (** p=0.008) but were not 
significantly different (p<0.01) from each other. Data pooled from 3 
experiments for each dose. 
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4.3.2.1.2. Phenotypic analysis of start morpholino-injected 
embryos 
The start morpholino was injected into zebrafish embryos, the fluorescent embryos 
monitored, as they showed good distribution of the morpholino, and the phenotypes 
of these embryos assessed daily. The embryos were categorised as either normal, 
mild or severe. Normal embryos displayed good development, a normal 
cardiovascular system with a functioning heart and blood circulation throughout the 
body (Figure 4.6). Embryos that were classified as mild were mostly normal but had 
a slower heart beat and circulation or mild body deformities whilst severe embryos 
had blood pooling, oedema or severe axis deformities (Figure 4.7).  
 
 
91 % of embryos injected with 1 ng of the start morpholino (n=171) were 
phenotypically normal at 1 dpf with 3 % showing a mild phenotype and 6 % showing 
a severe phenotype (Figure 4.8 A). This compared to 90 % of the 5 mis-pair 
morpholino-injected embryos (n=181) being normal, 5 % mild and 5 % severe and 
95 % normal non-injected embryos (n=149), 2 % mild and 3 % severe.  At 2 dpf 
91 % of start morpholino embryos (n=155) were normal, 2 % mild and 7 % severe 
compared to 92 % normal, 4 % mild and 4 % severe 5 mis-pair morpholino-injected 
embryos (n=165) and 96 % normal, 1 % mild and 3 % severe non-injected embryos 
(n=139) (Figure 4.8 B). 
 
 
 By 3dpf 90 % of the start morpholino embryos (n=152) were phenotypically normal, 
3 % mild and 7 % severe whilst 91 % of the 5 mis-pair morpholino-injected embryos 
(n=162) were normal, 3 % mild and 6 % severe and 95 % of the non-injected 
embryos (n=137) were normal, 2 % mild and 3 % severe (Figure 4.8 C). Two way 
ANOVA and Bonferroni post hoc tests were used to analyse the data and the 
phenotypes of the start morpholino-injected embryos were not significantly different 
to that of the 5 mis-pair morpholino-injected embryos or the non-injected embryos at 








Figure 4.6: 3 dpf phenotypically normal zebrafish embryos. Embryos had 
developed normally, had a well developed cardiovascular system including 
looped, beating heart with chambers and blood circulation throughout the 
body. A and B: non-injected; C and D: 5 mis-pair morpholino-injected; E and 
F: splice-site injected morpholino (MO2). A, C and E are taken with white 
light. B, D and F are fluorescence images showing good uptake of the 









Figure 4.7: 3 dpf phenotypically severe zebrafish embryos. Embryos 
displayed blood pooling (black arrows), oedema (red arrows) with altered 
heart morphology and altered body shape. A, C , E and F are taken with 
white light and B and D are fluorescence images showing uptake of the 
morpholino. A-D were taken at x5 magnification (Scale bars = 500 µm). E 
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Figure 4.8: Percentage of embryos that displayed a normal, mild or 
severe phenotype after being injected with 1 ng start morpholino. A: 1 
dpf, B: 2 dpf and C: 3 dpf. 2 way ANOVA and Bonferroni post hoc tests 
indicate that there were no significant differences in phenotypes at 1, 2 or 3 
dpf between Mospd 1 start morpholino-injected embryos and the 5 mis-pair 
morpholino and non-injected controls (p>0.05). Data is from 3 individual 
experiments.        
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The dose of the start morpholino was increased to 2 ng to check whether an increase 
would result in a Mospd 1 phenotype and the embryos monitored daily until 3 dpf. At 
1 dpf 65 % of the Mospd 1 morpholino-injected embryos (n=203) were normal, 17 %  
showed a mild phenotype and 18 % were severe (Figure 4.9A).  This compared to 
63 % normal, 16 % mild and 21 % severe phenotypes in the 5 mis-pair morpholino-
injected embryos (n=190) and 92 % normal, 3 % mild and 5 % severe embryos in the 
non-injected controls (n=172).  
 
 
At 2 dpf 93 % of the non-injected controls embryos (n=143) were normal, 1 % 
showed a mild phenotype and 6 % had a severe phenotype. Embryos injected with 
either the Mospd 1 morpholino (n=164) or the 5 mis-pair morpholino (n=159) had 
reduced numbers of normal embryos and increased numbers of mild and severe 
embryos (MO: 54 % normal, 17 % mild and 29 % severe; 5MP: 50 % normal, 19 % 
mild and 32 % severe embryos) (Figure 4.9B). By 3 dpf the Mospd 1 morpholino-
injected group (n=152) had 44 % normal, 19 % mild and 37 % severe embryos whilst 
the 5 mis-pair morpholino group (n=149) had 43 % normal, 16 % mild and 7 % 
severe embryos. The majority of the non-injected embryos (n=140), 92 %, were 




The differences in the numbers of embryos showing normal, mild and severe 
phenotypes were significantly different for both the Mospd 1 morpholino-injected 
and the 5 mis-pair morpholino-injected embryos when compared to the non-injected 
controls. Two way ANOVA and Bonferroni post hoc tests indicated p<0.001 for 2 
dpf and 3 dpf for all phenotypes. For 1 dpf p<0.001 for normal and p<0.05 for mild 
and severe. However, there were no significant differences in the numbers of normal, 
mild and severe embryos between the Mospd 1 morpholino and the 5 mis-pair 
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Figure 4.9: Percentage of embryos that displayed a normal, mild or 
severe phenotype after being injected with 2 ng start morpholino. A: 1 
dpf, B: 2 dpf and C: 3 dpf. 2 way ANOVA and Bonferroni post hoc tests 
indicate that there were significant differences in phenotypes at 1, 2 or 3 dpf 
between Mospd 1 start morpholino-injected embryos and the 5 mis-pair 
morpholino when compared to non-injected controls (*: p<0.05, **: p<0.01, 
***: p<0.001). There were no significant differences between Mospd 1 
morpholino and 5 mis-pair morpholino-injected embryo phenotypes. Data is 
from 3 individual experiments.        
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As injection of the 5 mis-pair control morpholino was resulting in a similar 
phenotype to that observed in the Mospd 1 start morpholino injected embryos it 
could not be concluded from this data whether the observed phenotype was specific 
and due to the knock down of  MOSPD1 or due to toxicity of the morpholino. It was, 
therefore, decided to use another morpholino to knockdown Mospd 1 expression to 
check whether the same phenotype seen with the start morpholino was observed. The 
injection of a splice-site morpholino would allow the level of Mospd 1 expression to 
be measured. Figure 4.10 shows a schematic representation of Mospd 1 showing the 
positions of the start morpholino and the splice-site morpholino. The splice-site 
morpholino was targeted to the splice junction between exons 2 and 3 and primers 

































Figure 4.10: Schematic representation of Mospd 1 and positions of 
morpholinos. The positions of the Start morpholino (red line) and the splice-
site morpholino (green) targeted to the splice junction between exons 2 and 3 
are indicated. The positions of the primers used for qPCR to measure 












4.3.2.2. Quantification of Mospd 1 knockdown  
Quantitative real-time PCR was used to measure the expression level of Mospd 1 in 
injected embryos to assess if injection of the splice-site morpholino resulted in 
knockdown of Mospd 1 expression. The embryos injected with different doses of 
either Mospd 1 morpholino or its 5 mis-pair morpholino were collected, RNA 
extracted and qPCR performed on the synthesised cDNA (n=3 per dose). Mospd 1 
expression levels were normalised against the endogenous control, Elongation factor 
1 alpha (Ef1α). The qPCR primers and probes for both Mospd 1 and ef1α were 
validated using a pool of zebrafish cDNA. All data was statistically analysed using 
One-way ANOVA with a Bonfferoni’s Multiple Comparison post test. There was no 
significant difference in Mospd 1 expression levels between non-injected and 5 mis-
pair morpholino- injected embryos. In embryos injected with 2 ng of the splice-site 
Mospd 1 morpholino there was a 53 % level of Mospd 1 expression compared to 
non-injected control levels (Figure 4.11A). The 5 mis-pair morpholino- injected 
embryos had a level of 92 % Mospd 1. The level of Mospd 1 in Mospd 1 
morpholino-injected embryos was significantly reduced to 47 % (p<0.001) compared 




When the dose of Mospd 1 morpholino injected was increased to 4 ng the Mospd 1 
expression level was 41 % of that of non-injected controls. Embryos injected with 4 
ng of the 5 mis-pair morpholino had 96 % Mospd 1 expression compared to non-
injected embryos (Figure 4.12A). This 59 % knockdown of Mospd 1 expression was 
significantly (p<0.001) lower than Mospd 1 expression levels in the control embryos 
(Figure 4.12B). A further increase in the dose of Mospd 1 morpholino to 6 ng 
resulted in a 36 % Mospd 1 expression level compared to non-injected embryos and 
96 % Mospd 1 expression in 5 mis-pair morpholino-injected embryos (Figure 4.13A).  
This 64 % reduction in Mospd 1 levels in the morpholino-injected embryos was 



















































































































Figure 4.11: Level of Mospd 1 expression and knockdown in 2 ng 
splice-site morpholino-injected embryos. The level of Mospd 1 expression 
(A) is significantly lower (53 %) in embryos injected with 2 ng morpholino 
compared to non-injected and negative-control injected embryos with a 
knockdown of Mospd 1 expression of 47 % (B). (*** p<0.001) (One-way 



















































































































Figure 4.12: Level of Mospd 1 expression and knockdown in 4 ng 
splice-site morpholino-injected embryos. The level of Mospd 1 expression 
(A) is significantly lower (41 %) in embryos injected with 4 ng morpholino 
compared to non-injected and negative-control injected embryos with a 
knockdown of Mospd 1 expression of 59 % (B). (*** p<0.001) (One-way 




























































































































Figure 4.13: Level of Mospd 1 expression and knockdown in 6 ng 
splice-site morpholino-injected embryos. The level of Mospd 1 expression 
(A) is significantly lower (36 %) in embryos injected with 6 ng morpholino 
compared to non-injected and negative control-injected embryos with a 
knockdown of Mospd 1 expression of 64 % (B). (*** p<0.001) (One-way 
ANOVA with Bonferroni post hoc test). n=3.  
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A dose-response analysis was carried out to determine whether the knockdown of 
Mospd 1 expression observed in the 2 ng, 4ng and 6 ng doses resulted in a significant 
reduction in Mospd 1 expression levels when compared to each other. The level of 
knockdown was not significantly increased when 2ng embryo levels were compared 
to 4 ng embryo levels or when 4 ng embryo levels were compared to 6 ng embryo 
levels. However, the level of knockdown in 6 ng embryos was significantly reduced 








Mospd 1 knockdown in response to increasing morpholino dose



























Figure 4.14: Knockdown of Mospd 1 in response to increasing 
morpholino dose. As the dose of morpholino injected into embryos is 
increased from 2 ng to 6ng the percentage of Mospd 1 knockdown increases. 
The increased knockdown of Mospd 1 gene expression is not significant 
between 2ng and 4 ng or between 4 ng and 6 ng but is significant between 2 




4.3.2.3. Assessment of Mospd 1 knockdown phenotype using 
a splice-site morpholino (MO2) 
 
4.3.2.3.1. Survival of embryos injected with a splice-site 
morpholino against Mospd 1 
To assess the general toxicity of the splice-site morpholino (MO2) the survival of 
embryos injected with different doses was monitored daily for 3 dpf for 3 individual 
experiments. This survival was then compared to the survival of 5 mis-pair 
morpholino-injected embryos and non-injected embryos. 90 % of 2ng Mospd 1 
morpholino-injected embryos survived to 3 dpf (n=207) compared to 87 % of 5 mis-
pair morpholino-injected embryos (n= 165) and 95 % of non-injected embryos 
(n=149) (Figure 4.15A). The survival curves of the three groups were not 
significantly different (p=0.10) when compared using a Log-rank (Mantel-Cox) Test 
and a log rank test for trend showed that the curves showed no significant difference 
in survival trends (p=0.23).  
 
 
When the dose of splice-site morpholino was increased to 4 ng 91 % of the Mospd 1 
morpholino-injected embryos (n=268) survived to 3 dpf compared to 89 % of the 5 
mis-pair morpholino-injected embryos (n=221) and 95 % non-injected embryos 
(n=189) (Figure 4.15B). The survival curves were not significantly different (p=0.10) 
and the curves did not show a significant difference in trend (p=0.29) (Log-rank test 
for trend).  
 
 
 An increase in the dose, to 6 ng, of morpholino injected resulted in a significant 
difference in the survival of morpholino-injected embryos (n=184) and the survival 
of non-injected controls (n=180) with 77 % Mospd 1 morpholino-injected embryos 
surviving to 3 dpf compared to 97 % of the non-injected embryos (p<0.001). 78 % of 
the 5 mis-pair morpholino-injected embryos (n=170) survived to 3 dpf, significantly 
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Figure 4.15: Survival to 3 dpf of splice site morpholino-injected 
embryos. A: 2 ng, B: 4 ng and C: 6 ng morpholino-injected embryo survival. 
Survival curves of 2 ng and 4 ng Mospd 1 morpholino and 5 mis-pair 
morpholino-injected embryos were not significantly different (p=0.10) (Log-
rank (Mantel-Cox) Test compared to non-injected embryo survival (A and B). 
The survival curves for the 6 ng Mospd 1 morpholino-injected and 5 mis-pair 
morpholino-injected embryos were significantly different to that of non-
injected controls (*** p<0.001) but were not significantly different (p=0.71) to 
each other. Data pooled from 3 experiments for each dose. 
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However, the survival of Mospd 1 morpholino-injected and 5 mis-pair morpholino-
injected embryos was not significantly different to each other (p=0.71) (Log-rank 
(Mantel-Cox) Test). This suggests that at a dose of 6 ng the morpholino was toxic to 
the embryos and that 2 ng and 4 ng doses would be more suitable to assessment of a 
Mospd 1 phenotype.  
 
 
4.3.2.3.2. Phenotypic analysis of splice-site morpholino 
(MO2)-injected embryos 
A  morpholino targeted to the splice junction between exons 2 and 3 of the Mospd 1 
gene was injected into zebrafish embryos in order to knockdown the gene expression 
of Mospd 1. A 5 mispair morpholino was also injected into embryos at the same dose 
as the splice-site morpholino (MO2) and non-injected embryos served as another 
negative control. The embryos were categorised into normal, mild or severe groups 




At a dose of 2 ng the majority of MO2-injected embryos (n=207) were 
phenotypically normal at 1 dpf with 96 % normal, 2 % mild and 2 % severe embryos 
compared to 5 mis-pair morpholino-injected embryos (n=165) that had 94 % normal, 
3 % mild and 3 % severe embryos. 96 % of the non-injected embryos (n=149) were 
normal whilst there were 2 % mild and 2 % severe embryos. At 2 dpf 91 % of the 
MO2-injected embryos (n=191) were normal with 4 % mild and 5 % severe embryos 
compared to 88 % normal, 6 % mild and 6 % severe embryos injected with the 5 
mis-pair morpholino (n=153). In the non-injected embryos (n=144) 92 % were 
normal, 3 % mild and 5 % severe. At 3 dpf the MO2-injected embryos (n=188) had 
the same percentage of normal, mild and severe phenotypes as at 2 dpf whilst the 5 
mis-pair morpholino-injected embryos (n=146) had 89 % normal, 6 % mild and 5 % 
severe embryos and 94 % of the non-injected controls (n=142) were normal with 1 % 
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Figure 4.16: Percentage of embryos that displayed a normal, mild or 
severe phenotype after being injected with 2 ng splice-site morpholino. 
A: 1 dpf, B: 2 dpf and C: 3 dpf. 2 way ANOVA and Bonferroni post hoc tests 
indicate that there were no significant differences in phenotypes at 1, 2 or 3 
dpf between Mospd 1 morpholino-injected embryos and the mis-pair 
morpholino and non-injected controls (p>0.05). Data is from 3 individual 
experiments.       
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2-way ANOVA with Bonferroni’s post tests showed that the percentage of normal, 
mild and severe phenotypes of 2ng MO2-injected embryos was not significantly 
different in comparison to both 5 mis-pair morpholino -injected embryos and non-
injected controls (p>0.05).  
 
 
The dose of the splice-site morpholino was increased to 4 ng to check whether an 
increase would result in a Mospd 1 knockdown phenotype. However, when the 
percentages of phenotypes were compared to both non-injected controls and 5 mis-
pair morpholino-injected controls there was no significant difference in the 
phenotypes observed at 1, 2 or 3 dpf. At 1 dpf 88 % of the MO2-injected embryos 
(n=268) were normal, 4 % mild and 8 % severe compared to 85 % normal, 6 % mild 
and 9 % severe embryos in the 5 mis-pair morpholino-injected group (n=221). 93 % 
of the non-injected controls (n=189) were normal, 2 % mild and 5 % severe at 1 dpf 
whilst at 2 dpf there were 89 % normal, 2 % mild and 9 % severe in this control 
group (n=185). Both the MO2-injected (n=247) and 5 mis-pair morpholino-injected 
(n=203) groups had 81 % normal embryos. There were 6 % mild and 13 % severe 5 
mis-pair morpholino-injected embryos compared to 4 % mild and 16 % severe in the 
MO2 group. At 3 dpf there were 82 % normal, 2 % mild and 16 % severe MO2-
injected embryos (n=246) whilst there were 80 % normal, 6 % mild and 14 % severe 
5 mis-pair morpholino- injected embryos (n=196). 90 % of the non-injected controls 
(n=182) were normal and 2 % mild and 16 % severe (Figure 4.17).    
 
 
To ensure that a phenotype that arose at a later stage of development was not missed 
4 ng morpholino-injected embryos were assessed until 5 dpf. 80 % of the MO2-
injected embryos (n=243) were normal, 4 % mild and 16 % severe compared to 78 % 
normal, 7 % mild and 15 % severe embryos in the 5 mis-pair morpholino-injected 
group (n=195). The non-injected control group (n=180) had 87 % normal, 4 % mild 
and 9 % severe embryos (Figure 4.18). There were no significant differences in the 
phenotypes observed in all three groups (p>0.05) (Two way ANOVA and 
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Figure 4.17: Percentage of embryos that displayed a normal, mild or 
severe phenotype after being injected with 4 ng splice-site morpholino. 
A: 1 dpf, B: 2 dpf and C: 3 dpf. 2 way ANOVA and Bonferroni post hoc tests 
indicate that there were no significant differences in phenotypes at 1, 2 or 3 
dpf between Mospd 1 morpholino-injected embryos and the 5 mis-pair 
morpholino and non-injected controls (p>0.05). Data is from 3 individual 
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Figure 4.18: Percentage of embryos that displayed a normal, mild or 
severe phenotype after being injected with 4 ng splice-site morpholino 
at 5 dpf. 2 way ANOVA and Bonferroni post hoc tests indicate that there 
were no significant differences in the percentage of embryos with normal, 
mild or severe phenotypes at 5 dpf between Mospd 1 morpholino-injected 
embryos and the 5 mis-pair morpholino and non-injected controls (p>0.05). 
Data is from 3 individual experiments.        
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The injected splice-site morpholino dose was increased to 6 ng and the observed 
phenotypes of the embryos compared to 6 ng 5 mis-pair morpholino-injected 
embryos and non-injected controls. At 1 dpf 46 % of the MO2-injected embryos 
(n=184) were normal, 11 % mild and 43 % had a severe phenotype. This was 
compared to 53 % normal, 11 % mild and 36 % severe embryos in the 5 mis-pair 
morpholino-injected group (n=137) and 95 % normal, 2 % mild and 3 % severe in 
the non-injected control group (n=180). There were significantly more normal 
embryos in the non-injected group compared to both Mospd 1 morpholino and 5 mis-
pair morpholino-injected embryos which had significantly more severe embryos 
(p<0.001). However, there was no significant difference between 5 mis-pair 
morpholino-injected embryos and MO2-injected embryos (p>0.05) (Figure 4.19 A).    
 
 
At 2 dpf there was no significant differences in the proportion of phenotypes 
observed between the MO2- (n=155) and 5 mis-pair morpholino-injected (n=121) 
groups with 44 % of the MO2-injected embryos being normal, 8 % mild and 48 % 
severe compared to 41 % normal, 18 % mild, 41 % severe embryos in the 5 mis-pair 
morpholino-injected group (p>0.05). The proportion of normal and severe 
phenotypes observed in the non-injected control group (n=176) was significantly 
different to the 2 injected groups (p<0.001) (Figure 4.19 B).   
 
 
By 3 dpf there were 42 % normal, 8  % mild and 50 % severe embryos in the MO2-
injected group (n=146) compared to 38 % normal, 17 % mild and 45 % severe in the 
5 mis-pair morpholino-injected group (n=115). The proportion of these phenotypes 
was not significantly different between the two groups (p>0.05). However, the 
proportion of normal and severe phenotypes was significantly different to that of the 
non-injected control group (n=174) that had 92 % normal, 1 % mild and 7 % severe 
embryos (p<0.001) (Figure 4.19 C). Data was analysed using 2 way ANOVA and 
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Figure 4.19: Percentage of embryos that displayed a normal, mild or 
severe phenotype after being injected with 6 ng splice-site morpholino. 
A: 1 dpf, B: 2 dpf and C: 3 dpf. The proportion of normal and severe embryos 
in Mospd 1 morpholino and 5 mis-pair morpholino-injected groups were 
significantly different (p<0.001) compared to non-injected controls but not to 
each other (p>0.05) (2 way ANOVA and Bonferroni post hoc tests). Data is 





The Mospd 1 gene is present in the zebrafish genome as expected as it is a vertebrate 
gene and Mospd 1 transcripts have been found to be expressed throughout the 
developing zebrafish embryo by WISH (Thisse et al., 2004). However, the presence 
of Mospd 1 transcripts does not necessarily mean that the MOSPD1 protein is present. 
Mouse MOSPD1 and zebrafish MOSPD1 share 77 % sequence identity and as the 
peptide used to generate the mouse monoclonal α-MOSPD1 (described in Chapter 3) 
shares 50 % sequence identity with the corresponding zebrafish sequence it was 
thought it could be used to detect MOSPD1 expression in the developing embryo.  
 
 
Immunohistochemistry showed that the mouse monoclonal α-MOSPD1antibody was 
able to detect MOSPD1 in zebrafish embryos and that MOSPD1 was localised 
throughout the developing embryo confirming the Mospd 1 transcript expression 
from the WISH. MOSPD1 was localised to the nucleus which is similar to its 
localisation in vitro in HaCaTs and in vivo in mouse adult tissues (Chapter 3). This 
could indicate that Mospd 1 has a conserved role in vertebrates. The cytoplasmic 
localisation of MOSPD1 in zebrafish embryos could be due to the presence of 
rapidly dividing cells in zebrafish embryos as they develop quickly and, therefore, 
have high cell proliferation rates. The localisation of MOSPD1 in somites was 
cytoplasmic in the anterior and nuclear in the posterior. This difference in MOSPD1 
localisation in somites could indicate that MOSPD1 is involved in different roles 
within different parts of the somites. The α-MOSPD3 antibody did not detect 
MOSPD3 protein expression in zebrafish embryos as expected due to the absence of 
a Mospd 3 gene in the zebrafish genome.  
 
 
When Mospd 1 gene expression is significantly reduced in zebrafish embryos using 
morpholinos the ability of these embryos to survive is not affected. The majority of 
these morpholino-injected embryos have a normal gross phenotype. Given the 
cardiac phenotype of the Mospd 3 gene trap mice (Pall et al., 2004) and the fact that 
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Mospd 1 is closely related to Mospd 3 the morpholino-injected embryos were 
assessed for any cardiac phenotype. The gross structure of the heart, heart rate and 
heart function appeared to be normal in Mospd 1 morpholino-injected embryos. This 
could possibly be due to Mospd 1 not being essential for early zebrafish embryo 
development or survival. However, the main limitation of the current study is the 
level of knockdown of Mospd 1 expression achieved which may not be sufficient to 
result in a phenotype. Embryos with approximately 50 % of Mospd 1 expression 
have the level of gene expression of a heterozygous embryo and many heterozygous 
animals do not display the phenotype of their homozygous null counterparts during 
early development which is when these zebrafish embryos are being assessed. The 
level of Mospd 1 knockdown may need to be increased further. Increasing the dose 
of the morpholino did not result in a very large increase in knockdown in Mospd 1 
expression and only resulted in an increase in non-specific phenotypes being 
observed, indicated by the fact that the 5 mis-pair control-injected embryos showed 
the same levels of phenotype but not significant knockdown of Mospd 1 expression. 
Therefore, these phenotypes were most likely due to off target effects such as 
knockdown of a gene other than the target Mospd 1 gene. (Morcos, 2007) reported 
that injection of an individual morpholino targeted to a splice-site could reduce 
knockdown of gene expression to 50 % whereas a combination of 3 non-overlapping 
morpholinos targeted to the same gene being co-injected into embryos could result in 
approximately 90 % knockdown. Therefore, in order to increase the amount of 
knockdown of Mospd 1 gene expression a second morpholino targeted to a different 




Off target effects are common in morpholino experiments as the dose of morpholino 
injected is increased (Robu et al., 2007). The injection of the 5 mis-pair morpholino 
is used to monitor whether an observed phenotype is specific as the 5 mis-pair 
morpholino should not result in the specific phenotype at a dose seen in the 
morpholino. Injection damage can also result in abnormal development. However, 
this should have been minimised in the experiments since 3 hours after the 
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morpholino was injected, embryos were sorted and injection damaged embryos 
removed. Morpholino toxicity can also result in abnormal phenotypes being observed 
and this makes the use of controls essential to confirming whether a phenotype is due 
to the knockdown of the gene of interest or an off target effect. The most common 
off target effect of morpholino use is the activation of the p53 pathway (Robu et al., 
2007) resulting in apoptosis and neural death, in about 15-20 % of morpholino 
experiments (Ekker and Larson, 2001). The co-injection of a p53 morpholino is often 
used to reduce this non-specific neural death phenotype. However, as this phenotype 
was not observed in the Mospd 1 morpholino experiments it does not seem to be 
necessary to co-inject the p53 morpholino.   
 
 
The morpholinos used to knockdown Mospd 1 expression in zebrafish embryos 
showed effects due to toxicity as demonstrated by the 5 mis-pair control morpholino-
injected embryos showing the same adverse developmental defects such as axis 
damage, oedema and blood pooling as those injected with the Mospd 1 morpholinos. 
At a dose of 2 ng the start morpholino was toxic and at a dose of 6 ng the splice-site 
morpholino was toxic. The severe phenotypes observed in morpholino-injected 
embryos were due to the toxicity of the morpholino at the doses used and not due to 
the knockdown of Mospd 1 expression.  
 
 
As only the gross phenotype of the embryos was assessed in these experiments the 
fact that they appeared normal does not necessarily mean that they were 
phenotypically normal. It is possible that intracellular changes have occurred in these 
embryos that cannot be measured by simple microscopic examination. As the 
immunohistochemistry of zebrafish embryos has shown that MOSPD1 is expressed 
in the nucleus of these embryos knockdown of Mospd 1 could result in a phenotype 




A recent study trying to identify genes important in angiogenesis investigated 50 
genes found to be highly expressed in the microvasculature, including Mospd 1 
(Kalen et al., 2009). Mospd 1 expression was knocked down using two non-
overlapping translational blocking morpholinos and the embryos examined at 24 hpf 
(1 dpf) and 56 hpf. The embryos were checked for any changes in morphology as 
wells as whether blood flow was defective and whether there was a reduction in 
intersegmental vessel sprouting. Microangiography was performed on the embryos 
and heart beat measured. In the Mospd 1 knockdown embryos no gross phenotype 
was reported and there were no changes in the microvasculature of these embryos. It 
was determined that Mospd 1 was not required for angiogenesis (Kalen et al., 2009). 
These findings have the limitation that the level of MOSPD1 knockdown was not 
reported and due to the lack of availability of a commercial α-MOSPD1 antibody it 
was likely not measured in this study. Therefore, the lack of phenotype may be due 
to insufficient knockdown.   
 
 
In conclusion, it appears that knockdown of Mospd 1 expression by about 60 % does 
not result in an observable phenotype. However, further knockdown of Mospd 1 may 
result in a phenotype and, therefore, due to the limitations discussed above the 
current study cannot establish whether Mospd 1 is essential to early zebrafish 
development and survival. In order to establish the function of Mospd 1 in zebrafish 
it would be useful to further knockdown expression. It would also be worth trying to 
identify any proteins that MOSPD1 may associate with and co-inject morpholinos 
against those genes with the Mospd 1 morpholino.  This may result an observable 
phenotype and establish the function of Mospd 1.  
 





















GENERATION AND PHENOTYPIC ASSESSMENT OF 




Mospd 1 is a gene that belongs to the, relatively uncharacterised, Mospd gene family 
and its function is yet to be determined. In parallel with the knockdown of Mospd 1 
in zebrafish, described in Chapter 4, a conditional knockout of Mospd 1 in ES cells 
was generated. A targeting vector was generated by Katrin Buerger (PhD thesis, 
2009) that has exons 2-4 of the Mospd 1 gene flanked by lox P sites (Figure 5.1 A). 
As the transcriptional start site of the Mospd 1 gene is in exon 2 the Cre recombinase 
(Cre) mediated deletion of these exons would result in functional loss of the 
MOSPD1 protein. A neomycin cassette was incorporated into the targeting vector 
allowing for the selection of targeted clones.  As Mospd 1 is an X-linked gene and 
the E14 IV ES cell line was generated from male mice the introduction of Cre 
recombinase would result in a null cell line.  
 
 
Generation of Mospd 1 null ES cells will provide a valuable tool to investigate the 
function of Mospd 1. These cells can be used for in vitro functional tests as well as 
assessment of the role of Mospd 1 in vivo if used to generate a Mospd 1 null mouse. 
The Mospd 1 null ES cells can be differentiated in vitro and compared to wild type 
ES cells to investigate whether Mospd 1 is required for differentiation. The use of 
Cre -mediated excision to generate null ES cells for functional studies has been used 
to study the function of genes in vitro. For example the function of Jsap 1, a gene 
encoding a scaffold protein involved in JNK signalling, in cardiomyocyte 
differentiation (Sato et al., 2005) and that of the LIM-domain binding protein 1 
(Ldb1) in neuronal differentiation (Hwang et al., 2008) have been determined using 
ES cells null for these genes.  
 
 
Conditional Mospd 1 and Mospd 3 alleles in the CGR8 ES cell line had been 
generated previously but were found to be karyotypically abnormal with trisomy of 
one of the chromosomes. It was found that the parental CGR8 cell line was also 
karyotypically abnormal (Katrin Buerger, PhD thesis, 2009). It is well established 
that in long term culture of ES cells the cells can become karyotypically unstable 
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resulting in trisomy of chromosomes (Liu et al., 1997; Rebuzzini et al., 2008). This 
abnormal chromosome number likely explains the low number of chimeric mice 
generated from the CGR8 conditional ES cells (Katrin Buerger, PhD thesis, 2009). 
Therefore, E14 IV ES cells were chosen as the wild type ES cells that the targeting 
vectors were electroporated into in this study because they were found to be the most 
karyotypically stable parental cell line in our hands. 
 
 
Epithelial- Mesenchymal Transition (EMT) (Greenburg and Hay, 1982) and its 
reverse process Mesenchymal- Epithelial Transition (MET) are essential processes 
during embryogenesis. As epithelial cells are held together by tight junctions, 
adherens junctions and desmosomes they are immobile and cannot migrate to other 
areas of the embryo. During EMT changes in gene expression result in the loss of 
these cell junctions and the ability for these cells to migrate. Epithelial cells express 
Chd1 (E-cadherin) which is important for cell adhesion (Takeichi, 1988). The genes 
Snail and Snai2 (Slug) repress Cdh1 expression which causes a disruption to cell 
adhesion in epithelial cells which then undergo EMT (Cano et al., 2000; Bolos et al., 
2003). Mospd 1 expression has been found to be up regulated in myoblastic and 
osteoblastic cell lines during differentiation. Knockdown of Mospd 1 expression in 
MC3T3-E1 cells using siRNA resulted in changes in gene expression with up 
regulation of epithelial genes such as Cdh1 and down regulation of mesenchymal 
genes Cdh11, and the Cdh1 repressor genes Snai1 and Snai2. The finding that the 
knockdown of Mospd 1 results in increased Cdh1 and decreased Snail and Snai2 
indicates Mospd 1 may play a role in MET (Thaler et al. 2010). However, this has 
only been shown during osteoblast differentiation.  
 
 
ES cells are pluripotent and can, therefore, differentiate into any cell type. Depending 
on culture conditions ES cells can be differentiated into cardiomyocytes 
(Doetschman et al., 1985; Maltsev et al., 1994) or osteoblasts (bone) (Buttery et al., 
2001). Using the Mospd 1 null ES cells the role of Mospd 1 in cardiomyocyte and 
osteoblast differentiation was assessed. Thaler et al. (2010) reported that knockdown 
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of Mospd 1 expression in the osteoblastic cell line MC3T3-E1 cells by siRNA 
resulted in down regulation of several genes including Cdh11, Snai1 and Snai2 
(Slug). We assessed the expression of these down-regulated genes and they show the 
same expression pattern as Mospd 1 during ES cell differentiation according to the 
FunGenES database (Schulz et al., 2009) (www.fungenes.org). Any changes in the 
expression levels of these genes in Mospd 1 null cells compared to wild type cells is 
reported in this chapter.  
 
 
This chapter describes the generation of Mospd 1 null ES cell lines and the 
phenotypic assessment of these null cell lines in comparison to wild type ES cells to 
assess the function of Mospd 1.  
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5.2. Aims 
Given that Mospd 1 is widely expressed in cells and tissues and its sub-cellular 
localisation changes during the cell cycle (Chapter 3) Mospd 1 may be critical for 
cell function and proliferation. To test this it was necessary to:  
 
 Generate a Mospd 1 conditional allele by targeting Mospd 1 in ES cells 
 
 Generate a Mospd 1 null ES cell line by expressing Cre recombinase in 
targeted Mospd 1 null ES cells 
 
 Assess the functional of Mospd 1 in vitro 
 
o Phenotypically characterise the Mospd 1 null clones to assess whether: 
  Mospd 1 plays a role in ES cell proliferation and/or self 
renewal  
 
 Mospd 1 is required for differentiation (early differentiation, 
cardiomyocyte and osteoblast differentiation). 
 
 Measure gene expression changes in differentiated Mospd 1 
null cells to assess whether any genes change expression level 





5.3.1. Generation of Mospd 1 conditional allele in ES cells 
 
5.3.1.1. Southern blot screening of Mospd 1 targeted ES 
clones 
To generate a conditional Mospd 1 allele the Mospd 1 targeting vector (Figure 5.1 A) 
was electroporated into wild type E14 IV ES cells and the cells grown under G418 
drug selection. 288 colonies were picked and Spe I digests of the ES clone DNA 
were analysed by Southern blot to determine whether any of the picked ES clones 
were correctly targeted (Figure 5.1 B). As Mospd 1 is an X-linked gene and the E14 
IV cell line used in the targeting experiments was generated from male mice there 
would only be one allele present. We designed a Southern blot strategy in which 
either a restriction fragment of 14.8 kb corresponding to the wild type allele or a 
restriction fragment of 7 kb (with the 5’ probe ) or 4.7 kb (with the 3’ probe) 
corresponding to the targeted allele  would be observed (Figure 5.1C). Of the 179 
clones that were successfully screened 4 clones appeared to have been correctly 
targeted. This corresponds to a targeting frequency of 2.2 % for Mospd 1 in the E14 
IV cell line. Previous studies using the CGR8 cell line had a targeting frequency of 
1.7 % (Katrin Buerger, PhD thesis, 2009).   
 
 
5.3.1.2. Karyotype of targeted Mospd 1 clones 
To check whether the targeted clones had a normal chromosome number and had not 
become unstable due to the electroporation and selection process the clones were 
karyotyped. The chromosome number was determined for at least 30 cells per clone 
by counting the chromosome spreads after DAPI staining. A clone was accepted as 
being of normal chromosome number, as shown in Figure 5.2, if more than 80 % of 
its cells possessed 39-40 chromosomes. Table 5.1 shows the percentage of cells for 








Figure 5.1: Southern blot screening of Mospd 1 targeted ES clones. ES 
cells were screened for the correct vector integration at the Mospd 1 locus 
using Spe I digestion. A: Schematic representation of the Mospd 1 targeting 
vector. B: Schematic representation of the wild type Mospd 1 allele and the 
targeted Mospd 1 allele (S= Spe I; neo= neomycin cassette; red triangle 
represents lox P sites; blue circles represent the frt loci; purple box 
represents the 5’ probe; green box represents the 3’ probe).  B: Southern blot 
showing wild type and targeted Mospd 1 clones. The 14.8 kb labelled 
fragment corresponds to wild type Mospd 1, 7 kb fragment (5’ probe) and the 
4.7 kb (3’ probe) correspond to the correctly targeted Mospd 1 locus (wt= 








Figure 5.2: A typical chromosome spread from a Mospd 1 targeted 
clone. An example of a chromosome spread (one cell) stained with DAPI 
showing the correct karyotype of 40 chromosomes (100x magnification).  
   
 
 
Clone Percentage clones with normal 
chromosome number (40) 
E14 IV (Passage 23) 93 
Mospd 1 B3 82 
Mospd 1 B10 85 
Mospd 1 C4 80 
Mospd 1 F6 100 
 
 
Table 5.1:  Karyotype of targeted Mospd 1 ES clones. All the clones were 
in the acceptable range of chromosome numbers i.e. more than 80 % of the 
cells had 39-40 chromosomes. No cells in any of the clones appeared to 
have more than 40 chromosomes. E14 IV cells of passage 23 were also of 




During long term ES cell culture the cells can accumulate chromosomal 
abnormalities (Liu et al., 1997) and, therefore, the chromosome number of E14 IV 
cells at passage 23 was determined. These cells and all the targeted clones that were 
karyotyped were of the correct chromosome number and none possessed extra 




5.3.2. Generation of Mospd 1 null ES clones  
 
5.3.2.1. Southern blot screening of Cre recombinase 
electroporated Mospd 1 targeted ES clones 
To generate a Mospd 1 null allele the pCAGGS-Cre-IRESpuro plasmid (Appendix 
Figure 4) was electroporated into Mospd 1 clone F6 targeted cells, which had normal 
karyotype, and 48 clones picked. To determine whether any of the picked ES clones 
were Mospd 1 nulls DNA was screened by Southern blot. As Mospd 1 is an X-linked 
gene and the E14 IV cell line used in the targeting experiments was generated from 
male mice either a restriction fragment corresponding to the targeted allele or to a 
null allele would be generated. Hind III digests of the ES clone DNA were analysed 
by Southern blot. For Mospd 1 the restriction fragment that corresponds to the 
targeted allele is predicted to be 6.7 kb in size and the restriction fragment that 
corresponds to the null allele is predicted to be 8.3 kb (Figure 5.3). 48 ES clones 
were screened of which only 10 clones showed a restriction fragment. 7 of these 


















Figure 5.3: Generation of Mospd 1 null allele. A: Schematic representation 
of the targeted Mospd 1 allele and null allele. B: Southern blot of Hind III 
digestion using the 3’ probe. The 6.7 kb fragment corresponds to the targeted 
allele and the 8.3 kb fragment to the Mospd 1 null allele. (H= Hind III; neo= 
neomycin cassette; red triangle represents lox P sites; blue circles represent 
the frt loci; purple box represents the probe; t= targeted).   
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5.3.2.2. Karyotype of Mospd 1 null clones  
To check whether the Mospd 1 null clones had a normal chromosome number and 
had not become unstable due to the electroporation of the Cre recombinase plasmid 
the clones were karyotyped. The chromosome number of wild type, E14 IV, cells at 
passage 23 was determined. Both Mospd 1 null clones, C10 and C11, which were 
checked, possessed the correct chromosome number, 86 % and 100 % respectively 
and none possessed extra chromosomes (Table 5.2). 
 
 
5.3.3. Mospd 1 and Mospd 3 expression in differentiating ES 
cells 
To determine when Mospd 1 and Mospd 3 were expressed during ES cell 
differentiation wild type E14 IV ES cells were differentiated using the hanging drop 
method and the embryonic bodies (EBs) collected every day for 5 days. Individual 
EBs were plated on gelatinised 24 well dishes and cultured for a further 10 days. 
Cells were monitored for the formation of beating regions. The plated cells were then 
trypsinised, pooled and the cells pelletted. RNA was extracted from wild type ES 
cells, EBs from each day and the differentiated cells with and without beating 
populations and cDNA was reverse transcribed. Semi-quantitative RT-PCR, using 
intron-spanning primers, was performed in order to examine whether Mospd 1 and 
Mospd 3 were expressed in differentiating cells. Mospd 1 expression appeared to be 
very low to absent in undifferentiated ES cells and its expression increased in older 
EBs (Figure 5.4). EBs collected from day 3 onwards expressed Mospd 1 as did 
differentiated cells. Mospd 3 expression varied to that of Mospd 1 in that Mospd 3 
was expressed from undifferentiated ES cells through the different stages of EBs and 
















Clone Percentage clones with normal 
chromosome number (40) 
E14 IV (Passage 23) 90 
Mospd 1 null C10 86 
Mospd 1 null C11 100 
 
Table 5.2:  Karyotype of Mospd 1 null ES clones. All the clones were in 
the acceptable range of chromosome numbers i.e. more than 80 % of the 
cells had 39-40 chromosomes. No cells in any clones appeared to have more 
than 40 chromosomes. E14 IV cells of passage 23 were also of the correct 













Figure 5.4: RT-PCR of Mospd 1 and Mospd 3 expression from 
undifferentiated ES cells, day 0 through to day 5 embryoid bodies and 
differentiated cells. β-tubulin was used as a housekeeping gene. E14 IV = 
undifferentiated ES cells; B = cultures containing beating regions; NB= 
cultures absent for beating regions; + RT= reverse transcriptase added 
during cDNA synthesis; -RT = no reverse transcriptase added to the cDNA 








5.3.4. Phenotypic assessment of Mospd 1 null ES cells to 
assess function of Mospd 1 in vitro 
 
5.3.4.1. Lack of Mospd 1 expression in Mospd 1 null day 5 
EBs compared to wild type   
The Mospd 1 null clones, C10 and C11, which had been screened by Southern blot, 
were used to confirm that the Mospd 1 null ES cells did not express Mospd 1 by 
qPCR. Briefly, the cells were differentiated using the hanging drop method and after 
2 days the resulting embryoid bodies (EBs) were harvested and cultured for a further 
5 days and then collected for RNA extraction.  As Mospd 1 is not expressed in ES 
cells and its expression increases during differentiation (Figure 5.4) the expression of 
Mospd 1 in day 5 EBs was checked in Mospd 1 null cells and compared to wild type 
E14 IV cells. Wild type E14 IV day 5 EBs expressed Mospd 1 and were used as the 
internal calibrator (gene expression in the Mospd 1 null cells was measured in 
relation to this) and was set as 1. The Mospd 1 null cells did not express Mospd 1 in 
the differentiated cells (Figure 5.5). This served as confirmation that the Cre 
recombinase electroporation was a success and Mospd 1 null cells had been 
successfully generated.   The difference in expression of Mospd 1 between wild type 
and Mospd 1 null C10 and C11 clones was significantly different (p<0.001) and there 
was no difference between the Mospd 1 null clones (One-way ANOVA and 
Bonferroni post test).  
 
 
5.3.3.2. Mospd 3 expression in Mospd 1 null cells compared 
to wild type   
To determine whether Mospd 3 could be compensating for the loss of Mospd 1 in 
Mospd 1 null cells the level of Mospd 3 in day 5 EBs was measured by qPCR. Mospd 
1 null clones C10 and C11 had a 0.84 and 0.76 level of Mospd 3 expression, 
respectively, compared to wild type E14 IV expression which was set at 1 (Figure 
5.6). There was no significant difference (p=0.20) in Mospd 3 expression between 













































Figure 5.5: Mospd 1 null cells lack Mospd 1 expression. qPCR was used 
to confirm that the Mospd 1 null cells did not express Mospd 1 in 
differentiated cells. Mospd 1 was expressed in wild type E14 IV day 5 EBs 
whilst Mospd 1 null cells did not express Mospd 1. One-way ANOVA and 
Bonferroni post hoc test indicated that the difference in expression of Mospd 
1 between wild type and Mospd 1 null C10 and C11 clones was significantly 
















































Figure 5.6: The level of Mospd 3 expression is not significantly changed 
in cells lacking Mospd 1. qPCR was used to measure the expression of 
Mospd 3 in Mospd 1 null day 5 EBs compared to wild type E14 IV Mospd 3 
expression. Mospd 3 expression was not significantly altered (p=0.20) in 
Mospd 1 null cells compared to E14 IV wild type day 5 EBs (One-way 








5.3.4.3. Mospd 1 null ES cells express stem cell markers 
To check that the Mospd 1 null cells were still behaving as ES cells and to determine 
whether lack of Mospd 1 expression resulted in the loss of ES cell characteristics a 
number of phenotypic tests were carried out on the Mospd 1 null clones, C10 and 
C11. ES cells express the genes Oct 4 (Niwa et al., 2000) and Nanog (Chambers et 
al., 2003) which are responsible for maintaining the self renewing abilities of ES 
cells. In generating the Mospd 1 null ES cells the cells have been electroporated 
twice, once with the Mospd 1 targeting vector and once with the Cre recombinase 
vector as well as selected with G418 to select targeted clones. RT-PCR was used to 
check whether the Mospd 1 null clones C10 and C11 expressed the ES cell markers 
Oct 4 and Nanog. Figure 5.7 shows that like wild type ES cells, both Mospd 1 null 
clones, C10 and C11, expressed Oct 4 and Nanog indicating that these Mospd 1 null 
ES cells still express ES cell markers and are, therefore, still ES cells. β-tubulin was 
used as an endogenous control. 
 
 
5.3.4.4. Self-renewal capacity of Mospd 1 null ES cells  
The Mospd 1 null ES cells express ES cell markers but do they still function as ES 
cells that can self renew? To assess whether the loss of Mospd 1 from ES cells 
affected their ability to self-renew or begin early differentiation depending on growth 
conditions a self-renewal assay was undertaken. The self-renewal capability of 2 
Mospd 1 null clones, C10 and C11, was compared to wild type E14 IV cells. 2 
different Mospd 1 null clones were assessed to show that there were no clonal 
differences. Briefly, undifferentiated cells were plated in 2 wells of a gelatinised 6 
well tissue culture dish and grown in the presence of LIF. The following day the cells 
were washed with PBS and one set of cells grown in the presence of LIF, to maintain 
the ES cells in a self-renewing, undifferentiated state, and the other in the absence of 
LIF, to differentiate the ES cells. The cells were grown in these conditions for 5 days, 
after which they were fixed and stained for alkaline phosphatase, a known stem cell 












Figure 5.7: Mospd 1 null cells express the ES cell markers Oct 4 and 
Nanog. RT-PCR shows that Mospd 1 null clones C10 and C11 expressed 
the ES cell markers Oct 4 and Nanog at a similar level to wild type E14 IV ES 
cells. β- tubulin was used as an endogenous control. (RT = reverse 
transcriptase; bp = base pairs). There was no contamination in either the 





Colonies were scored according to their colour; stem cell colonies were pink, mixed 
were a mixture of pink and white cells and differentiated cells were white. The 
number of colonies was analysed by a one way ANOVA followed by a Dunnett’s 
Multiple Comparison Test. No significant differences in the self renewal capability 
was found between wild type E14 IV cells and Mospd 1 null (C10 and C11) ES cells 
with p values of 0.12, 0.85 and 0.64 for stem, mixed and differentiated colonies, 
respectively, in the cells grown in the presence of LIF (Figure 5.8 A). In the absence 
of LIF (Figure 5.8 B) there was no significant difference in the Mospd 1 null ES 
cells’ ability to differentiate compared to wild type ES cells (p=0.18, p=0.34 and 
p=0.16 for stem, mixed and differentiated colonies, respectively.)  
 
 
5.3.4.5. Ability of Mospd 1 null ES cells to differentiate into 
cardiomyocytes 
The ability of Mospd 1 null clones to differentiate into beating cardiomyocytes was 
assessed by differentiating the cells using the hanging drop method described 
previously. Individual day 5 EBs were plated in gelatinised 24 well culture dishes 
and monitored for the presence of beating cells for 10 days. The ability to 
differentiate and form beating cells of 2 different Mospd 1 null clones, C10 and C11, 
was assessed and compared to wild type E14 IV cells (Figure 5.9). 85 % of EBs 
formed from wild type E14 IV cells were able to form beating cells, whilst 89 % of 
Mospd 1 null C10 EBs and 86 % of Mospd 1 null C11 EBs formed beating cells. The 
data was analysed using a One way ANOVA followed by a Bonferroni’s Multiple 
Comparison Test. There was no significant difference in the ability of Mospd 1 null 



















































































































































Figure 5.8: Self-renewal of Mospd 1 null ES cells compared to wild type 
E14 IV cells. The graphs show the number of stem (undifferentiated), mixed 
or differentiated colonies formed by wild type E14 IV cells, Mospd 1 null 
clones C10 and C11 cells grown in the presence (A) or absence (B) of LIF. A 
one way ANOVA followed by Dunnett’s Multiple Comparison Test indicated 
that there is no statistically significant difference between the stem, mixed 
and differentiated colonies of wild type E14 IV cells and both clones of Mospd 
1 null ES cells grown in the presence (stem p=0.12, mixed p=0.85 and 
differentiated p=0.64) or absence (stem p=0.18, mixed p=0.34 and 























































Figure 5.9: Mospd 1 null ES cell can differentiate and form beating 
cardiomyocytes. 85 % of embryoid bodies (EBs) differentiated from wild 
type E14 IV cells showed the presence of beating cardiomyocytes compared 
to 89 % of Mospd 1 null C10 EBs and 86 % Mospd 1 null C11 EBs. There 
was no significant difference in the percentage of beating EBs between 
Mospd 1 nulls when compared to wild type EBs (p=0.81). (Analysed by a 









5.3.4.6. Ability of Mospd 1 null ES cells to differentiate into 
bone (osteoblasts) 
As Mospd 1 expression had been reported to be higher in osteoblastic cells (Thaler et 
al., 2010) the Mospd 1 null ES cells, C10 and C11, were differentiated into 
osteoblasts. EBs were formed, as previously described, 1 day EBs plated in 
gelatinised tissue culture flasks and allowed to differentiate until day 5 (Figure 2.10 
A). These cells were then trypsinised to form a single cell suspension and 5 x 10
4
 
cells were plated in each gelatinised well of a 6 well culture plate.   A 6 well plate 
was stained with Alizarin Red to check for mineralisation at days 12, 19 and 26 
(Figure 5.10 B-D). The colonies were counted and analysed using a One way 
ANOVA and Bonferroni Multiple Comparison Test). 
 
 
At day 12 there was a significant reduction (p<0.01) in the number of colonies 
formed by Mospd 1 null cells for both clones C10 and C11 (Figure 5.11 A). Wild 
type ES cells formed an average of 106 colonies compared to 32 colonies formed by 
Mospd 1 null clone C10 and 25 colonies formed by Mospd 1 null clone C11 (n=3).  
 
 
By day 19 there was an average of 82 E14 IV colonies, 28 Mospd 1 null C10 
colonies and 21 Mospd 1 null C11 colonies formed (Figure 5.11 B). This reduction in 
the number of colonies formed was significantly different (p<0.001). From Day 19 to 
the end of the experiment (Day 26) the cells were cultured with media supplemented 
with 50 mM β- glycerophosphate, 50 µg/ml ascorbic acid and 1 µM dexamethasone. 
At day 26 when the colonies were stained there was an average of 83 E14 IV 
colonies compared to 31 and 22 colonies formed by Mospd 1 null C10 and C11, 
respectively (Figure 5.11 C). By this time the wild type clones covered the majority 
of the surface of the culture dish whilst there were large spaces in the Mospd 1 null 
cultures (Figure 5.10 D).  This reduction in the number of colonies was significant 
(p<0.001). There was no significant difference in the number of colonies formed 








Figure 5.10: Differentiation of ES cells into bone. Protocol used to 
differentiate ES cells into bone (A) and Photos of the clones formed at Day 
12(B), Day 19 (C) and Day 26(D) by E14 IV and Mospd 1 null cells, clones 































































































































Figure 5.11: The ability of Mospd 1 null cells to differentiate into bone.  
The number of colonies formed by Mospd 1 null clones, C10 and C11, is 
significantly different when compared to wild type E14 IV cells at Day 12 (A), 
Day 19 (B) and Day 26 (C) of differentiation (** p<0.01;***p<0.001) (One way 
ANOVA and Bonferroni post test). (n=3).   
 180 
5.3.4.7. Gene expression changes in differentiation of Mospd 
1 null ES cells into bone 
Thaler et al. (2010) reported that knockdown of Mospd 1 expression in MC3T3-E1 
cells by siRNA resulted in down regulation of several genes including Cdh11, Snai1 
and Snai2 (Slug) which showed a similar expression pattern to Mospd 1 (Figure 5.12 
A) according to FunGenES database (Schulz et al., 2009) (www.fungenes.org). 
Therefore, the expression level of Cdh11, Snai1 and Snai2 was assessed in the day 5 
EBs used for the bone differentiation protocol to check whether the level of these 
genes was altered in Mospd 1 null cells compared to wild type E14 IV cells (n=3). 
The expression level of Cdh11 was 0.81 and 0.76 in day 5 Mospd 1 null EBs (C10 
and C11, respectively) compared to E14 IV expression level (1)  (p= 0.16) (Figure 
5.12 B). Snai1 expression was not significantly different (p=0.17) between E14 IV (1) 
and Mospd 1 null EBs (0.78 and 0.97) (Figure 5.12 C) nor was the expression of 
Snai2. Mospd 1 null clones C10 and C11 had 0.81 and 1.04 Snai2 expression (Figure 
5.12 D) compared to E14 IV cells (1) and this difference was not significant (p=0.31) 
(One way ANOVA and Bonferroni post test).   
 
 
Cells were collected at Day 12, 19 and 26 for RNA extraction and subsequent qPCR 
analysis. Mospd 1 null cells were confirmed to be absent for Mospd 1 expression 
compared to wild type cells that expressed Mospd 1 at all time points (Figure 5.13.) 
(p<0.001) (One way ANOVA and Bonferroni post test). Day 12 Mospd 1 null 
differentiated cells showed an up-regulation of Mospd 3, Cdh11, Snai1 and Snai2 
(Figure 5.14). Mospd 1 null clones C10 and C11 had a 2.84 and 2.48 fold increase, 
respectively, in Mospd 3 expression when compared to wild type cells (Figure 5.14 
A). There were 1.47 and 1.45 fold increases in Cdh11 expression in Mospd 1 null 
clones C10 and C11, respectively (Figure 5.14 B). Snai1 expression was increased 
1.73 and 1.89 fold (Figure 5.14 C) and Snai2 expression was increased 1.46 and 1.75 
fold (Figure 5.14 D) in Mospd 1 null clones C10 and C11, respectively. These 
increases in gene expression in Day 12 differentiated cells were statistically 
significant for Mospd 3 (p<0.001), Cdh11 (p<0.01), Snai1 (p<0.05), Snai2 (p<0.01) 











































































































Figure 5.12: Expression changes of Cdh11, Snai1 and Snai2.  FunGenES 
heat map for expression of Snai2, Mospd 1, Cdh11 and Snai1 (A) (Day 0= 
undifferentiated ES cells; blue=no expression, black= very low expression, 
yellow=high expression). The expression levels of Cdh11 (B), Snai1 (C) and 
Snai2 (D) were not significantly different between wild type E14 IV cells and 
Mospd 1 null cells (p=0.16, p=0.17, p=0.31, respectively) in day 5 EBs. Data 




























































































































Figure 5.13: Mospd 1 expression is absent in differentiating osteoblasts 
from Mospd 1 null ES cells. Wild type E14 IV cells expressed Mospd 1 at 
Days 12, 19 and 26. As expected neither Mospd 1 clone C10 nor C11 had 
any Mospd 1 expression at any time point which was significantly different to 
wild type Mospd 1 expression (*** p<0.001) (One way ANOVA and 





























































































































































Figure 5.14: Gene expression in cells differentiating into bone at Day 12. 
The level of Mospd 3 (A), Cdh11 (B), Snai1 (C) and Snai2 (D) were 
significantly up regulated between wild type E14 IV cells and Mospd 1 null 
cells (* p<0.05; **p<0.01; ***p<0.001). Data analysed by One way ANOVA 




At Day 19 of bone differentiation there were no significant changes in gene 
expression for Mospd 3 (p=0.25), Cdh11 (p=0.13), Snai1 (p=0.83) and Snai2 (p=0.31) 
(One-way ANOVA and Bonferroni post test) (n=3) (Figure 5.15). Fold changes were 
measured against wild type E14 IV gene expression levels (set as 1). Mospd 1 null 
clones C10 and C11 had a 1.09 and 1.37 level of Mospd 3 expression, respectively, 
and 0.95 and 1.38 for Cdh11 expression, respectively. Snai1 and Snai2 expression in 
Mospd 1 null C10 was 0.90 and 0.82, respectively, and in Mospd 1 null C11 was 1.07 
and 1.05, respectively. The differences in gene expression between clones C10 and 
C11 were not significantly different for any of the genes tested.  
 
 
From Day 19 to Day 26 cells were cultured with media containing ascorbic acid, 
dexamethasone and β-glycerophosphate to enhance osteoblast cell formation. At Day 
26 there was no significant difference in the level of Mospd 3 in Mospd 1 null cells 
(p=0.09) as clone C10 had a 1.21 level and C11 a 1.07 level of Mospd 3 expression 
(Figure 5.16 A). Cdh11 expression was also not significantly altered in Mospd 1 null 
cells (p=0.06) at day 26 as Mospd 1 null clone C10 and C11 had a 1.12 and 0.91 
Cdh11 expression, respectively (Figure 5.16 B). At Day 26 both Snai1 and Snai2 
expression was significantly reduced in Mospd 1 null cells compared to wild type 
(p<0.001) (One way ANOVA and Bonferroni post test) (Figure 5.16 C and D). 
Mospd 1 null C10 and C11 had 0.75 and 0.61 level of Snai1 expression compared to 
an E14 IV expression of 1. The reduction of Snai1 expression in clone C10 was less 
significant (p<0.05) than that of clone C11 (p<0.001). Snai2 expression was reduced 
to 0.65 and 0.60 in Mospd 1 null clones C10 and C11, respectively, which was 
significantly different in both clones (p<0.001) (One way ANOVA and Bonferroni 
post test). There were no significant differences in gene expression between the two 
























































































































































Figure 5.15: Gene expression in cells differentiating into bone at Day 19. 
The level of Mospd 3 (A), Cdh11 (B), Snai1 (C) and Snai2 (D) were not   
significantly different between wild type E14 IV cells and Mospd 1 null cells 
(p=0.25, p=0.13, p=0.83 and p=0.31, respectively. Data analysed by One 
way ANOVA and Bonferroni post test. (n=3).  


















































































































































Figure 5.16: Gene expression in cells differentiating into bone at Day 26. 
The level of Mospd 3 (A) and Cdh11 (B) were not significantly different, 
between wild type E14 IV cells and Mospd 1 null cells (p=0.09 and p=0.06, 
respectively). Snai1 (C) and Snai2 (D) were significantly down regulated in 
Mospd 1 null cells (* p<0.05; **p<0.01; ***p<0.001). Data analysed by One 
way ANOVA and Bonferroni post test. (n=3).  
 
     
 187 
5.5. Discussion 
Mospd 1 is a gene that belongs to the Mospd gene family and there is little 
information in the literature about its function. To address this Mospd 1 targeted ES 
cells were successfully generated and Cre recombinase mediated deletion of the lox 
P flanked exons resulted in the generation of Mospd 1 null ES cells. These ES cells 
allowed functional analysis of Mospd 1 in vitro as they could be used to test whether 
Mospd 1 was essential for ES cell self renewal or differentiation.  
 
 
Mospd 1 is not essential for ES cell survival or self-renewal as there were no 
differences in the ability of the Mospd 1 null ES cells to self renew in the presence of 
LIF when compared to wild type cells. This can be explained by the fact that Mospd 
1 expression is very low in undifferentiated ES cells and, therefore, not likely to be 
essential for ES cells characteristics. This is further confirmed by the fact that the 




Investigating whether Mospd 1 is essential for differentiation was done by looking at  
whether Mospd 1 null cells could begin early differentiation by the removal of LIF 
and by trying to differentiate these cells into cardiomyocytes and osteoblasts. 
Osteoblast differentiation was chosen due to evidence that Mospd 1 expression was 
up regulated in differentiating osteoblastic cells (Thaler et al., 2010). Mospd 1 is not 
essential for early differentiation nor was it involved in cardiomyocyte differentiation. 
However, in a differentiation protocol to form osteoblasts the reduction in colonies 
formed by Mospd 1 null cells in comparison to wild type cells indicates that Mospd 1 
could be involved in osteoblastic differentiation. The reduction in the number of 
bone colonies from the first time point (day 12) checked indicates Mospd 1 plays a 
role early in osteoblast differentiation. The population of cells at day 12 is less 
differentiated than at later time points (Days 19 and 26) and may be a population of 
mesenchymal stem cells (MSCs)/ progenitors. MSCs can give rise to osteoblasts, 
adipogenic and myogenic cells (Muraglia et al., 2000; Sung et al., 2008)). The 
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reduction in colonies may be due to a loss of these progenitor cells.  This population 
of MSCs could be measured using flow cytometry to detect cell surface markers such 
as CD29, CD44, CD105 and SCA-1 (Sung et al., 2008). The later time points (Days 
19 and 26) had reduced numbers of colonies because those colonies had not formed 
at Day 12.  
 
 
To check whether the loss of Mospd 1 is responsible for the reduction in the number 
of colonies by Day 12 a rescue experiment could be performed. A vector containing 
Mospd 1 could be electroporated into the Mospd 1 null ES cells and clones that 
expressed Mospd 1 could be differentiated in the same way as control Mospd 1 null 
ES cells. If the number of colonies differentiated from the rescued Mospd 1 ES cells 
do not show the reduction in colony numbers than that proves Mospd 1 is responsible 
for the reduction in the Mospd 1 null cells.  
 
 
The hypothesis that Mospd 1 and Mospd 3 are genetically redundant may be 
supported by the increase in Mospd 3 expression in Day 12 Mospd 1 null 
differentiating cells as this could indicate that the cells are trying to compensate for 
the loss of Mospd 1 by up regulating Mospd 3 initially. This difference is lost as 
differentiation continues and could mean these genes have different roles as 
development continues or that Mospd 1 is not required at later time points so 
compensation is not required.  
 
 
From the genes that showed a change in expression reported in Thaler et al. (2010) 
Snai1, Snai2 (Slug) and Cdh11 showed a similar expression pattern to Mospd 1 in 
differentiating ES cells (FunGenES database) (Schulz et al., 2009) and were, 
therefore, chosen as genes to check during the differentiation of Mospd 1 null ES 
cells. Snail and Snai2 are expressed during organogenesis in mesenchymal tissues in 
the developing embryo (Smith et al., 1992; Oram et al., 2003).  The initial increase 
in Cdh11, Snai1 and Snai2 expression compared to wild type observed at Day 12 
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could indicate the loss of Mospd 1 leads to an Epithelial-Mesenchymal Transition 
(EMT) during this stage of differentiation. This is because Snai1 and Snai2 are 
essential for mesenchyme formation and for EMT (Alberga et al., 1991; Nieto et al., 
1994). As Snai1 and Snai2 repress Cdh1 (E-cadherin) (Cano et al., 2000; Bolos et al., 
2003) the cadherin present in epithelial cells (Takeichi, 1988) the increase of these 
repressors should decrease the expression of Cdh1. Cdh11 is a mesenchymal 
cadherin expressed in the osteoblastic lineage (Kii et al., 2004) and, therefore, the 
increase in Cdh11 expression compared to wild type at Day 12 indicates more 
mesenchyme is present in Mospd 1 null cells and these cells are differentiating into 
osteoblastic cells. However, due to the presence of non-specific amplification in the 
qPCR reaction using the Cdh11 primers (Appendix Figure 3) this increase in 
expression may not be accurate and, therefore, this should be repeated with another 
set of primers for Cdh11 which do not amplify non-specific products.  
 
 
The addition of ascorbic acid, β-glycerophosphate and dexamethasone to the culture 
medium between days 19 and 26 of differentiation enhances osteoblast 
differentiation (Buttery et al., 2001). It has been reported that dexamethasone acts on 
mesenchymal stem cells to make bone (Beresford et al., 1993). Therefore, at Day 26 
of differentiation the cells present are osteoblasts. The decrease in Snai1 and Snai2 
expression in Day 26 osteoblast cells indicates that there is a reduction in 
mesenchyme formation. It would be useful to measure the level of Cdh1 in Mospd 1 
null cells, at this time, to check whether it is increased due to the down regulation of 
its repressors. This together would mean that Mospd 1 was essential for mesenchyme 
formation and loss of Mospd 1 resulted in a Mesenchymal- Epithelial Transition 
(MET) during osteogenesis. The down regulation of Snai1 and Snai2 in Mospd 1 null 
cells confirms the findings of Thaler et al. (2010) who reported that Snai1 and Snai2 
expression was reduced in osteoblastic cells where Mospd 1 expression had been 




The Mospd 1 null cells described in this chapter are better tools than the siRNA 
knockdown described by Thaler et al. (2010) as these cells lack any Mospd 1 
expression and all cells differentiated from them will lack Mospd 1 expression 
whereas siRNA knocks down expression for shorter time periods. Using these Mospd 
1 null ES cells the role of Mospd 1 during ES cell differentiation can be found. 
Thaler et al. (2010) only examined gene expression changes in osteoblast 
differentiation whereas I have examined the role of Mospd 1 from earlier 




The use of ES cells to study EMT has previously been reported using wild type 
MESC20 ES cells (Spencer et al., 2007). During differentiation a decrease in CDH1 
(E-CADHERIN) protein expression occurred and an increase in Cdh1 repressor 
genes, Snail and Snai2. Interestingly Cdh1 transcript levels remained the same during 
-differentiation when measured by semi-quantitative RT-PCR (Spencer et al., 2007). 
Similar findings have been reported using human ES cells (Eastham et al., 2007). 
During human ES cell differentiation Snail and Snai2 transcript levels as well as 
mesenchymal markers, such as Vimentin, increase whilst Cdh1 expression falls 
(Eastham et al., 2007). Snail and Snai2 transcript levels increased in Cdh1 null ES 
cells and N-cadherin null ES cells upon spontaneous differentiation by removal of 
LIF indicating these two Cadherin genes are not required for the up-regulation of 
Snail and Snai2 (Spencer et al., 2007). The Mospd 1 null ES cell line reported here 
could be another useful tool to study EMT in vitro. Expression changes of other 
genes involved in EMT, such as Cdh1 (E-cadherin), N-cadherin and mesenchymal 
markers would need to be measured in Mospd 1 null cells to determine whether 
Mospd 1 was involved in their regulation.     
 
 
Figure 5.17 shows a summary of the differentiation process of the Mospd 1 null ES 
cells and proposes the possibility that the loss of Mospd 1 may result in EMT during 
ES cell differentiation (at Day 12) but may result in MET during osteogenesis (Day 
 191 
26). This could be a possibility as during embryogenesis EMT and MET occur 
depending on the tissues being formed. Cells can switch from epithelial to 






Figure 5.17: Summary of findings of Mospd 1 null cells during osteoblast differentiation. The protocol for differentiation 
of wild type (WT) and Mospd 1 null (Mospd 1-/-) ES cells from undifferentiated ES cells to differentiated osteoblasts is shown. 
The changes in the numbers of colonies and gene expression (yellow) measured at each time point (pink) of bone 















CHAPTER 6:  
















6.1.1. MOSPD1 localisation 
I successfully generated specific monoclonal α-MOSPD1 and α-MOSPD3 antibodies 
as described in Chapter 3. The monoclonal α-MOSPD1 antibody was used to study 
the sub-cellular localisation of MOSPD1 in vitro in HaCaTs and in vivo in mouse 
tissue sections and zebrafish embryo sections. MOSPD1 was found to be localised to 
the nucleus in HaCaTs and showed the same localisation in keratinocytes of the 
mouse ear. This indicates that MOSPD1 may play the same role in vitro as in vivo. 




MOSPD1 localisation changed depending on the cell cycle in HaCaTs in vitro with 
dividing cells showing MOSPD1 localised to the cytoplasm and not associated with 
the DNA. At certain cell cycle stages MOSPD1 also showed perinuclear localisation 
which is due to localisation of MOSPD1 to the ER. The finding that MOSPD1 was 
co-localised with a DSRed-ER marker in some cells is similar to the localisation of 
another MSP domain-containing family, the VAPs. This common localisation of 
MOSPD1 and VAP may indicate a common role. 
 
 
The sub-cellular localisation of MOSPD1 and MOSPD3 was different in HaCaTs in 
vitro as MOSPD1 was predominantly nuclear and MOSPD3 was nuclear and 
cytoplasmic. However, both MOSPD1 and MOSPD3 were cytoplasmic in dividing 
cells indicating that they may have a similar role in cell division. Within certain 
tissues such as the heart the two proteins have similar localisation in the nuclei of 
cardiomyocytes and cytoplasm of endothelial cells of blood vessels but within other 
tissues such as the kidney their localisation was different. This data could indicate 
that these proteins could compensate for each other in certain tissues but to answer 
the question of genetic redundancy a double knockout of Mospd 1 and Mospd 3 
would be required.  
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6.1.2. Functional analysis of Mospd 1  
To assess the function of Mospd 1 in vivo morpholinos against Mospd 1 were 
injected into zebrafish embryos. Injection of the morpholino targeted to the start site 
of Mospd 1 (MO1) resulted in a severe phenotype being observed in both MO1-
injected embryos and 5-mispair control morpholino-injected embryos indicating the 
phenotype could be non-specific. Injection of a morpholino targeted to a splice-site 
of Mospd 1 (MO2) resulted in approximately 60 % knockdown of Mospd 1 
expression but no phenotype was observed in these embryos. 
 
 
In parallel to the functional analysis of Mospd 1 in zebrafish embryos the function of 
Mospd 1 in vitro was assessed by generating a Mospd 1 null ES cell line. Mospd 1 
null ES cells were capable of self renewal and expressed the ES cell markers Oct4 
and Nanog indicating that the loss of Mospd 1 did not alter their stem cell 
characteristics. The Mospd 1 null cells did not show any early differentiation defects 
as they formed differentiated colonies upon the removal of LIF. The cells were also 
able to form EBs and did not show any difference in their ability to form beating 
cardiomyocytes compared to wild type E14 IV control cells. 
 
 
We did, however, observe a phenotype when cells were differentiated along the 
osteoblastic lineage. At Day 12 of differentiation there was a significant reduction in 
the number of colonies formed by Mospd 1 null cells compared to wild type. In 
addition to the reduced number of colonies a difference in gene expression was 
measured using qPCR in the Mospd 1 null cells compared to wild type. The genes 
assessed had been reported to have been down regulated in MC3T3-E1 cells in which 
Mospd 1 had been knocked down using siRNA (Thaler et al., 2010). An increased 
expression of Snail and Snai2 was measured at Day 12 indicating that the cells could 
be undergoing EMT at Day 12 of differentiation. At this time an increase in the 
osteoblastic cadherin, Cdh11 (Kii et al., 2004), was also observed in the Mospd 1 
null cells indicating an increased mesenchymal cell population formed by the Mospd 
1 null cells. There was a significant increase in Mospd 3 expression in Day 12 Mospd 
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1 null cells compared to wild type and this increase could indicate that the cells may 
be trying to compensate for the loss of Mospd 1 by up regulating Mospd 3 expression 
and, therefore, there may be some genetic redundancy between Mospd 1 and Mospd 
3. By Day 19 of differentiation there were no changes in the levels of Snail, Snai2 
and Cdh11 in Mospd 1 null cells compared to wild type cells. At Day 26 the level of 
Snail and Snai2 expression was decreased in Mospd 1 null cells compared to wild 
type indicating that MET may be occurring. This reduction of Snail and Snai2 at Day 
26 is similar to the down regulation of these genes in MC3T3-E1 cells when Mospd 1 
was knocked down using siRNA (Thaler et al., 2010) as MC3T3-E1 cells are 
osteoblastic and by Day 26 of differentiation of the Mospd 1 null cells reported here 
were osteoblasts.  
 
In conclusion, the tools to study Mospd 1 have been generated and reported in this 
thesis. Specific monoclonal antibodies have been generated to assess the sub-cellular 
localisation of MOSPD1 and its close relative MOSPD3. Tools to study the function 
of Mospd 1 have been generated, morpholinos to knockdown Mospd 1 expression in 
zebrafish in vivo, and a Mospd 1 null ES cell line which can be used for in vitro 
functional analysis or used for the generation of a Mospd 1 null mouse for functional 












6.2.1.1. Investigation of MOSPD1 during the cell cycle 
The change in localisation of MOSPD1 during the cell cycle, in which MOSPD1 was 
predominantly nuclear in non-dividing cells and cytoplasmic in dividing cells, could 
indicate that MOSPD1 is involved in the cell cycle.  The levels of MOSPD1 should 
be assessed at the different cell cycle stages by western blot to investigate whether 
there is a change in MOSPD1 expression during the cell cycle. This could provide 
further evidence that MOSPD1 may be involved in the cell cycle. As synchronicity 
was lost at later stages in cells treated with thymidine alternative synchronisation 
methods could be used to collect cells at the different cell cycle stages. To further 
increase the numbers of dividing cells in culture an alternative drug to thymidine 
such as Colcemid which blocks cells at mitosis (Lam et al., 1997) could be used.  
 
 
The localisation of MOSPD1 in the cytoplasm in dividing cells may be a passive 
occurrence due to the loss of the nuclear envelop during mitosis or an active process 
involving nuclear export. CRM1 (EXPORTIN1) is a receptor that binds to the NES 
of proteins and exports them from the nucleus (Fukuda et al., 1997). It has been 
shown that CRM1 can be blocked by addition of the antifungal agent Leptomycin B 
(Nishi et al., 1994; Fukuda et al., 1997).  Proteins that show a similar change in sub-
cellular localisation during the cell cycle, such as BRCA1, have been shown to be 
exported from the nucleus via its NES binding to CRM1 and that treatment with 
Leptomycin B blocks their export from the nucleus (Glover-Collins and Thompson, 
2008). The discovery of a putative NES in the last exon of MOSPD1 (Thaler et al., 
2010) could indicate that MOSPD1 could bind to CRM1 and be actively removed 
from the nucleus. To investigate this, the HaCaT cells could be treated with 
Leptomycin B and the sub-cellular localisation of MOSPD1 assessed. If treatment 
with Leptomycin B blocks nuclear export this would indicate that MOSPD1 was 




6.2.1.2. Identification of MOSPD1 protein partners 
MOSPD1 is localised the nucleus and loss of MOSPD1 results in the expression of 
EMT genes being altered. MOSPD1 does not have a DNA binding domain so it 
cannot act as a transcription factor and directly alter gene expression. However, the 
IgG-like fold of the MSP domain is thought to be involved in protein-protein 
interactions (Bork et al., 1994). It is possible that MOSPD1 may interact with other 
proteins, perhaps in a complex, and in this way alter gene expression. To determine if 
MOSPD1 forms protein complexes the monoclonal α-MOSPD1 antibody could be 
used for co-immunoprecipitation experiments. Cell lysates can be incubated with the 
monoclonal α-MOSPD1 antibody which will bind to MOSPD1. Addition of Protein 
G sepharose beads will bind the antibody allowing the antibody- protein complex to 
be obtained which can then be further analysed. The proteins bound to MOSPD1 
could be identified using mass spectrometry. However, co-immunoprecipitation can 
result in non-specific binding to the antibody due to the fact that proteins are more 
likely to precipitate during cell lysis. Also during cell lysis the disruption of 
organelles results in proteins that may not interact physiologically, mixing and 
binding to the target complex. Another problem with co-immunoprecipitation is that 
low affinity bound proteins can be lost during the lysis and wash steps. 
 
  
An alternative to determine protein-protein interactions is the yeast two hybrid 
system which makes use of bait and prey plasmids introduced into yeast. The bait 
plasmid carries the DNA binding domain of the reporter protein linked to the protein 
of interest, in this case MOSPD1, whilst the prey is a library of proteins linked to the 
activation domain of the reporter. When the bait protein binds to a prey protein the 
DNA binding domain and the activation domain are brought into close proximity 
resulting in transcription of the reporter gene. Using this system a protein that 






6.2.2. Functional analysis of Mospd 1  
 
6.2.2.1. Functional analysis of Mospd 1 in zebrafish 
 As there was no phenotype observed in zebrafish embryos when the level of 
knockdown of Mospd 1 expression was approximately 60 % the level of Mospd 1 
knockdown should be increased. To increase the level of knockdown another 
morpholino (MO3) targeted to a different splice junction should be designed and co-
injected with the splice-site morpholino (MO2) reported in this thesis. It has been 
reported that knockdown of gene expression can be increased from 50 % to 90 % by 
the injection of three morpholinos targeted to the same gene (Morcos, 2007). The 
optimal doses of the morpholinos injected would have to be determined to prevent 
toxicity. The correct controls, such as co-injection of the 5-mispair morpholinos, 
would also be essential to ensure any phenotype observed was not due to non-
specific effects. 
 
As there was expression changes for genes involved in EMT in the Mospd 1 null ES 
cells reported in Chapter 5, and in cells where Mospd 1 expression had been knocked 
down by siRNA (Thaler et al., 2010) the level of these genes should be measured in 
the morpholino-injected zebrafish embryos. If the expression levels of Snail, Snai2, 
Cdh11 and Cdh1 are altered in embryos where Mospd 1 has been knocked down this 
gives further evidence that Mospd 1 may be involved in EMT. As this would be in 
zebrafish embryos this would show Mospd 1 may be involved in EMT in vivo which 
has yet to be shown.  
 
 
In zebrafish embryos that have had Mospd 1 expression further knocked down the 
embryos should be observed for any changes during gastrulation as this is the stage 
of embryo development that is affected when E-cadherin (Cdh1) expression (Babb 
and Marrs, 2004) and Snail expression (Blanco et al., 2007) is knocked down in 
zebrafish embryos. This stage is affected as this is when cell movement starts to 
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occur in the embryo to form the three germ layers and EMT is important and, 
therefore, altering the genes involved in EMT can affect gastrulation. 
 
 
If a phenotype is observed when the level of Mospd 1 is further knocked down a 
rescue experiment would be required to prove that the phenotype observed is due to 
the reduction of Mospd 1. To rescue a phenotype the full length Mospd 1 mRNA 
would need to be co-injected with the morpholinos and the embryos observed. If the 
phenotype is not observed in these ‘rescued’ embryos then the phenotype was due to 
the loss or reduction of Mospd 1. To determine the optimal dose of mRNA to inject 
to rescue a phenotype a dose- response experiment would need to be done. As the 
mRNA does not have the splice-site that the morpholinos recognise these 
morpholinos cannot knockdown the injected ‘rescue’ mRNA level. This is only true 
for the splice-site morpholinos as a start morpholino would still be able to 
knockdown mRNA expression as the recognition site would be the same.  
 
 
6.2.2.2. Analysis of MOSPD1 in EMT in vitro 
As there were fewer colonies at Day 12 in the differentiating Mospd 1 null ES cells 
compared to wild type it was hypothesised this could be due to a reduction in the 
differentiation of mesenchymal stem cells (MSC). Using flow cytometry the 
presence of MSC markers could be assessed. There are MSC markers such as CD29, 
CD44, Cd105 and SCA-1 (Sung et al., 2008) and antibody panels are available to 
assess the presence of these markers. 
 
 
 To prove that the loss of Mospd 1 is responsible for the reduction in colonies a 
rescue experiment would need to be carried out. This would involve electroporating a 
vector containing Mospd 1 into the Mospd 1 null ES cells and differentiating them in 
the same way. If there is no reduction in the colony numbers in the ‘rescued’ cells 
this proves that the loss of Mospd 1 was responsible for the reduction.  
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Further to finding that genes involved in EMT have altered expression levels in 
Mospd 1 null cells it would be interesting to observe whether knockdown of Mospd 1 
in an epithelial cell type can induce EMT. To do this siRNA could be introduced into 
HaCaTs to knockdown Mospd 1 expression and the cells observed to check for the 
characteristic morphology changes that occur during EMT such as the loss of cell-
cell contacts and the cells looking more spindle shaped. The expression of genes 
involved in EMT, mesenchymal markers and epithelial markers should be measured 
by qPCR in these siRNA knockdown cells and their controls. This would determine 
if knockdown of Mospd 1 in epithelial cells made them more mesenchymal. 
Alternatively, Mospd 1 could be knocked down in mesenchymal cells to determine 
the role of Mospd 1 in MET as Mospd 1 may be involved in EMT and MET 
depending on the differentiation or developmental stage.  
 
 
6.2.2.3. Functional analysis of Mospd 1 in mice 
The ultimate functional assessment of a gene is creating a mouse knockout. Loss of 
function mouse models are very useful tools in identifying the function of a gene. 
The generation of conditional Mospd 1 cell lines will allow conditional knockout 
mouse models to be generated. Using Cre-mediated deletion, whether in a tissue-
specific or at a specific time of development depending on the promoter controlling 
Cre expression, will allow the function of Mospd 1 to be determined.  The Mospd 1 
null ES cells can also be used to generate Mospd 1 null mice in a shorter time frame 
to the conditional ES cells. However, if Mospd 1 was essential to development and 
loss of Mospd 1 resulted in neonatal lethality there would be no mice to assess. 
Therefore, the conditional Mospd 1 mice offer more control as to when the Mospd 1 
gene is knocked out. 
 
 
 To address the issue of whether Mospd 1 and Mospd 3 are genetically redundant the 
Mospd 1 null mice generated using the ES cells described in this chapter could be 
crossed with Mospd 3 null mice resulting in a double knockout. Conditional Mospd 3 
ES cells have been generated (Katrin Buerger, PhD thesis, 2009). In this way if the 
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loss of one Mospd gene compensates for the loss of the other than knocking out both 
genes could result in a phenotype or a more severe phenotype being observed. This 
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Forward primer Reverse Primer  
Mouse   
Mospd 1 GACAACCAGAGTTAGTGGAAGGG GACAGTTAGCAAACTAGGTCCTG 
Mospd 3 TCAAGGAAAGGGCACAGGGAC GCACAGAACTCGGAAGCGAAG 
β-tubulin GGAACATAGCCGTAAACTGC TCACTGTGCCTGAACTTACC 
Nanog CAGATAGGCTGATTTGGTTGGTGT CATCTTCTGCTTCCTGGCAA 
Oct4 GGCGTTCTCTTTGGAAAGGTGTTC CTCGAACCACATCCTTCTCT 
Zebrafish   




β-actin CTGGGTATGGAATCTTGCGGTATC CGAGAGTTTAGGTTGGTCGTTCG 
Gapdh GTCTGGTGACCCGTGCTGCT GTTTGCCGCCTTCTGCCTTAAC 
 






Appendix Table 3: Primers and probes used for zebrafish qPCR. 
Elongation factor 1 α (elf1 α) was used as an endogenous control and Mospd 
1 was the target. The probe had 3’ Black Hole Quencher 1 and 5’ FAM 














Mospd 1_forward CACGCTCTACAACCCCTATGAGT 
Mospd 1_reverse CGTCCACCACGGCATACTT 
Mospd 1 probe TGCACAGCGCCAAA 
Elongation factor 1 α (elf1 
α)_forward 
TGCGGTGGAATCGACAAGA 
Elongation factor 1 α (elf1 
α)_reverse 
CCATCTCAGCGGCTTCCTT 










Gene Forward primer Reverse primer 
Hprt GCTCGAGATGTCATGAAGGAGA AAAGAACTTATAGCCCCCCTTGA 
Mospd 1 GCTGCCGGTGCAGTGAA AGGATCGAACATCTCTATGACGAAT 
Mospd 3 CGATGCAGAGGGATATGTGAAG GGCCACGTGCCGTATCA 
Cdh11 GACAACCCACCAAAGTTTCCA CGGGACAGCTGCTTCTGATAC 
Snai1 GCCGGAAGCCCAACTATAGC AGGGCTGCTGGAAGGTGAA 
Snai2 CCCTGGCTGCTTCAAGGA TGAGGGCAAGAGAAAGGCTTT 
 
Appendix Table 4: Primers used for qPCR for bone experiments.  
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Primer efficiency and melting curve analysis for QPCR  
Serial dilutions of template cDNA were amplified using qPCR and standard curve 
generated. The efficiency of each primer set were calculated using the slope of the 
standard curve using the primer efficiency calculator at 
www.finnzymes.fi/java_applets/qPCR_efficiency.html (Appendix Table 5). Primer 
efficiencies should be in the range of 90-110 %. The efficiency of the Mospd 3 
primers (112%) and the Snai2 primers (111 %) fall out of this range. When primer 
efficiencies are not in the correct range this could indicate that the qPCR reaction 
will not be as sensitive as desired and, therefore, the quantification of gene 
expression may not be accurate. 
 
Another important control for qPCR reactions in which SYBR green has been used 
for fluorescence detection is melting curve analysis. This is due to the fact that 
SYBR green binds to all double stranded DNA and, therefore, in addition to bind the 
specific product it will also bind to primer dimers and non-specific PCR products. 
This will alter the accuracy of the data obtained. To check that only specific products 
are being amplified a dissociation step is added at the end of the qPCR amplification 
and a melting curve generated. The melting curve should only show one peak 
indicating only the specific product has been amplified. If there are other peaks it 
indicates the presence of non-specific products. The melting curves for the hprt, 
Mospd1, Snail and Snai2 (Appendix Figures 1 and 2) qPCR reactions only show one 
peak indicating that these qPCR reactions were specific. The melting temperature 
(Tm) of the hprt, Mospd1, Snai1 and Snai2 PCR products is 77.2 ºC, 75.7 ºC, 79.5 ºC 
and 75.5 ºC, respectively. The Tm for Mospd 3 was 75.3 ºC and for Cdh11 was 75.8 
ºC (Appendix Figure 3). However, both these curves showed an additional much 
smaller peak at 80 ºC indicating some non-specific amplification. The second Mospd 
3 melting peak was very low so may be too small to affect the quantification 
significantly. However, the Cdh11 secondary peak is larger and may indicate that the 
primers are amplifying a non-specific product. Therefore, the quantification of gene 
expression using these primers may not be accurate and should be repeated with 










Gene Primer efficiency 
Hprt 105 % 
Mospd1 109 % 
Mospd3 112 % 
Cdh11 109 % 
Snai1 104 % 
Snai2 111 % 
zElf1a 110 % 
zMospd1 109 % 
 
Appendix Table 5: Efficiencies of primers used for qPCR experiments. 
Primer efficiencies were calculated using the slope of the standard curve 
generated from qPCR of serial dilutions of template cDNA using the primer 

















Appendix Figure 1: Melting curves representing products from the qPCR 
amplification using Hprt and Mospd1 primers. The different colours represent the 
different samples .A: The Tm for hprt is 77.2 ºC and B: the Tm for Mospd 1 is 75.7 
ºC. Both sets of melting curves only have one peak indicating that the specific 







Appendix Figure 2: Melting curves representing products from the qPCR 
amplification using Snail and Snai2 primers. A: The Tm for Snail is 79.5 ºC and B: 
the Tm for Snai2 is 75.5 ºC. Both sets of melting curves only have one peak 








Appendix Figure 3: Melting curves representing products from the qPCR 
amplification using Mospd3 and Cdh11 primers.  A: The Tm for Mospd3 is 75.3 
ºC and whilst there is a small peak at 80 ºC indicating some non-specific 
amplification it is a very low level. B: The Tm for Cdh11 is 75.8 ºC. However, there 
is also a smaller peak at 80 ºC indicating non-specific amplification in this qPCR 
reaction. This would decrease amplification efficiency of the specific product and the 
accuracy of the data.  The qPCR reactions would have to be repeated using another 










Appendix Figure 4: pCAGGS-Cre IRES puro plasmid map. Image from 














Appendix Figure 5: Plasmid map of pCMV6-AC-GFP. The plasmid 
obtained from Origene (USA).  Mospd 1 was cloned into the multiple cloning 











Appendix Figure 6: Plasmid maps of the pEGFP-C2 (top) and pEGFP-












Appendix Figure 7: Plasmid map of the pEYFP-Nuc plasmid. Image from 

















Appendix Figure 8: Plasmid map of the pDSRed2-ER plasmid. Image 








Determination of the isotype of the monoclonal α-MOSPD1 
and α-MOSPD3 antibodies 
It is important to determine that there is only one isotype for each antibody as this 
determines whether the antibody is from one B cell clone and, therefore, specific to a 
particular epitope. The determination of the isotype of the monoclonal α –MOSPD1 
and α –MOSPD3 antibodies was done by mixing the supernatant from the hybridoma 
cultures with coloured microparticles and allowing the mixture to flow up individual 
isotype test strips. After 5-10 minutes a blue band appeared in the heavy chain IgG2b 
window of the α-MOSPD1 test strip and in the IgG1 window for both α-MOSPD3 
clones E1 and E4 (Appendix Figure 6). The α-MOSPD1 has a lambda (λ) light chain 
whilst both α-MOSPD3 clones have a kappa (κ) light chain.  IgG1 and IgG2b isotype 









Appendix Figure 9: Isotype determination of α-MOSPD1 and α-MOSPD3 
antibodies. The isotype test strips are shown with a band in the window of 
the isotype of each antibody. α -MOSPD1’s isotype is IgG2b λ and α-
MOSPD3 clones E1 and E4 isotype is IgG1 κ. ++ window of the isotype test 
strip shows that the supernatant/ coloured microparticle mixture had 












Splice-site (MO2) AGATAAATGTGTAGAACTCACCTTT 
5 mispair for splice-site (5MP2)  AGAaAAATcTGTAcAACTgAgCTTT 
Start (MO1) GGCTCTGCTGCTGCTGCATTGGCTC 
5 mispair for Start (5MP1) GGCTgTGCTcCTcCTcCATTGGgTC 
 
Appendix Table 6: Morpholino Sequences. Morpholinos had a 3’ 
fluorescein tag and were obtained from GeneTools (www.GeneTools.com), 
resuspended in distilled water to a concentration of 1 mM and stored at room 
temperature in the dark. 
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Chordin knockdown in zebrafish 
Microinjection into early zebrafish embryos can be a challenging technique. In order 
to ensure the technique was being performed correctly a standard positive control 
chordin morpholino was obtained from GeneTools and injected into zebrafish 
embryos and the embryos observed for the published chordin phenotype. Nasevicius 
and Ekker (2000) reported that when 2 ng of the chordin morpholino was injected 
into embryos a mild chordin phenotype, characterised by the presence of a small 
blood island, U-shaped somites and a tail with multiple folds, was observed. 
Injecting 4 ng of the morpholino resulted in the observation of a severe phenotype 
characterised by a larger blood island, U-shaped somites, a tail with multiple folds 
and a reduced head.  Appendix Figure 7 shows the phenotypes observed when the 
chordin morpholino was injected into embryos in our laboratory indicating the 
technique was being performed correctly and a published phenotype was able to be 
replicated.  
 
The embryos were assessed at 28 hpf and categorised as normal, mild chordin 
phenotype, severe chordin phenotype or other phenotypes, such as oedema or body 
axis deformed. 99 % of the non-injected control embryos were phenotypically 
normal with 1 % showing other phenotypes and no embryos with either a mild or 
severe chordin phenotype. Of the embryos injected with 2 ng of morpholino 14 % 
were normal, 65 % showed a mild chordin phenotype, 15 % showed a severe 
phenotype and 6 % had other phenotypes. 6 % of the 4 ng injected embryos were 
normal, 16 % had the mild phenotype and 69 % were severe. 9 % showed other 
phenotypes (Appendix Figure 8). The data was analysed using a Two way ANOVA 
followed by a Bonferroni post hoc test comparing non-injected, 2 ng chordin 
morpholino and 4 ng chordin morpholino-injected embryos to each other. Both the 2 
ng and 4ng chordin injected embryos were statistically significant (p<0.001) when 
compared to non-injected embryos for the normal, mild and severe phenotypes. 
There was a statistically significant difference (p<0.001) in the number of mild and 
severe embryos observed when the 2 ng chordin and 4 ng chordin  injected embryos 











Appendix Figure 10: Chordin knockdown in zebrafish embryos (28 hpf). 
A: wild type embryo; B: weak chordin phenotype; C and D: severe chordin 
phenotype viewed with white light and fluorescence, respectively. The red 
arrows indicate blood islands; in the weak phenotype (B) the blood island is 
small compared to that seen in the severe phenotype (C and D). The black 
and white arrows indicate the reduced head in the severe phenotype 
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Appendix Figure 11: Percentage of embryos that displayed normal, mild, 
severe and other phenotypes after being injected with 2 ng and 4 ng 
chordin morpholino (MO). Two way ANOVA followed by a Bonferroni post 







This was due to the fact that there was a higher number of mild phenotype embryos 
in the 2 ng injected group compared to 4 ng-injected embryos and a higher number of 
severe phenotypes in the 4 ng embryos compared to 2 ng injected embryos. This data 
is similar to the Nasevicius and Ekker  (2000) findings that as the dose of chordin 
morpholino is increased the severity of the phenotype increases. There was a 
significant difference between other non-related phenotypes observed between non 
injected embryos and 4 ng chordin MO injected embryos (p<0.05) possibly due to 
some embryos having a slightly toxic effect of the higher morpholino dose as this 
difference was not observed between the non-injected embryos and 2 ng chordin MO 
embryos.   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
